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CHAPTER  1  INTRODUCTION  
Parts  of  this  chapter  have  been  published  in  the  Journal  of  Chem  Phys  Lipids  179:  49-­
56,  2014  (an  invited  review  for  a  special  issue  on  cardiolipin).    
  
1.     CL  BIOSYNTHESIS  AND  REMODELING    
Cardiolipin   (CL)   (1,3-­diphosphatidyl-­sn-­glycerol)   is   the  signature  phospholipid  of  
the   mitochondrial   membrane.   First   isolated   from   beef   heart   (Pangborn,   1942),   it   is  
ubiquitous   in   eukaryotes   and   also   present   in   prokaryotes.   In   yeast   (Saccharomyces  
cerevisiae),  CL  is  synthesized  de  novo  in  the  inner  mitochondrial  membrane  (Gallet  et  al.  
1997),  and  it  undergoes  a  remodeling  step  to  replace  the  saturated  fatty  acyl  chains  with  
unsaturated   fatty   acyl   chains   (Gu  et   al.,   2004   and  Fig.   1.1).  CL   synthesized   de   novo  
contains  predominantly  saturated  fatty  acyl  chains  that  are  replaced  with  unsaturated  fatty  
acyl   groups.   This   remodeling   is   a   two-­step   process   in  which   a  CL   specific   deacylase  
(encoded  by  CLD1)  removes  one  fatty  acyl  group,  forming  monolysocardiolipin  (MLCL),  
and   tafazzin   reacylates   the  MLCL   to   form  a  generally  more  unsaturated  CL   (Xu  et  al.  
2003).   Tafazzin   is   a   CoA-­independent   transacylase   that   transfers   acyl   chains  
preferentially  from  phosphatidylcholine  (PC)  to  CL  (Xu  et  al.  2003).  The  accumulation  of  
MLCL  in  yeast  and  human  tafazzin-­deficient  cells  (Gu  et  al.,  2004;;  Vaz  et  al.,  2003)  is  
consistent   with   the   two-­step   pathway   of   remodeling   shown   in   Fig.   1.1.   In   a   study  
comparing  CL   species   from  a  wide   variety   of   organisms,   it  was   shown   that   the  most  
abundant  species  of  CL  contained  only  one  or  two  types  of  fatty  acids,  which  results  in  a  
high  degree  of  structural  uniformity  and  molecular  symmetry  in  CL  (Schlame  et  al.,  2005).  




Studies  in  yeast  utilizing  well-­characterized  deletion  mutants  of  CL  synthesis  (Fig.  
1.1)   indicate   that   CL   regulates   many   cellular   functions   and   signaling   pathways,   both  
inside  and  outside  of   the  mitochondria.   The  ubiquitous  association   of  CL  with   energy  
transducing  membranes  is  consistent  with  the  role  of  this  lipid  in  bioenergetics  (reviewed  
by  Joshi  et  al.,  2009).   In   fact,  CL  synthesis  and  mitochondrial  bioenergetics  are   inter-­
dependent,   as   CL   synthesis   is   both   required   for   and   stimulated   by   oxidative  
phosphorylation  (Gohil  et  al.,  2004).  Within  the  mitochondria,  the  effects  of  CL  deficiency  
extend  beyond  bioenergetics  to  decreased  mitochondrial  protein  import  and  perturbation  
of  mitochondrial  fusion  (Jiang  et  al.,  2000;;  Gebert  et  al.,  2009;;  Joshi  et  al.,  2012).  The  
deleterious  effects  of  CL  deficiency  outside  the  mitochondria  include  perturbation  of  the  
PKC-­Slt2   cell   integrity   and   high   osmolarity   glycerol   (HOG)   signaling   pathways   and  
decreased  vacuolar  function  (Zhong  et  al.,  2005;;  Zhong  et  al.,  2007;;  Chen  et  al.,  2008b;;  
Zhou  et  al.,   2009).  Perturbation  of  CL  synthesis  has   long  been  associated  with  aging  
(Paradies  et  al.,  2010),  and   loss  of  CL  was   found   to  decrease   longevity   in  yeast  cells  
(Zhou   et   al.,   2009).   The   significance   of  CL   in   human   health   is   apparent   from   clinical  
findings  that  perturbation  of  CL  metabolism  leads  to  the  life-­threatening  disorder  known  































FIGURE  1.1:  Synthesis  and   remodeling  of  cardiolipin   (CL)   in  yeast.  CDP-­DAG   is  
converted   to   phosphatidylglycerolphosphate   (PGP)   by   phosphatidylglycerolphosphate  
synthase  (PGPS),  encoded  by  PGS1  (Chang  et  al.,  1998;;  Dzugasova  et  al.,  1998).  PGP  
phosphatase   (Gep4)   catalyzes   the   conversion   of   PGP   to   phosphatidylgylcerol   (PG)  
(Osman  et  al.,  2010).  PG  is  converted  to  cardiolipin  (CL)  by  CL  synthase  (Crd1)  (Jiang  et  
al.,  1997;;  Chang  et  al.,  1998;;  Tuller  et  al.,  1998).    CL  is  remodeled  in  a  two-­step  process  
in  which  the  CL  specific  deacylase  encoded  by  CLD1  removes  a  fatty  acyl  group,  forming  
monolysocardiolipin  (MLCL)  (Beranek  et  al.,  2009),  and  tafazzin  (Taz1)  reacylates  MLCL  
to  form  a  generally  more  unsaturated  CL  (Xu  et  al.,  2003).     In  mammalian  cells,  CL  is  
deacylated  by  more  than  one  enzyme  (Kiebish  et  al.,  2013).  Tafazzin  is  the  enzyme  that  








In  addition  to  the  cellular  functions  listed  above,  recent  studies  indicate  that  CL  is  
intricately  involved  in  cellular  metabolism  (Fig.  1.2).  These  studies  are  the  focus  of  this  
dissertation.  CL  interacts  with  components  of  the  electron  transport  chain  and  is  required  
for  stabilization  of  electron   transport  chain  supercomplexes  and   for  optimal   respiratory  
control  (Bazan  et  al.,  2013;;  Pfeiffer  et  al.,  2003;;  Zhang  et  al.,  2002;;  Zhang  et  al.,  2005).  
Perturbation  of  iron-­sulfur  (Fe-­S)  biogenesis  has  been  reported  in  CL  deficient  yeast  cells,  
suggesting  that  iron  homeostasis  as  well  as  enzymatic  activities  requiring  Fe-­S  cofactors  
are  dependent  on  CL  biosynthesis  (Patil  et  al.,  2013).  CL  is  also  required  for  activities  of  
carrier  proteins  that  transport  metabolites  for  energy  metabolism  (Kadenbach  et  al.,  1982;;  
Fiermonte  et  al.,  1998;;  Sedlak  et  al.,  1999;;  Lange  et  al.,  2001;;  Hoffmann  et  al.,  1994;;  
Jiang  et  al.,  2000;;  Bisaccia  and  Palmieri,  1984),  as  well  as  for  enzymes  in  the  carnitine  
shuttle  (Pande  et  al.,  1986;;  Noel  and  Pande,  1986).  In  addition,  CL  might  also  be  required  
for   cellular   metabolism   outside   mitochondria.      CL   is   present   in   the   membrane   of  
peroxisomes  (Zinser  et  al.,  1991)  and  may  affect  b-­oxidation  and  other  metabolic  activities  
of  this  organelle.  The  role  of  CL  in  mitochondrial  protein  import  is  discussed  as  a  potential  
mechanism   underlying   the   metabolic   defects   associated   with   CL   deficiency.   We  
speculate  that  defects  in  these  functions  may  be  physiological  modifiers  that  account  for  
the   wide   disparity   of   clinical   phenotypes   observed   in   BTHS,   and   conclude   with   a  












FIGURE   1.2:   Functions   of   cardiolipin   (CL)   in   metabolic   pathways.   CL   is   most  
abundant   in   the   inner   membrane   and   is   also   present   in   the   outer   membrane   of  
mitochondria.      It   is   required   for   activities   of   transporters   and   electron   transport   chain  
enzymes  and  for  stabilization  of  electron  transport  supercomplexes.  Loss  of  CL  leads  to  
perturbation  of  Fe-­S  biogenesis,  resulting  in  decreased  activity  of  Fe-­S  enzymes  in  the  
TCA  cycle,  electron  transport,  and  other  pathways.  The  mechanism  linking  CL  and  Fe-­S  
biogenesis   is   unknown.   Because   CL   is   required   for   the   import   of   proteins   through  
mitochondrial  import  complexes  (TOM,  SAM  and  TIM),  it  is  possible  that  import  of  specific  
proteins   required   for   Fe-­S   synthesis   is   defective   in   CL   deficient   cells.   Alternatively,  
increased   ROS   generated   by   inefficient   electron   transport   in   CL   deficient   cells   may  
damage   Fe-­S   proteins.   CL   is   also   present   in   the   membrane   of   the   peroxisome,   an  
organelle  that  carries  out  β-­oxidation  of  fatty  acids,  ether  lipid  synthesis,  and  reactions  of  
the   glyoxylate   cycle.   The   route   whereby   CL   is   transported   from   mitochondria   to  
peroxisomes  is  unclear,  but  may  involve  mitochondria  derived  vesicles  (MDVs).  Acyl  CoA  
produced  by  β-­oxidation  of   long  chain   fatty  acids   in  peroxisomes   is   transported   to   the  
mitochondria   via   the   carnitine   shuttle.   The   acyl   CoA   is   transferred   to   carnitine   in   the  
peroxisome  by  carnitine  acyltransferase  (Cat).  Acylcarnitine  from  the  peroxisome  crosses  
the  mitochondrial  membrane,  facilitated  by  the  carnitine/acylcarnitine  translocase  (Crc).  






2.     CL  AND  MITOCHONDRIAL  BIOENERGETICS  
CL  is  enriched  in  the  membranes  of  bacteria,  mitochondria,  and  hydrogenosomes,  
which   play   a   role   in   ATP   synthesis   through   the   generation   of   a   transmembrane  
electrochemical  gradient  (Daum  et  al.,  1985;;  Dowhan  et  al.,  1997;;  de  Andrade  Rosa  et  
al.,  2006).  The  association  of  CL  with  energy  transducing  membranes  is  consistent  with  
the  crucial  role  of  this  lipid  in  cellular  bioenergetics  (reviewed  by  Schlame  et  al.,  2000;;  
Hoch,  1992).  The  physical   interaction  between  CL  and  mitochondrial   respiratory  chain  
complexes  and  other  components  of  membranes  also  helps   in   the   formation  of  a   lipid  
scaffold,   which   functions   to   stabilize,   tether,   and   increase   the   enzyme   activity   of  
interacting  proteins  (Beyer  et  al.,  1985;;  Beyer  et  al.,  1996;;  Sedlak  et  al.,  1999).  In  this  
light,  it  is  not  surprising  that  perturbation  of  CL  synthesis  affects  the  structure  and  function  
of  mitochondrial  respiratory  chain  complexes  and  transporters.  
2.1     CL  and  respiration  
Analyses  of  CL  function  in  yeast  have  been  facilitated  by  the  availability  of  yeast  
mutants  of  each  step  in  CL  synthesis  (Fig.  1.1).    In  particular,  the  CL  synthase  null  mutant  
crd1Δ,  which  lacks  CL  (Jiang  et  al.,  1997;;  Tuller  et  al.,  1998;;  Chang  et  al.,  1998),  has  
been  the  focus  of  numerous  studies.  Although  crd1Δ  cells  can  grow  in  non-­fermentable  
carbon   sources,   indicating   that   CL   is   not   essential   for   respiration,   the   ADP/O   and  
respiratory  control  ratios  (RCR)  of  crd1Δ  mitochondria  are  reduced  in  these  conditions  
(Koshkin   et   al.,   2002).   CL   is   required   for   optimal   RCR   and   ADP/O   ratios   and   for  
maintenance  of  the  mitochondrial  membrane  potential  (Jiang  et  al.,  2000;;  Claypool  et  al.,  
2008),   especially   during   unfavorable   conditions   such   as   increased   temperature   and  
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osmolarity  (Koshkin  et  al.,  2002;;  Koshkin  et  al.,  2000).  The  role  of  CL  in  respiration  has  
been  recently  reviewed  (Joshi  et  al.,  2009;;  Patil  and  Greenberg,  2013).    
2.2     CL  is  required  for  stabilization  of  supercomplexes  
The   electron   transport   chain   complexes   are   organized   into   supramolecular  
structures   referred   to  as  supercomplexes   (Schagger  and  Pfeiffer,  2000).  S.  cerevisiae  
lacks   complex   I   (NADH  complex)   but   contains  NADH  dehydrogenase   composed  of   a  
single  subunit  (Ndi1).  Yeast  supercomplexes  are  formed  by  the  association  of  two  units  
of  complex  III  with  units  of  complex  IV.  Supercomplexes  in  mammalian  cells  are  formed  
by  the  association  of  complex  I  with  two  units  of  complex  III  and  multiple  units  of  complex  
IV  (Schagger,  2002).  The  proposed  role  of  supercomplexes  is  that  of  efficient  substrate  
channeling  between  the  individual  complexes.  The  crd1Δ  mutant  exhibits  destabilization  
of  the  supercomplexes  (Pfeiffer  et  al.,  2003;;  Zhang  et  al.,  2002;;  Zhang  et  al.,  2005).  Bazan  
and  co-­workers  reported  the  in  vitro  reconstitution  of  supercomplexes  and  showed  that  
supercomplex  III2IV2  reconstitution  is  dependent  on  CL  (Bazan  et  al.,  2013).  The  loss  of  
CL   decreases   activity   of   ADP/ATP   carrier   protein   activity   and   its   association  with   the  
supercomplexes   (Claypool   et   al.,   2008;;   Jiang   et   al.,   2000).   Destabilization   of  
supercomplexes  was  also  reported  in  tafazzin-­deficient  human  fibroblasts  (McKenzie  et  
al.,  2006)  and,  more  recently,  in  tafazzin-­deficient  induced  pluripotent  stem  cells  (Dudek  
et  al.,  2013).    
2.3     Loss  of  CL  leads  to  increased  generation  of  reactive  oxygen  species  (ROS)    
Destabilization   of   supercomplexes   is   expected   to   result   in   increased   electron  
leakage  and  ROS  production  (Maranzana  et  al.,  2013).  Not  surprisingly,  the  absence  of  
CL  in  yeast  cells  leads  to  increased  protein  carbonylation,  a  hallmark  of  increased  ROS  
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(Chen   et   al.,   2008a).   The   primary   sites   of   ROS   generation   are   complexes   I   and   III  
(Turrens  et  al.,  1985;;  Barja,  1999;;  Kushnareva  et  al.,  2002;;  Grivennikova  and  Vinogradov,  
2006).  The  CL  acyl  chains,  which  are  in  close  proximity  to  these  ROS  generating  sites,  
are   susceptible   to   peroxidation   (Li   et   al.,   2010;;   Li   et   al.,   2012;;   Liu   et   al.,   2012).   The  
superoxides  generated  by  respiratory  complex  III  were  shown  to  cause  peroxidation  of  
CL  and  to  reduce  the  activity  of  cytochrome  c  oxidase  (Paradies  et  al.,  1998;;  Paradies  et  
al.,   2000;;   Paradies   et   al.,   2001).   The   exogenous   supplementation   of   CL,   but   not  
peroxidized  CL  or  other  phospholipids,   rescued  both   reduced  activity  of  cytochrome  c  
oxidase  and   increased  generation   of  ROS   in   reperfused  heart   (Paradies   et   al.,   2001;;  
Petrosillo   et   al.,   2007).   As   CL   is   extensively   remodeled   by   the   transacylase   tafazzin  
(Malhotra  et  al.,  2009),  we  speculate  that  this  may  be  a  mechanism  whereby  damaged  
fatty  acyl  chains  are  replaced.  Under  oxidative  stress  conditions,  acyl-­CoA:lysocardiolipin  
acyltransferase-­1   (ALCAT1)   may   also   be   involved   in   remodeling   of   CL.      Increased  
expression  of  ALCAT1  leads  to  aberrant  remodeling  of  CL  with  long  polyunsaturated  fatty  
acyl  chains,  which  are  sensitive  to  ROS  (Watkins  et  al.,  1998;;  Hong  et  al.,  2002;;  Li  et  al.,  
2010).  Increased  expression  of  ALCAT1  is  linked  to  diabetes  and  diet-­induced  obesity  in  
humans  and  to  hyperthyroid  cardiomyopathy  in  mice  (Cao  et  al.,  2009;;  Li  et  al.,  2010;;  Li  
et  al.,  2012;;  Liu  et  al.,  2012).    In  summary,  CL  deficiency  is  linked  to  increased  generation  
of  ROS,  which  in  turn  damage  CL  by  peroxidation  of  CL  acyl  chains.  
3.       PERTURBATION  OF  IRON  HOMEOSTASIS  IN  CL  DEFICIENT  CELLS  
A   recent   report   indicates   that   CL   is   required   for   Fe-­S   biogenesis   and   iron  
homeostasis  (Patil  et  al.,  2013).  Fe-­S  clusters  are  present  in  all  kingdoms  of  life  (Lill  and  
Muhlenhoff,   2008;;   Johnson   et   al.,   2005).   They   are   cofactors   for   many   biochemical  
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reactions,   including   those   required   for   electron   transport   and   for   the   TCA   cycle  
(Hausmann  et  al.,  2008;;  Gerber  et  al.,  2004;;  Li  et  al.,  1999;;  Lill  and  Muhlenhoff.  2008).  In  
eukaryotes,   three  Fe-­S  cluster  biogenesis  systems  have  been  characterized,   including  
the  iron-­sulfur  cluster  (ISC)  import  system  in  mitochondria  (required  for  the  generation  of  
all  cellular  Fe-­S  proteins),  the  cytosolic  Fe-­S  protein  assembly  (CIA)  machinery,  and  the  
ISC   export   apparatus   in   mitochondria.   The   latter   two   processes   are   also   involved   in  
maturation  of  Fe-­S  proteins  in  the  cytosol  and  nucleus  (Balk  et  al.,  2004;;  Ye  et  al.,  2006;;  
Kessler  et  al.,  2005;;  Balk  et  al.,  2005).    
A  role  for  CL  in  iron  homeostasis  was  first  suggested  by  a  microarray  analysis  of  
genes  exhibiting  altered  expression  in  the  crd1Δ  mutant  (Patil  et  al.,  2013).  Most  notably,  
the   genes   for   iron   uptake   were   greatly   upregulated   in   crd1Δ   cells,   which   exhibited  
increased   mitochondrial   iron   as   well   as   increased   sensitivity   to   iron   and   to   oxidative  
stress.  Perturbation  of   iron  homeostasis   is  a  demonstrated  outcome  of  defective  Fe-­S  
biogenesis   (Rutherford  et  al.,   2005;;  Hausmann  et  al.,   2008).  Consistent  with  an  Fe-­S  
defect,  the  crd1Δ  mutant  exhibits  decreased  activities  of  both  mitochondrial  and  cytosolic  
enzymes   that   require   Fe-­S   co-­factors,   including   mitochondrial   enzymes   succinate  
dehydrogenase,   aconitase,   and  ubiquinol   cytochrome   c   oxidoreductase,   and   cytosolic  
enzymes  sulfite   reductase  and   isopropylmalate   isomerase   (Patil   et  al.,  2013).  The  CL  
deficient  mutant  also  exhibited  synthetic  interaction  with  the  Fe-­S  scaffold  mutant  isu1.      
The  mechanism   linking  CL   to  Fe-­S  biogenesis   is   not   currently   understood.  We  
speculate  that  defective  import  of  proteins  required  for  Fe-­S  biogenesis  may  underlie  the  
defect,   as   several   studies   have   shown   that   mitochondrial   protein   import   as   well   as  
assembly   of   outer   membrane   complexes   are   decreased   in   yeast   CL  mutants   and   in  
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lymphoblasts   derived   from   BTHS   patients   (Jiang   et   al.,   2000;;   Gebert   et   al.,   2009).    
Additional   evidence   for   the   role   of   CL   in   mitochondrial   protein   import   comes   from  
functional  studies  of  the  translocator  assembly  and  maintenance  protein  Tam41,  which  is  
required   for   the   assembly   and  maintenance   of   the   TIM  mitochondrial   import   complex  
(Gallas  et  al.,  2006;;  Tamura  et  al.,  2006).   Interestingly,   the  phenotypes  of   the   tam41Δ  
mutant  were  found  to  be  similar  to  those  of  the  CL  mutant  crd1Δ.    These  include  defective  
protein  translocases  and  respiratory  chain  supercomplexes,  decreased  assembly  of  the  
ADP/ATP  carrier   (AAC),  and  decreased  CL   levels   (Tamura  et  al.,   2006;;  Gallas  et  al.,  
2006;;  Kutik   et   al.,   2008).   These   findings   suggested   that   protein   import   defects   in   the  
tam41Δ  mutant  were  due  to  the  loss  of  CL.  Consistent  with  this  possibility,  Tamura  and  
co-­workers   demonstrated   that   Tam41   is   the   mitochondrial   CDP-­DG   synthase   that  
catalyzes  the  synthesis  of  CDP-­DG,  which  is  required  for  CL  synthesis  (Tamura  et  al.,  
2013).  An  alternative  mechanism  is  that  Fe-­S  proteins  may  be  damaged  by  the  increase  
in  ROS  in  CL  deficient  cells,  as  the  inactivation  of  Fe-­S  enzymes  by  superoxide  has  been  
demonstrated   (Flint   et   al.,   1993;;   Gardner,   1997).   Increasing   antioxidants   by  
overexpression  of  the  YAP1  gene  did  not  rescue  the  iron  sensitivity  phenotypes  of  the  CL  
mutant   (Patil   et   al.,   2013),   a   finding   that   might   argue   against   Fe-­S   damage   due   to  
increased  ROS.    However,  it  is  quite  possible  that  free  radicals  that  are  not  scavenged  by  
Yap1-­induced  antioxidants  may  cause  Fe-­S  damage  in  CL  deficient  cells.  In  light  of  the  
role   of   Fe-­S   clusters   in   a   wide   variety   of   cellular   functions   (Rouault   et   al.,   2012),  





4.       CL  AND  MITOCHONDRIAL  TRANSPORTERS    
Soluble  molecules  and  substrates  are  transferred  across  organelle  membranes  via  
carrier   proteins.   Transporters   that   play   major   roles   in   energy   transfer   include   the  
ADP/ATP   translocase   (AAC),   phosphate   carrier   (PiC),   pyruvate   carrier,   fatty   acid  
transport   protein   (FATP),   tricarboxylate   transporter,   and   2-­oxoglutarate/malate   carrier  
protein,  among  others  (Nury  et  al.,  2006;;  Klingenberg,  1990;;  Walker,  1992;;  Kuan  et  al.,  
1993;;  Nelson  et  al.,  1993;;  Palmieri,  1994).  The  reader  is  referred  to  an  excellent  review  
of   the   role  of  CL   in   the  stabilization  of  mitochondrial  carrier  proteins   (Claypool,  2009).  
Membrane  lipids  play  an  important  role  in  the  assembly  of  carrier  proteins  (Hunte,  2005).  
Both  the  AAC  and  PiC,  which  are  required  for  oxidative  phosphorylation,  interact  with  CL  
(Kadenbach  et  al.,  1982;;  Fiermonte  et  al.,  1998;;  Sedlak  et  al.,  1999;;  Lange  et  al.,  2001).  
Of  the  three  isoforms  of  AAC  that  have  been  identified  in  yeast  and  humans,  activity  of  
the  major  isoform,  AAC2,  requires  CL  (Hoffmann  et  al.,  1994).    Furthermore,  activity  of  
AAC  purified   from   the  yeast  crd1D  mutant   is  decreased   (Jiang  et  al.,   2000).  A   recent  
report   indicates   that   AAC   also   interacts   with   the   TIM   mitochondrial   protein   import  
complex,  and  this  interaction  is  dependent  on  CL  (Gebert  et  al.,  2011).    
In   addition   to   oxidative   phosphorylation,   transporters   play   a   role   in   two   other  
sources  of  energy  production,   the  oxidation  of  pyruvate  and  β-­oxidation  of   fatty  acids.  
Pyruvate  is  transported  into  the  mitochondria  of  yeast,  Drosophila,  and  humans  by  the  
pyruvate  carrier  proteins  MPC1  &  MPC2  (Bricker  et  al.,  2012).  The  purification  of  pyruvate  
carrier  proteins  requires  phospholipids,  especially  CL  (Bisaccia  and  Palmieri,  1984).  In  
the  absence  of  CL,   transport  activity  of   the  pyruvate  carrier  protein  was  not  observed  
(Nalecz  et  al.,  1986).  Fatty  acids  are  taken  up  by  fatty  acid  transport  proteins  (FATP1  –  
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FATP  6)  in  the  plasma  membrane  (Van  der  Vusse  et  al.,  2000;;  Gimeno,  2007;;  Jia  et  al.,  
2007).  While  a  role  for  CL  in  FATP  activation  has  not  been  reported,  Mitchell  et  al.  (2009)  
demonstrated  that  knockdown  of  FATPs  in  HEK  293  cells  inhibits  de  novo  CL  synthesis,  
suggesting  that  fatty  acid  transport  and  CL  synthesis  may  be  interdependent.  In  summary,  
CL   is   required   for   the   transport   of   metabolites   utilized   in   the   major   cellular   energy  
producing  metabolic  pathways. 
5.     INTER-­RELATIONSHIP  BETWEEN  CL  AND  CARNITINE  
Activated   fatty   acids   (fatty   acyl-­CoAs)   are   metabolized   to   acetyl-­CoA   by   the  
enzymes  of  β-­oxidation.  As  membranes  are   impermeable  to  activated  acyl-­CoAs,  their  
transport   into   mitochondria   is   facilitated   by   the   quaternary   ammonium   compound   L-­
carnitine   (3-­hydroxy-­4-­N-­trimethylaminobutanoate)   (Reuter   and   Evans,   2012).   The  
transfer  of  acyl  residues  from  CoA  to  carnitine  is  catalyzed  by  carnitine  acyltransferase  
(van   der   Leij   et   al.,   2000;;   Jogl   and   Tong,   2003;;   Franken   et   al.,   2008).  
Carnitine/acylcarnitine   translocase   catalyzes   the   transport   of   acylcarnitine   across   the  
mitochondrial  membrane   (Murthy  and  Pande,  1984;;  Van  Roermund  et  al.,  1995).  The  
carnitine  shuttle  is  conserved  throughout  the  eukaryotic  kingdom  (Bremer,  1983).  A  role  
for  CL  in  the  carnitine  shuttle  is  suggested  by  reports  that  CL  is  required  for  the  activities  
of   the   carnitine   shuttle   enzymes.   Carnitine   acyltransferase   (carnitine  
palmitoyltransferase)  purified   from   rat   liver   cells  was  shown   to   contain  CL   (Fiol   et   al.,  
1984),  and  enzymatic  activity  of  the  enzyme  was  stimulated  by  CL  (Pande  et  al.,  1986).  
Carnitine/acylcarnitine   translocase   activity   was   also   shown   to   require   CL   (Noel   and  
Pande,  1986).  Furthermore,  the  stimulating  effect  of  carnitine  on  state  2  respiration  in  rat  
liver   mitochondria   was   abolished   by   doxorubicin,   which   binds   CL,   and   activity   was  
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restored  by  adding  CL  (Battelli  et  al.,  1992).    
In  addition  to  its  function  in  the  transport  of  acyl  groups,  carnitine  also  plays  a  role  
in  oxidative  stress  and  aging.  In  S.  cerevisiae,  carnitine  was  shown  to  improve  growth  in  
the  presence  of  oxidative  stress  (Franken  et  al.,  2010).  Several  features  of  aging  in  rats  
are   reversed   by   supplementation   with   carnitine,   including   both   decreased   CL   and  
mitochondrial   dysfunction.   Decreased   levels   and   pathological   remodeling   of   CL   with  
polyunsaturated   fatty   acids   (arachidonic   and   docosahexaenoic   acids)   have   been  
described  in  old  rats  (Lee  et  al.,  2006;;  Sparagna  et  al.,  2009;;  Maftah  et  al.,  1994;;  Lewin  
et  al.,  1984;;  Paradies  et  al.,  1993;;  Paradies  et  al.,  1997;;  Lenaz  et  al.,  1997;;  Paradies  et  
al.,  1990).  Mitochondrial  dysfunction  in  old  animals  is  also  associated  with  defects  in  ATP  
synthesis  and  oxidative  phosphorylation  (Maftah  et  al.,  1994;;  Hoch,  1992;;  Hagen  et  al.,  
1998;;   Sen   et   al.,   2006;;   Sen   et   al.,   2007).   Dietary   supplementation   of   old   rats   with  
acylcarnitine   significantly   improved   cellular   respiration   and   mitochondrial   membrane  
potential  and,  interestingly,  also  increased  CL  levels  (Hagen  et  al.,  1998).  These  studies  
suggest   an   inter-­relationship   between   CL   and   carnitine   in   regulating   mitochondrial  
functions.  CL  is  required  for  optimal  activity  of  the  carnitine  acetylcarnitine  transloacse,  
with  implications  for  the  generation  of  energy  from  b-­oxidation  and  mitochondrial  functions  
associated   with   aging.   In   addition,   CL   levels   may   be   affected   by   carnitine  
supplementation.    
6.     CL,  PEROXISOMES,  AND  b -­  OXIDATION  
The  peroxisome  is  a  unique,  versatile,  single  membrane  bound  organelle  found  in  
all  eukaryotes.  The  number,  size,  and  function  of  peroxisomes  vary  among  cell  types  and  
in   response   to   physiological   conditions   (Van  den  Bosch  et   al.,   1992;;  Veenhuis   et   al.,  
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1988).  Studies  of  peroxisomal  biogenesis  have  been  hampered  by  the  fragility  and  low  
abundance   of   the   organelle   (Platta   et   al.,   2007).   Peroxisomal   enzymes   carry   out   β-­
oxidation  of  fatty  acids,  ether  lipid  synthesis,  and  reactions  of  the  glyoxylate  cycle  (Van  
den  Bosch  et  al.,  1992).  In  eukaryotes,  fatty  acids  are  degraded  by  α-­,  β-­,  and  ω-­oxidation  
(Wanders  et  al.,  2003).  The  major  pathway,  β-­oxidation,  is  conserved  from  yeast  to  higher  
eukaryotes   (Houten   et   al.,   2010;;   Wanders   et   al.,   2010),   although   localization   of   the  
pathways  differs.  In  yeast,  peroxisomes  are  the  sole  site  of  β-­oxidation.  In  mammals,  β-­
oxidation  takes  place   in  both  mitochondria  and  peroxisomes  (Barlett  and  Eaton,  2004;;  
Van  der  Klei  and  Veenhuis,  1997).    β-­oxidation  of  fatty  acids  plays  a  key  role  in  energy  
homeostasis  in  liver,  heart,  and  skeletal  muscle  (Houten  et  al.,  2010).  The  depletion  of  
glucose  during  fasting  is  compensated  by  β-­oxidation  of  fatty  acids  in  many  tissues  (but  
not  brain)   to  generate  energy   (Houten  et  al.,  2010).  Fatty  acids  are  also  converted   to  
ketone  bodies,  an  additional  source  of  energy  that  can  be  utilized  by  all  tissues,  including  
the  brain  (Houten  et  al.,  2010).  The  reader  is  referred  to  excellent  recent  reviews  of  b-­
oxidation  in  peroxisomes  and  mitochondria  (Houten  et  al.,  2010;;  Wanders  et  al.,  2010).    
Zinser   et   al.   (1991)   reported   that   the   peroxisomal   membrane   of  S.   cerevisiae  
grown  in  rich  media  (yeast  extract-­peptone-­dextrose)  contains  considerable  levels  of  CL  
(7%  of  total  phospholipid).  This  amount  of  CL  is  slightly  more  than  half  the  level  observed  
in  mitochondria  (13%  of  total  phospholipid).  The  CL  content  of  peroxisomal  membranes  
of  Pichia  pastoris   cells   grown  under   conditions   that   induce  peroxisomes   (methanol   or  
oleic  acid  as   the  sole  source  of   carbon)  was   reported   to  be  about  a   third  of   the   level  
observed   in  mitochondria   (Wriessneggar   et   al.,   2007).   It   is   unclear   how  CL,  which   is  
synthesized   in   mitochondria,   is   transported   to   peroxisomes.   Neuspiel   et   al.   (2008)  
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showed  that,  in  mammalian  cells,  mitochondria  derived  vesicles  (MDV)  fuse  to  a  fraction  
of  pre-­existing  peroxisomes.  The  MDVs  formed  are  of  two  types,  single-­membrane  MDVs  
(mitochondrial   outer   membrane   derived   vesicles)   and   double-­membrane   MDVs  
(mitochondrial  inner  and  outer  membrane  derived  vesicles).  Both  types  of  MDVs  fuse  to  
form  single  membrane  enclosed  peroxisomes  (Neuspiel  et  al.,  2008).  MDVs  are  thought  
to   be   involved   in   vesicular   trafficking   of  membrane   lipids   (possibly   including  CL)   and  
proteins  from  the  intermembrane  space  of  mitochondria  to  peroxisomes  (Schumann  et  
al.,  2008;;  Braschi  et  al.,  2010;;  Sugiura  et  al.,  2014).    
In   summary,   while   there   is   currently   no   direct   evidence   for   a   role   of   CL   in  
peroxisomal  metabolism,  CL   is   clearly   present   at   significant   levels   in   the  peroxisomal  
membrane.  As   discussed   above,   it   is   now  well   established   that  CL   affects   numerous  
mitochondrial  functions  by  interacting  with  proteins  and  complexes  in  the  mitochondrial  
membrane.      We   speculate   that   this   structurally   unique   lipid   also   affects   peroxisomal  
function   as   a   consequence   of   interacting   with   peroxisomal   membrane   enzymes   and  
transporters.    
7.     BARTH  SYNDROME  (BTHS)  
BTHS   is   a   severe   X-­linked   disorder   characterized   by   cardiomyopathy,   skeletal  
myopathy,   neutropenia,   3-­   methylglutaconic   aciduria   and   growth   retardation   due   to  
abnormal  mitochondria  and  defective  oxidative  phosphorylation  (Barth  et  al.,  1981).  Other  
metabolic  abnormalities  found  in  BTHS  patients  include  elevated  urinary  excretion  of  3-­
methylglutaconic  acid  (Cardonick  et  al.,  1997)  and  hypercholesterolemia  (Mazzocco  et  
al.,  2007).  About  ten  years  after  the  first  description  of  BTHS,  the  locus  was  mapped  to  
Xq28  (Bolhuis  et  al.,  2007),  and  mutations  were   identified   in  G4.5,  now  referred   to  as  
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tafazzin   (TAZ1)   (Bione  et  al.,  1996).  Mutations   in  BTHS  result   in   the  complete   loss  of  
Taz1p  or  the  expression  of  severely  truncated  Taz1p;;  a  biochemical  explanation  for  the  
phenotypes  associated  with  any  identified  BTHS  point  mutation  is  not  known  (Bione  et  
al.,  1996).  Cardiomyopathy  is  a  characteristic  feature  and  primary  cause  of  death  in  BTHS  
patients.  Cardiomyopathy  is  a  structural  disease  in  which  the  heart  muscle  is  marked  by  
rigidity  and  loss  of  flexibility  of  the  heart  walls,  leading  to  weakness  and  fatigue  (Barth  et  
al.,  1983).  Skeletal  myopathy  and  cardiomyopathy  lead  to  delayed  motor  development  in  
some  BTHS  patients   and   to   changes   in   cardiac  mitochondrial   appearance   (Xu   et   al.,  
2006).  Skeletal  myopathy  and  cardiomyopathy  are  due  to  muscle  weakness,  which  can  
be  related  to  deficient  oxidative  phosphorylation  (Barth  et  al.,  1999).  The  molecular  basis  
underlying  the  pathologies  observed   in  BTHS  patients   is  not  understood.   Interestingly,  
tafazzin  mutations  do  not  correlate  with  the  extent  of  clinical  abnormalities  in  BTHS,  and  
substantial  phenotypic  variation  occurs  even  for  a  single  tafazzin  mutation  (Johnston  et  
al.,   1997).   Thus,   the   clinical   symptoms   of   BTHS   vary   from   those   who   have   severe  
incapacitating  disease  to  those  who  are  nearly  asymptomatic,  even  among  patients  with  
the  identical  mutation.  The  high  degree  of  variation  in  the  symptoms  of  BTHS  patients  
with  the  same  TAZ1  mutation  suggests  that  physiological  factors  influence  the  outcome  
of  defective  tafazzin.  
8.     IMPLICATIONS  FOR  BARTH  SYNDROME  
BTHS  is  characterized  by  a  decrease  in  total  CL,  an  accumulation  of  MLCL,  and  
the   absence   of   the   predominant   unsaturated   CL   species   due   to   the   loss   of   the   CL  
remodeling  enzyme  tafazzin  (Schlame  and  Ren,  2006).  The  molecular  basis  underlying  
the   pathology   observed   in   BTHS   patients   is   not   understood.   Interestingly,   tafazzin  
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mutations   do   not   correlate   with   the   extent   of   clinical   abnormalities   in   BTHS,   and  
substantial   phenotypic   variation   occurs   even   for   a   single   tafazzin  mutation.   The   high  
degree  of  variation  in  the  symptoms  of  BTHS  patients  with  the  same  tafazzin  mutation  
suggests  that  physiological  factors  influence  the  outcome  of  defective  tafazzin  (Johnston  
et   al.,   1997).  We   suggest   that   the   functions  of  CL  discussed  above  may  be  potential  
physiological  modifiers  of  the  BTHS  phenotype.  
8.1     Fatty  acid  metabolism,  peroxisome  biogenesis  and  the  carnitine  shuttle  
In   a   landmark   study,   Spencer   et   al.   (2011)   observed   that   impaired   oxygen  
utilization   directly   contributes   to   exercise   intolerance   in   BTHS   patients.   It   is   well-­
established   that   mild   or   moderate   exercise   is   driven   by   a   significant   increase   in   fat  
oxidation.  This  suggests   the  possibility   that  BTHS  patients  exhibit  exercise   intolerance  
due  to  the  inability  to  adequately  metabolize  fat.  The  clinical  outcomes  observed  in  many  
human  disorders  of   β-­oxidation  are   similar   to   those   seen   in  BTHS.  Perturbation  of   β-­
oxidation   of   fatty   acids   in   mitochondria   was   shown   to   cause   cardiomyopathy   and  
arrhythmia  (Bonnet  et  al.,  1999;;  Saudubray  et  al.,  1999).  The  role  of  CL  in  the  carnitine  
shuttle  suggests  that  the  loss  of  CL  may  lead  to  defects  in  β-­oxidation  and  or  carnitine  
mediated  transport  of  acyl-­CoA.  Consistent  with  this  possibility,  carnitine  mutations  lead  
to   clinical   outcomes   similar   to   those   seen   in   BTHS   (Wanders   et   al.,   2010).   Exercise  
intolerance   has   been   demonstrated   in   carnitine   palmitoyltransferase   deficiency  
(Ørngreen   et   al.,   2003).   Carnitine-­acylcarnitine   translocase   deficiency   results   in  
cardiomyopathy   with   arrhythmia   (Longo   et   al.,   2006).   Cardiomyopathy   and   skeletal  
myopathy  are  observed  in  deficiencies  of  the  OCTN2-­encoded  carnitine  transporter  and  
very  long  chain  acyl-­CoA  dehydrogenase  (Rinaldo  et  al.,  2002).  In  summary,  numerous  
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disorders  of   fatty  acid  metabolism  lead  to  clinical  phenotypes  similar   to   those  found   in  
BTHS,   including   cardiomyopathy,   skeletal   myopathy,   arrhythmia,   and   exercise  
intolerance.  Elucidating  the  role  of  CL  in  β-­oxidation  and  carnitine-­mediated  transport  of  
fatty  acids  may  identify  potential  avenues  for  treatment  of  BTHS.  
8.2     Bioenergetics  and  Fe-­S  biogenesis  
Three  human  genetic  disorders  of  Fe-­S  biogenesis  have  been  described  (Rouault  
and  Tong,  2008).  These   include  defects   in   the   iron  chaperone   frataxin,   the   iron  sulfur  
cluster   assembly  protein   ISCU,  and  glutaredoxin.  Mutations   in   frataxin   in   the  disorder  
Friedreich  ataxia  lead  to  hypertrophic  cardiomyopathy,  heart  failure,  and  deficiencies  in  
enzymes   requiring   Fe-­S   cofactors,   including   aconitase   and   complex   I-­III   enzymes.    
Interestingly,  mitochondrial  deficiencies  similar  to  those  seen  in  CL  deficient  cells  can  be  
rescued   by   overexpression   of   frataxin,   including   decreased   mitochondrial   membrane  
potential  and  ATP  levels,  sensitivity  to  oxidative  stress,  and  reduced  life  span  (Ristow  et  
al.,   2000;;  Runko  et   al.,   2008).  Cardiomyopathy   and   cardiac   failure   in  mice  were   also  
shown  to  be  relieved  by  overexpression  of  frataxin  (Schulz  et  al.,  2010).  A  mutation  in  the  
Fe-­S  scaffold  protein  ISCU  has  been  described  in  an  inherited  skeletal  muscle  disorder  
characterized   by   muscle   weakness,   exercise-­induced   lactic   acidosis,   deficiencies   in  
aconitase  and  succinate  dehydrogenase,  and  iron  overload  (Mochel  at  al.,  2008;;  Kollberg  
et  al.,  2009).  This  finding  was  consistent  with  earlier  reports  of  aconitase  and  succinate  
dehydrogenase  deficiencies  in  muscle  disorders  (Haller  et  al.,  1991;;  Hall  et  al.,  1993).  In  
light  of  the  role  of  CL  in  Fe-­S  biogenesis,  we  speculate  that  the  clinical  presentation  in  




8.3     Mitochondrial  protein  import  
The  clinical  presentation  of  a  disorder  known  as  dilated  cardiomyopathy  with  ataxia  
(DCMA)   syndrome   is   very   similar   to   BTHS   despite   normal   CL  metabolism   in   DCMA.    
Symptoms  include  cardiomyopathy,  elevated  3-­methylglutaconic  acid,  and  neutropenia.  
DCMA  syndrome   is  due   to  a  mutation   in  a  gene   thought   to   function   in  protein   import,  
TIM14  (which  shares  homology  with  yeast  Tim14p)  (Davey  et  al.,  2006).  The  similarity  in  
the   clinical   outcomes   of   DCMA   and   BTHS   suggests   that   BTHS   may   be   caused   or  
exacerbated  by  defective  mitochondrial  import  of  specific  proteins,  the  identities  of  which  
may  shed  light  on  the  pathology  of  the  disorders.  We  speculate  that  proteins  required  for  
Fe-­S  biogenesis  may  be  likely  candidates.  
9.   YEAST  AS  A  MODEL  FOR  STUDYING  BTHS  
Yeast  (Saccharomyces  cerevisiae)  is  an  excellent  model  organism  for  the  study  of  
BTHS.  Yeast  is  nonpathogenic,  can  be  easily  used  for  genetic  analyses,  and  has  a  rapid  
growth  rate,  which  renders  it  one  of  the  most  favorable  eukaryotic  model  systems.  The  
tafazzin  gene,  which  is  defective  in  BTHS,  is  conserved  from  yeast  to  humans  (Vaz  et  al.,  
2003;;  Gu  et  al.,  2004;;  Ma  et  al.,  2004).  The  CL  biosynthetic  pathway  is  well  characterized,  
and  knockout  mutants  of  all  steps  are  available  in  S.  cerevisiae  (Schlame  and  Greenberg,  
1997;;  Schlame  and  Hostetler,  1997;;  Schlame  et  al.,  2000;;  Osman  et  al.,  2010;;  Xu  et  al.,  
2003;;  Beranek  et  al.,  2009).  This  has  enabled  us  to  study  the  effects  of  a  defective  CL  
pathway  in  yeast  cells.  The  availability  of  the  yeast  deletion  mutant  collection  of  all  non-­
essential   genes   facilitates   the   construction   of   double  mutants   for   studies   of   synthetic  
lethality.   Synthetic   lethality   analysis   is   a   technique   in   which   double   mutants   of   two  
nonessential   genes   show  a   lethal/sick   phenotype  when   they   interact  with   each   other,  
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directly  or   indirectly   (Hartman  et  al.  2001).  Synthetic   lethality  studies  can  contribute   to  
understanding   the   functions   of   the   interacting   genes.   The   genetic   screen   to   identify  
synthetic   interactions  with  CL  mutants  (discussed  in  chapter  2  and  4)  among  all  4,800  
yeast  deletion  mutants  is  not  currently  possible  in  any  other  model  for  BTHS. We  used  
synthetic  lethality  to  screen  4,800  non-­essential  genes  for  synthetic  interaction  with  CL  
mutant  cells  and  identified  pathways  relevant  to  the  clinical  presentation  of  BTHS.  The  
role  of  CL  in  there  pathway  is  the  subject  of  my  dissertation.  
10.   PROJECT  OUTLINE  
The  goal  of  my  doctoral  research  described  in  this  dissertation  was  to  elucidate  
the   role  of  CL   in   cellular  processes   that  may   identify  mechanisms   responsible   for   the  
variations  in  BTHS  symptoms,  especially  cardiomyopathy.  Using  the  “awesome  power  of  
yeast  genetics,”  I  have  conducted  the  following  studies.  
As   discussed   above,   the   loss   of   CL   causes   a   wide   variety   of   phenotypes,  
suggesting   that   the   identification   of   different   physiological   modifiers   will   elucidate   the  
various  biochemical  pathways  defective  due  to  CL-­deficiency.  A  genome-­wide  Synthetic  
Genetic  Array  (SGA)  screen  of  all  the  non-­essential  yeast  genes  was  performed  to  identify  
mutants   that   synthetically   interact  with  CL  mutants.   I   grouped   these   genes   based   on  
biological   function  and  validated   interactions  by   tetrad  analysis.  The   interacting  genes  
could  identify  cellular  functions  that  require  CL.  Preliminary  experiments  indicated  that  CL  
mutants  interact  with  the  pyruvate  dehydrogenase  complex  (PDH).  Because  the  role  of  
PDH  is  to  convert  pyruvate  to  acetyl-­CoA  by  a  process  called  pyruvate  decarboxylation,  
I  hypothesized  that  the  loss  of  CL  leads  to  decreased  acetyl-­CoA  synthesis.  The  studies  
in  Chapter  2  show  that  cells  lacking  CL  exhibit  decreased  acetyl-­CoA  levels  and  acetate  
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utilization,   suggesting   that   CL   is   required   for   acetyl-­CoA   synthesis.   Thus,   Chapter   2  
identifies   acetyl-­CoA   synthesis   as   a   metabolic   pathway   that   may   affect   the   clinical  
presentation  in  BTHS.  
Previous   studies   have   reported   that   perturbation   of   Fe-­S   biogenesis   leads   to  
defects   in   the  TCA  cycle.  The  studies   in  Chapter  2,  demonstrating   that   the   loss  of  CL  
decreases  acetyl-­CoA  synthesis,  identifies  another  route  whereby  the  TCA  cycle  may  be  
perturbed,  i.e.,  the  intracellular  transport  of  acetyl-­CoA.  Because  acetyl-­CoA  synthesized  
in  different  compartments  is  transported  into  mitochondria  by  specific  shuttle  systems,  I  
hypothesized   that  perturbation  of   the  acetyl-­CoA  shuttle  system  may  contribute   to   the  
TCA  cycle  deficiency.  The  studies  in  Chapter  3  show  that  decreased  growth  of  the  CL  
mutant  at  elevated  temperature  was  rescued  by  carnitine  and  acetylcarnitine.  Consistent  
with  this,  the  loss  of  CL  leads  to  decreased  carnitine-­acetylcarnitine  translocase  activity.  
I  also  provide  evidence  that  the  decreased  transport  of  acetyl-­CoA  into  the  mitochondria  
increases  the  need  for  transfer  of  TCA  cycle  intermediates  by  the  glyoxylate  cycle.  These  
findings  suggest  that  in  addition  to  decreased  activity  of  Fe-­S  enzymes  in  the  TCA  cycle,  
another  mechanism  that   is  expected  to  contribute   to  TCA  cycle  deficiency   is  defective  
transport   of   acetyl-­CoA,  which   contributes   to   the   depletion   of   precursors   for   the   TCA  
cycle.  
Chapter  4  identifies  cellular  functions  that  are  perturbed  in  the  absence  of  tafazzin.  
An   SGA   screen   was   carried   out   with   the   taz1Δ   mutant   to   identify   potential   synthetic  
interactions,  which  are  likely  to  identify  genes  that  share  essential  functions  with  tafazzin.  
The  screen  identified  70  potential  synthetic  lethal  mutants  and  102  potential  synthetic  sick  
mutants,   which  were   then   grouped   based   on   biological   function.   Exciting   interactions  
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were  observed  with  genes  coding  for  phospholipase  B,  argininosuccinate  shunt  enzyme,  
mitochondrial  iron  homeostasis,  and  vacuolar  protein  sorting.  These  findings  suggest  that  
tafazzin  may  be  involved  in  remodeling  of  phospholipids  other  than  CL,  and  that  CL  and  
tafazzin   deficiency   may   result   in   a   defective   TCA   cycle   and   perturbation   of   vacuole  
function.  
Although  the  studies  described  in  this  thesis  identify  interesting  cellular  functions  
of   CL,   many   questions   related   to   the   mechanism   underlying   the   role   of   CL   in   these  
processes   remain   unclear.   I   anticipate   that   understanding   the   role   of   CL   in   essential  
cellular  processes  could  help  to  elucidate  the  phenotypic  disparities  in  BTHS  and  will  have  
a  significant  positive  impact  on  the  disorder,  because  it  may  identify  new  metabolic  targets  















CHAPTER  2  LOSS  OF  CARDIOLIPIN  LEADS  TO  PERTURBATION    
OF  ACETYL-­COA  SYNTHESIS  
INTRODUCTION    
   Cardiolipin   (CL)   is  a  unique  phospholipid  with  dimeric   structure   that   constitutes  
about  15%  of   total   phospholipid   in  mitochondria   (Pangborn,   1947;;  Schlame  and  Ren,  
2009;;  Schlame  et  al.,  2000;;  Jakovcic  et  al.,  1971).  CL  is  synthesized  de  novo  in  the  inner  
mitochondrial  membrane  (Gallet  et  al.  1997),  and  it  undergoes  remodeling  to  replace  the  
saturated  fatty  acyl  chains  with  unsaturated  fatty  acyl  chains  (Beranek  et  al.,  2009;;  Xu  et  
al.,  2003).  CL  plays  an  important  role  in  maintaining  mitochondrial  structure,  interaction  
with   mitochondrial   membrane   proteins,   stability   of   respiratory   chain   supercomplexes  
(Cruciat  et  al.,  2000;;  Zhang  et  al.,  2002b;;  Pfeiffer  et  al.,  2003),  and  other  mitochondrial  
functions  such  as  membrane  potential,  protein  import,  and  respiration  (Schlame  and  Ren,  
2006;;   Jiang   et   al.,   2000;;   Gebert   et   al.,   2009).   Loss   of   CL   perturbs   mitochondrial  
bioenergetics  and  decreases  ATP  synthesis  (Koshkin  and  Greenberg,  2000;;  Jiang  et  al.,  
2000;;   Koshkin   and  Greenberg,   2002;;  Claypool   et   al.,   2008).   Aberrant  CL   remodeling  
leads   to   the   severe   genetic   disorder   Barth   syndrome   (BTHS)   (Schlame   et   al.,   2005).  
Mutation  of   tafazzin,   the   transacylase   that   remodels  CL,   leads   to  decreased   total  CL,  
increased  MLCL,  and  aberrant  CL  species  (Schlame  et  al.,  2002;;  Valianpour  et  al.,  2005;;  
Schlame  et  al.,  2003).  The  clinical  presentation  of  BTHS   includes  cardio-­  and  skeletal  
myopathy,   neutropenia,   3   -­   methylglutaconic   aciduria,   growth   retardation,   abnormal  
mitochondria,  and  defective  oxidative  phosphorylation  (Barth  et  al.,  1981).  Interestingly,  
disparities  in  clinical  manifestation  are  identified  in  BTHS  (Johnston  et  al.,  1997;;  Bleyl  et  
al.,  1997;;  Barth  et  al.,  1999b),  indicating  that  physiological  modifiers  affect  the  phenotype  




To   identify   modifiers   that   exacerbate   CL   deficiency,   I   carried   out   a   Synthetic  
Genetic   Analysis   (SGA)   with   the   yeast   CL   synthase   mutant   crd1Δ,   which   lacks   CL.  
Interestingly,  genetic   interaction  of  crd1Δ  was  observed  with  pyruvate  dehydrogenase  
(PDH),  which  converts  pyruvate  to  acetyl-­CoA  (Pronk  et  al.,  1996).  PDH  null  mutants  are  
viable  because  acetyl-­CoA  can  be  synthesized  by   the  cytosolic  PDH-­bypass  pathway,  
the   last  step  of  which   is   the  acetyl-­CoA  synthetase  catalyzed  conversion  of  acetate   to  
acetyl-­CoA,  which  is  shuttled  into  the  mitochondria.  Other  routes  to  acetyl-­CoA  synthesis  
include  oxidative  degradation  of  amino  acids  (Vorapreeda  et  al.,  2012),  decarboxylation  
of  pyruvate  (Guest  et  al.,  1989),  and  oxidation  of  fatty  acids  (Trotter,  2001).  I  hypothesized  
that  synthetic   lethality  with  PDH  mutants  may  be  explained  by  a  requirement  for  CL  in  
one  or  more  alternate  routes  of  acetyl-­CoA  synthesis.  In  this  study,  I  demonstrate  that  
crd1Δ   cells   have   reduced   acetyl-­CoA   levels   and   diminished   ability   to   utilize   acetate,  
suggesting  that  the  PDH-­bypass  pathway  is  perturbed  in  cells  lacking  CL.  These  results  
show  for   the   first   time   that  CL   is   required   for  acetyl-­CoA  synthesis   to  maintain  energy  
metabolism.    
MATERIALS  AND  METHODS  
Yeast  strains,  plasmids,  and  growth  media  
The  yeast  S.  cerevisiae  strains  used  in  this  study  are  listed  in  Table  2.1.  Single  
deletion  mutants  were  obtained  from  the  yeast  knockout  deletion  collection  (Invitrogen).  
Double  mutants  were  obtained  by  tetrad  dissection.  Synthetic  complete  (YNB)  medium  
contained  adenine  (20.25  mg/liter),  arginine  (20  mg/liter),  histidine  (20  mg/liter),  leucine  
(60   mg/liter),   lysine   (200   mg/liter),   methionine   (20   mg/liter),   threonine   (300   mg/liter),  
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tryptophan   (20  mg/liter),   uracil   (20  mg/liter),   yeast   nitrogen   base  without   amino   acids  
(Difco),  and  glucose   (2%)   (YNBD)  or  sodium  acetate   (2%)   (YNBA).  Synthetic  dropout  
medium   contained   all   ingredients   mentioned   above   but   lacked   specific   compounds  
required  for  selection.  Sporulation  medium  contained  potassium  acetate  (1%),  glucose  
(0.05%),  and  the  essential  amino  acids.  Complex  medium  contained  yeast  extract  (1%),  
peptone  (2%),  and  glucose  (2%)  (YPD).  Solid  medium  was  prepared  by  adding  2%  agar.    
To  construct  the  crd1Δcan1Δ  starting  strain,  a  1.8  kb  CAN1  deletion  cassette  was  
amplified   from   Y5563   (kindly   provided   by   Dr.   Charles   Boone)   by   sense   primer   (5’-­
TAGGGCGAACTTGAAGAATAACC-­3’)   and   antisense   primer   (5’-­
ACGAAAAATGAGTAAAAATTATCTT-­3’)   and   inserted   into   the   genome   of   BY4741  
(MATa)  with  the  disruption  confirmed  by  PCR.  The  can1Δ  mutant  was  then  crossed  to  
BY4742  (MATα)  to  obtain  an  MATα  can1Δ  strain  by  tetrad  analysis.  The  CRD1  gene  in  
the  can1Δ  mutant  (MATα)  was  disrupted  by  a  1.8  kb  URA3  fragment  released  from  the  
PUC19  plasmid  digested  using  PvuII.  The  disruption  of  CRD1  was  confirmed  by  PCR,  
Southern  blot,  and  phospholipid  analysis.	  
Synthetic  Genetic  Array  (SGA)  
The  MATα  can1Δcrd1Δ  mutant  was  crossed  to  the  array  of  deletion  mutants  in  the  
MATa  background,  in  which  the  deletions  are  linked  to  the  dominant  selectable  marker  
for  geneticin  resistance,  KanMX4.  Diploids  were  selected  and  sporulation  was  induced.  
Haploid   spore   progeny   were   transferred   to   synthetic  medium   lacking   histidine,   which  
allowed  for  selective  germination  of  MATa  cells.  Following  two  rounds  of  selection  in  His-­  
synthetic   medium,   double   mutant   MATa   progeny   were   selected   in   Ura-­   medium  
supplemented  with  geneticin.  Independent  confirmation  of  synthetic  lethality  was  carried  
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out  by  tetrad  analysis  to  rule  out  false  positives  and  false  negatives  (Tong  et  al.,  2001).  
Synthetic   interaction  between  CL  and  deletion  mutants  was  determined  by  examining  
growth  of  the  double  mutant  compared  to  single  mutants  and  wild-­type  on  YPD.  
Acetyl-­CoA  determination  
Cells  were  grown  to  the  logarithmic  growth  phase  and  a  sample  (3  ml)  of  the  culture  
was  centrifuged  at  1700  g.  Pellets  were  resuspended  in  1  ml  ddH2O  and  centrifuged  for  
1  min  at  9300  g.  The  resulting  cell  pellet  was  subjected  to  cell  lysis  and  the  lysed  samples  
were  rapidly  quenched  with  130  μl  of  45:45:10  acetonitrile  /  methanol  /  H2O  +  0.1%  glacial  
acetic   acid   and   spiked   with   10   μmol   l-­1   glutaryl-­CoA   as   an   internal   standard.   The  
resuspended  extract  was  incubated  on  ice  with  intermittent  vortexing  for  15  min.  An  equal  
molar  volume  of  ammonium  hydroxide  was  added  post  incubation  to  neutralize  the  acetic  
acid,  and  each  extract  was  centrifuged  for  3  min  at  15,700  g,  transferred  to  a  new  1.5  ml  
microfuge  tube  and  centrifuged  for  5  min  at  15,700  g.  The  clarified  extract  (10  μl)  was  
injected  for  HPLC-­MS/MS  analysis  (Bennett  et  al.,  2009;;  Armando  et  al.,  2011).  
Quantitative  PCR  (qPCR)      
Cultures  (10  ml)  were  grown  to  the  logarithmic  growth  phase,  cells  were  harvested,  
and  total  RNA  was  isolated  using  the  RNeasy  Plus  mini  kit  from  Qiagen.  Complementary  
DNA   (cDNA)   was   synthesized   using   a   Transcriptor   First   Strand   cDNA   Synthesis   Kit  
(Roche   Applied   Science)   according   to   the   manufacturer’s   manuals.   qPCRs   were  
performed  in  a  25µl  volume  using  Brilliant  III  Ultra-­Faster  SYBR  Green  qPCR  Master  Mix  
(Agilent  Technologies,  Santa  Clara,  CA).  The  primers  for  qPCR  are  listed  in  Table  2.2.  
PCRs  were  initiated  at  95°C  for  10  min  for  denaturation  followed  by  40  cycles  consisting  
of  30  s  at  95°C  and  60  s  at  55°C.  RNA  levels  were  normalized  to  ACT1.  Relative  values  
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of  mRNA  transcripts  are  shown  as  fold  change  relative  to  indicated  controls.  Primer  sets  
were   validated   according   to   the   Methods   and   Applications   Guide   from   Agilent  
Technologies.  Optimal  primer  concentrations  were  determined,  and  primer  specificity  of  
a  single  product  was  monitored  by  a  melt  curve  following  the  amplification  reaction.  All  
primers  were  validated  by  measurement  of  PCR  efficiency  and  have  calculated  reaction  
efficiencies  between  95  and  105%.    
Gene  tagging,  SDS-­PAGE,  and  Western  blot  analysis  
The  C-­terminal  HA-­tagged  Pda1,  Pdb1,  Lat1,  Lpd1,  and  Pdx1  strains  were  derived  
from   the   BY4742   wild-­type   and   crd1Δ   strains   by   transforming   with   a   PCR   product  
amplified  from  pFA6-­3HA-­TRP1  (TRP  marker).  The  primers  used  for  tagging  are  listed  in  
Table  2.3.  Proteins  were  extracted  from  cells  grown  to  an  A550  of  0.5,  separated  by  8%  
SDS-­PAGE,  transferred  to  a  PVDF  membrane,  and  analyzed  using  primary  antibodies  to  
the  HA  tag  (1:1000)  and  to  a-­tubulin  (1:1000)  (Santa  Cruz  Biotechnology).  Proteins  were  
visualized  using  appropriate  secondary  antibody  conjugated  to  horseradish  peroxidase  
(1:3000)  and  detected  using  the  ECL  chemiluminescence  system  (GE  Healthcare).    
PDH  activity  
Mitochondria   were   isolated   from   cell   lysates   prepared   as   described   previously  
(Diekert  et  al.,  2001).  Briefly,  spheroplasts  created  by  lyticase  were  ruptured  by  dounce  
homogenization,   and   mitochondria   were   isolated   by   differential   centrifugation.   Total  
protein  concentration  was  determined  with  a  Bradford  assay  kit  (Pierce)  with  BSA  as  the  
standard.   The   activity   of   PDH   in   isolated   mitochondria   was   measured  
spectrophotometrically  by  determining   the  reduction  of  NAD+   to  NADH,  coupled   to   the  
reduction   of   a   reporter   dye   to   yield   a   colored   reaction   product   with   an   increase   in  
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absorbance  at  450  nm   in  kinetic  mode   for  10-­60  min.  at  37°C  (BioVision  PDH  activity  
colorimetric  assay  kit;;  Catalog  #  K679-­100).  
RESULTS  
Genome-­wide  synthetic  lethal  SGA  screen  with  crd1Δ    
Genome-­wide  synthetic  lethality  screen  was  performed  using  SGA  methodology  
by  mating   the  query  strain   (BY4742  MATα  can1Δcrd1Δ)   to   the  yeast  deletion  set  and  
selecting  double  mutants   (Tong  et   al.,   2001)   at   two  different   temperatures   (30°C  and  
37°C).   In   the   query   strain,   the   crd1Δ  mutation  was   linked   to   the   dominant   selectable  
marker  URA3  and  the  can1Δ  mutation  was  linked  to  the  reporter  construct  MFA1pr-­HIS3,  
which  is  expressed  only  in  MATa  cells.  This  strain  (MATα)  was  separately  crossed  with  
the  array  of  all  4,800  deletion  mutants  in  the  MATa  background,  in  which  the  deletion  is  
linked   to   the  dominant   selectable  marker   for  geneticin   resistance,  KanMX.  The  MATα  
strain  was  lys-­  met+,  and  the  MATa  strain  was  met-­  lys+.  Diploids  were  selected  on  plates  
lacking  both  lysine  and  methionine,  and  sporulation  was  induced.  Haploid  spore  progeny  
were   transferred   to   synthetic   medium   lacking   histidine,   which   allows   for   selective  
germination   of  MATa   cells.   Following   two   rounds   of   selection,   the  MATa   cells   were  
transferred  to  medium  lacking  uracil  and  containing  geneticin.  Synthetic  interaction  was  
indicated  by  decreased  growth  of   the  haploid  progeny.  As  expected,   the  SGA  screen  
identified   a   large   number   of   synthetic   interactions   that   include   105   potential   synthetic  
lethal   interactions   at   30°C   and   65   potential   lethal   interactions   at   37°C.   These   were  
grouped  based  on  biological  function  (Fig.  2.1A,  Tables  2.4  and  2.5).    
The   screen   identified   mutants   previously   shown   to   be   synthetically   lethal   with  
crd1Δ,  including  psd1Δ  (Gohil  et  al.,  2005),  tom5Δ  (Gebert  et  al.,  2009),  and  get3Δ  (Joshi  
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et   al.,   2016).   Synthetic   lethal   mutants   were   also   identified   in   two   cellular   functions  
previously   shown   to   require   CL,   including   cell   wall   biogenesis   and   Fe-­S   biogenesis.  
Synthetic  lethality  with  PDH  identified  a  new  role  of  CL  in  energy  metabolism.  
a.  Cell  wall  biogenesis:  The  SGA  screen   identified  genes   involved   in  cell  wall  
biogenesis,  a  process  that  was  previously  shown  to  require  a  functional  CL  pathway  (Fig.  
2.1B).  CL  mutants  exhibit  temperature-­sensitive  growth  that  is  associated  with  defects  in  
the  cell  wall  and  vacuole  (Zhong  et  al.,  2005;;  Zhong  et  al.,  2007;;  Chen  et  al.,  2008b).  
Zhong  et  al.  (2007)  showed  that  the  PKC-­Slt2  cell  integrity  pathway  and  glucan  synthase  
activity  require  the  synthesis  of  mitochondrial  phospholipids  PG  and/or  CL.  pgs1Δ  cells,  
which  are  blocked  in  the  first  step  of  CL  synthesis,  have  reduced  glucan  synthase  activity  
and  a  decreased  glucan   synthase   catalytic   subunit.   In   addition,   activation  of  Slt2,   the  
downstream  effector  of   the  PKC-­activated  cell   integrity  pathway  was  defective.   In   this  
light,  it  was  interesting  that  the  SGA  screen  identified  KRE6,  which  encodes  an  integral  
membrane  protein  required  for  b-­1,6  glucan  biosynthesis  (Roemer  and  Bussey,  1991).  
Disruption  of  KRE6  results  in  perturbation  of  cell  wall  biogenesis  and  decreased  growth  
on   fermentable   carbon   source.   Mutants   of   other   genes   involved   in   the   cell   integrity  
pathway  were  identified  in  the  screen,  including  MSG5,  PIR3,  RHO2,  ROM2,  and  UTR2.  
b.  Mitochondrial  processes:  The  synthetic  lethality  screen  identified  mutants  in  
mitochondrial  processes  that  have  been  shown  to  required  CL  (Fig.  2.1B).  These  include  
ISA1,   ISA2   and   SSQ1   in   Fe-­S   biogenesis,   and   SOD2   and   GRX5   required   for  
oxidoreductase   activity.   Previous   studies   indicated   that   the   loss   of   CL   leads   to  
perturbation  of  mitochondrial  and  cellular  iron  homeostasis  (Patil  et  al.,  2013).  ISA1  and  
ISA2  encode  a  protein  required  for  maturation  of  mitochondrial  Fe-­S  proteins.  GRX5  and  
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SSQ1  encode  a  protein  required  for  assembly  of  Fe-­S  clusters.  These  findings  support  a  
role  for  CL  in  Fe-­S  cluster  formation  and/or  transfer  of  Fe-­S  clusters  to  apoprotein.  crd1Δ  
was   also   synthetically   lethal   with   a   mutant   in   SOD2,   which   codes   for   mitochondrial  
manganese  superoxide  dismutase,  an  enzyme  that  protects  cells  against  oxygen  toxicity  
(Saffi  et  al.,  2006;;  van  Loon  AP  et  al.,  1986).  Disruption  of  SOD2  leads  to  lethality  due  to  
the   accumulation   of   free   radicals.   It   is   likely   that   the   crd1Δ   mutant   accumulates   free  
radicals  due  to  defects  in  mitochondrial  respiration  (Chen  et  al.,  2008a).  Therefore,  SOD2  
may  play  a  pivotal  role  in  scavenging  free  radicals  in  crd1Δ.  
Loss  of  CL  leads  to  decreased  acetyl-­CoA  synthesis    
The  SGA  screen  revealed  that  crd1Δ   is  synthetically  lethal  with  pdb1Δ  (the  E1b  
subunit   of   PDH),   as   shown   in   Fig.   2.2A.   This   finding   was   especially   interesting   as   it  
suggested   for   the   first   time   that  CL  may   play   a   role   in   the   synthesis   of   acetyl-­CoA.   I  
screened   all   mutants   of   the   PDH   complex   for   synthetic   lethality   with   crd1Δ.   In   S.  
cerevisiae,  PDH  is  an  ~8  MDa  multi  enzyme  complex  (Uhlinger  et  al.,  1986)  consisting  of  
multiple   copies   of   three   enzymes:   pyruvate   dehydrogenase   (E1)   (Pda1p,   and  Pdb1p)  
(Steensma   et   al.,   1990;;   Miran   et   al.,   1993),   dihydrolipoamide   acetyltransferase   (E2)  
(Lat1p)  (Niu  et  al.,  1988),  and  dihydrolipoamide  dehydrogenase  (E3)  (Lpd1p)  (Dickinson  
et  al.,  1986).  A  fourth  component,  protein  X  (Pdx1p),  does  not  appear  to  have  a  catalytic  
function  but  is  probably  involved  in  assembly  of  the  complex  (Lawson  et  al.,  1991).  The  
double  mutants  were  checked  for  growth  at  elevated  temperatures.  The  crd1Δ  mutant  in  
this  genetic  background  (BY4741)  can  grow  at  37°C  but  not  at  39°C.  With  the  exception  
of  E3,  all  PDH  mutants  were  synthetically  lethal  with  crd1Δ,  including  mutants  of  E1  &  E2  
subunits   and   protein   X   of   the   PDH   complex   (Fig.   2.2B).   Because   acetyl-­CoA   levels  
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depend  primarily  on  pyruvate  utilization  by  PDH  in  the  mitochondria  and  PDH-­bypass  in  
the  cytosol,  decreased  growth  of  the  double  mutants  suggested  that  crd1Δ  cells  exhibit  
defective  synthesis  of  acetyl-­CoA.  
Acetyl-­CoA  levels  were  measured  in  wild-­type  and  crd1Δ  cells  at  optimal  (30°C)  
and  elevated  (35°C,  37°C,  and  39°C)  temperatures.  The  acetyl-­CoA  levels  in  crd1Δ  were  
decreased  at  elevated  temperature  relative  to  those  in  wild-­type  cells.  At  39°C,  an  80%  
reduction  was  observed  in  crd1Δ  cells  (Fig.  2.3).  Previous  studies  reported  that  the  PDH-­
bypass   pathway   predominates   over   the   PDH   pathway   during   fermentative   growth  
(Boubekeur   et   al.,1999;;   Ciriacy,   1975;;   Paquin   and   Williamson,   1986;;   Briquet,   1977;;  
Nalecz   et   al.,   1991;;   Johnston,   1999),   suggesting   that   decreased   acetyl-­CoA   levels   in  
crd1Δ  cells  is  likely  due  to  perturbation  of  this  pathway.    
PDH-­bypass  deficiencies  in  crd1Δ    
The   PDH-­bypass   pathway,   which   converts   pyruvate   to   acetyl-­CoA   during  
fermentative   growth,   occurs   predominantly   in   the   cytosol.   Pyruvate   decarboxylase  
decarboxylates  pyruvate  to  acetaldehyde,  which  is  converted  to  acetate  by  acetaldehyde  
dehydrogenase.   The   conversion   of   acetate   to   acetyl-­CoA   is   catalyzed   by   acetyl-­CoA  
synthetase  (Pronk  et  al.,  1996;;  Dickinson,  1996;;  Van  den  Berg  et  al.,  1995;;  Meaden  et  
al.,  1997;;  Van  den  Berg  et  al.,  1996).  I  explored  the  possibility  that  decreased  acetyl-­CoA  
levels  in  the  crd1Δ  mutant  resulted  from  perturbation  of  the  PDH-­bypass.  Defects  in  this  
pathway  cause  decreased  growth  on  medium  containing  acetate  as  a  sole  carbon  source,  
because  the  last  step  of  the  PDH-­bypass  is  the  conversion  of  acetate  to  acetyl-­CoA  (De  
Virgilio  et  al.,  1992;;  Remize  et  al.,  2000;;  Boubekeur  et  al.,  1999;;  Kozak  et  al.,  2014).  On  
acetate  medium,  crd1Δ  cells  exhibited  decreased  growth  (Fig.  2.4A)  and  an   increased  
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doubling  time  (Fig.  2.4B).  Decreased  growth  on  acetate  suggested  that  acetyl-­CoA  levels  
might   be   decreased.   In   agreement  with   this,   crd1Δ   cells   exhibited   ~50%  decrease   in  
acetyl-­CoA  levels  in  these  growth  condition  (Fig.  2.5).  
PDH  and  PDH-­bypass  null  mutants  are  viable,  which  suggests  that  either  pathway  
is  sufficient  to  synthesize  acetyl-­CoA  in  CL-­deficient  cells.  If  CL  is  required  for  synthesis  
of  acetyl-­CoA  in  the  cytosol  by  the  PDH-­bypass,  further  perturbation  of  PDH-­bypass  is  
not   expected   to   exacerbate   growth   of  crd1Δ   cells.   To   test   this   prediction,   I   examined  
genetic   interaction   between   crd1Δ   and  mutants   in   acetyl-­CoA   synthetase   (ACS1   and  
ACS2).   In  agreement  with  the  prediction,  acs1Δ  and  acs2Δ  did  not   interact  genetically  
with  crd1Δ  (Fig.  2.6).  
Published  studies  have  shown  that  cells  compensate  for  a  defective  PDH-­bypass  
by  up-­regulating  PDH  gene  expression  and  increasing  protein  levels  (Boubekeur  et  al.,  
1999;;  Kozak  et  al.,  2014;;  Wei  et  al.,  2009;;  Avidan  and  Pick,  2015).  The  crd1Δ  mutant  
exhibited  more  than  2-­fold   increased  PDH  gene  mRNA  levels,   including  PDA1,  PDB1,  
LAT1,  LPD1,  and  PDX1  (Fig.  2.7A).  Protein  levels  of  PDB1,  LAT1,  LPD1,  and  PDX1  were  
also  elevated  in  crd1Δ  cells,  although  levels  of  PDA1  were  not  (Fig.  2.7B).  However,  in  
spite  of  increased  mRNA  and  protein  levels,  the  specific  activity  of  PDH  was  not  increased  
in  the  crd1Δ  mutant  (Fig.  2.8).  As  CL  is  required  for  mitochondrial  protein  import  (Jiang  et  
al.,   2000;;   Gebert   et   al.,   2009)   and   association   of   mitochondrial   matrix   proteins   with  
mitochondrial  membrane  (Campuzano  et  al.,  1997),  it  is  possible  that  CL  deficiency  may  
account   for   decreased   specific   activity   of   PDH.   Taken   together,   these   experiments  
indicate  that  CL-­deficient  cells  have  a  decreased  ability  to  convert  acetate  to  acetyl-­CoA  







FIGURE  2.1.  Functional  classification  of  genes  exhibiting  synthetic   lethality  with  
crd1Δ.  (A)  Synthetic  lethal  interactions  identified  by  the  SGA  were  classified  by  biological  
process,  based  on  gene  ontology.  (B)  Synthetic  lethal  partners  of  crd1Δ  identified  eight  


















FIGURE   2.2.  Genetic   interaction   of   PDH  mutants  with  crd1Δ.   (A)   Cells   were   pre-­
cultured  in  YPD  overnight,  serially  diluted,  plated  on  YNBD,  and  incubated  at  30°C  and  
37°C   for   3-­5   days.   (B)   Synthetic   interaction   between   CRD1   and   PDH   mutants   was  
determined  by  examining  growth  of   the  double  mutant   compared   to   isogenic  parental  















FIGURE  2.3.  Decreased  acetyl-­CoA  levels  in  crd1Δ  cells.  Wild-­type  and  crd1Δ  cells  
were  grown  at  the  indicated  temperatures  in  YPD  until  cells  reach  an  A550  of  1.  Cells  
were  pelleted  and  acetyl-­CoA  was  extracted  using  glutaryl-­CoA  as  an  internal  standard.  
The  clarified  extract  (10  μl)  was  analyzed  by  HPLC-­MS/MS.  Data  shown  are  mean  ±  
S.E.  (n  =  6)  (*p<0.05,  **p<0.01).  (Mass  spectrometry  was  carried  out  by  Krishna  Rao  














                                                 
FIGURE  2.4.  Decreased  growth  of  crd1Δ  cells  on  acetate.  (A)  Cells  were  pre-­cultured  
overnight   in  YNBD  and  serially  diluted,  plated  on  YNBD  and  YNBA,  and   incubated  at  
30°C  for  3-­5  days.  (B)  Growth  in  liquid  YNBA  was  determined  by  measuring  A550.  The  
















FIGURE  2.5.  Decreased  acetyl-­CoA  levels  in  crd1Δ  cells  grown  on  acetate.  Acetyl-­
CoA  levels  in  wild-­type  and  crd1Δ  cells  grown  in  YNBA  was  determined  as  described  in  
“Methods  and  Materials”.  Data  shown  are  mean  ±  S.E.  (n  =  6)  (**p<0.01).  Data  shown  
are  mean  ±  S.E.  (n  =  3).  (Mass  spectrometry  was  carried  out  by  Krishna  Rao  Maddipati,  


















FIGURE   2.6.   crd1Δ   and   acetyl-­CoA   synthetase   mutants   do   not   exhibit   genetic  
interaction.  Cells  were  pre-­cultured  in  YPD  overnight,  serially  diluted,  plated  on  YNBD,  
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FIGURE  2.7.  Increased  expression  and  protein  levels  of  PDH  subunits  in  crd1Δ.  (A)  
The  mRNA  levels  of  PDH  genes  from  cells  grown  in  YPD  at  30°C  to  the  logarithmic  phase  
were  quantified  by  qPCR.  Values  are  reported  as  fold  change  in  expression  over  wild-­
type.  Expression  was  normalized  to  the  mRNA  levels  of  the  internal  control  ACT1.  Data  
shown  are  mean  ±  SE  (n=6).  (B)  Wild-­type  and  crd1Δ  cells  expressing  the  indicated  HA-­
tagged  genes  were  cultured  in  YPD  to  the  mid-­logarithmic  phase  (A550  of  0.5)  at  30°C  and  
cell   lysates  were   prepared.   Anti-­HA   antibody  was   used   to   detect   HA-­tagged   proteins  
using  Western  blot  analysis.  50  μg  of  total  protein  was  loaded  for  each  sample,  and  α-­
tubulin  was  used  as  an  internal  control.  The  levels  of  PDH  protein  were  quantified  using  



















FIGURE  2.8.  PDH  activity  is  not  altered  in  crd1Δ  cells.  Wild-­type  and  crd1D  cells  were  
grown  in  YPD  at  30°C  to  the  logarithmic  phase  and  activity  was  calculated  in  mitochondria  
prepared  from  wild-­type  and  crd1D  cells  (10  µg).  PDH  activity  (mU/mg)  or  (nmol/min/ml)  
were  assayed  as  described  in  the  “Materials  and  Methods”.  One  unit  of  PDH  is  the  amount  
of  enzyme  that  generates  1.0  µmol  of  NADH  per  min.  at  pH  7.5  at  37°C.  Data  shown  are  

















In   this   study,   I   carried   out   a   genome-­wide   genetic   screen   to   identify   cellular  
processes  that  require  CL.  The  most  striking  finding  was  synthetic  lethality  between  crd1Δ  
and   PDH  mutants.   Subsequent   experiments   revealed   that   acetyl-­CoA   synthesis   was  
perturbed  in  CL-­deficient  cells.  The  mechanism  underlying  this  defect  is  perturbation  of  
the   PDH-­bypass,   as   crd1Δ   cells   exhibit   decreased   acetyl-­CoA   levels   and   decreased  
growth   on   acetate   as   sole   carbon   source.   The   screen   also   identified   synthetic   lethal  
interactions  that  support  a  role  for  CL  in  cell  wall  biogenesis  and  mitochondrial  processes  
previously  shown  to  require  CL.  
How  does  CL   deficiency   cause   perturbation   of   the  PDH-­bypass   pathway?  The  
PDH-­bypass  pathway  converts  acetate  to  acetyl-­CoA  in  the  cytosol  during  fermentative  
growth.   Indeed,   I   found   that,   compared   to   WT,   crd1D   cells   grew   poorly   on   medium  
containing  acetate  as  a  sole  carbon  source  and  exhibited  decreased  acetyl-­CoA  levels.  
The  most   likely   defect   is   in   acetyl-­CoA   synthetase   (ACS1   and  ACS2),   as   deletion   of  
acetyl-­CoA  synthetase  does  not  exacerbate  growth  of  crd1D.  Several  possibilities  may  
account  for  the  hypothesized  decreased  acetyl-­CoA  synthetase  activity  in  the  CL  mutant.  
Acetyl-­CoA   synthetase   may   require   CL   for   activation   or   stability,   as   the   enzyme   is  
localized  in  the  outer  mitochondrial  membrane  and  may  this  interact  with  CL  (Fujino  et  
al.,   2001).   It   is   also   possible   that   import   of   the   protein   into   mitochondria   may   be  
decreased,  as  cells  lacking  CL  exhibit  decreased  mitochondrial  protein  import  (Jiang  et  
al.,   2000;;  Gebert   et   al.,   2009).  Another   possibility   is   that  mRNA  and  protein   levels   of  
acetyl-­CoA  synthetase  may  be  decreased.  
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Based  on  these  results,  I  propose  the  following  model  to  account  for  decreased  
acetyl-­CoA   synthesis   in   crd1Δ   (Fig.   2.9).   The   two   common   routes   for   acetyl-­CoA  
synthesis   are   through  direct   conversion   of   pyruvate,   either   by   the  PDH-­bypass   under  
fermentative  conditions  (Shiba  et  al.,  2007)  or  PDH  under  respiratory  conditions  (Guest  
et   al.,   1989).  These   routes  complement  each  other  when  either  pathway   is  defective.  
Under  fermentative  conditions,  CL-­deficient  cells  cannot  convert  acetate  to  acetyl-­CoA,  
resulting  in  decreased  acetyl-­CoA  levels.  The  cellular  response  to  decreased  acetyl-­CoA  
in  crd1Δ   is   increased  PDH  gene  expression  and  protein  synthesis.  However,   in  crd1Δ  
cells  PDH  enzyme  activity  is  not  increased,  and  acetyl-­CoA  levels  are  decreased.    
The   SGA   screen   also   provided   additional   support   for   the   role   of   CL   in   Fe-­S  
biogenesis   and   cell  wall   synthesis.  Patil   et   al.   (2013)   showed   that  crd1Δ   cells   exhibit  
defective  Fe-­S  biogenesis  resulting  in  perturbation  of  iron  homeostasis.  Defective  Fe-­S  
biogenesis  leads  to  decreased  activity  of  Fe-­S  enzymes,  including  TCA  cycle  enzymes  
aconitase  and  succinate  dehydrogenase,  which  in  turn  perturbs  the  TCA  cycle.  This  study  
identified   genes   that   are   involved   in   assembly   of   the   Fe-­S   cluster   and  maturation   of  
mitochondrial   Fe-­S   proteins.   These   findings   further   support   a   role   of   CL   in   Fe-­S  
biogenesis.  The  CL  pathway  was  also  shown  to  be  required  for  cell  wall  synthesis  (Zhong  
et   al.,   2007).   The   cell   wall   integrity   mitogen-­activated   protein   kinases   Slt2   is   not  
phosphorylated  in  the  pgs1Δ  mutant.  Perturbation  of  the  PKC  pathway  in  pgs1Δ  leads  to  
the  breakdown  of  glucan  and  chitin  in  the  cell  wall.  The  current  study  identified  the  cell  
wall  biogenesis  gene  KRE6  as  synthetically  lethal  with  crd1Δ,  further  supporting  the  role  


















FIGURE   2.9.   Model:   Perturbation   of   acetyl-­CoA   synthesis   in   crd1Δ   cells.   In   the  
proposed  model,  loss  of  CL  leads  to  decreased  conversion  of  acetate  to  acetyl-­CoA  by  
acetyl-­CoA  synthetase.  To  compensate   for   this,  PDH  gene  expression   is  up-­regulated  










How  is  the  role  of  CL  in  acetyl-­CoA  synthesis  relevant  to  BTHS  and  other  cardiac  
disorders?   Acetyl-­CoA   interconnects   metabolic   pathways   that   are   crucial   for   cardiac  
energy  metabolism   (Abo   Alrob   and   Lopaschuk,   2014).   Mutations   in   the   human   E1-­α  
subunit   of   the   PDH   complex,   which   is   homologous   to   yeast   PDA1,   leads   to   Leigh's  
syndrome,   which   is   characterized   by   hypertrophic   cardiomyopathy   among   other  
phenotypes  (Stacpoole  et  al.,  1997;;  Fyer  et  al.,  2008).  Mutations  in  mitochondrial  acetyl-­
CoA  synthetase  (AceCS1  and  AceCS2)  impair  acetyl-­CoA  synthesis  and  induce  cardiac  
hypertrophy  (Ellis  et  al.,  2011;;  Fujino  et  al.,  2001).  Cardiomyopathy  and  heart  failure  are  
generally  caused  by  depletion  of  cardiomyocyte  ATP  and  impaired  energy  homeostasis  
(Ingwall,  2009;;  Neubauer,  2007).  Elucidating  the  role  of  CL  in  acetyl-­CoA  synthesis  may  
shed  light  on  the  wide  disparities  in  clinical  phenotypes  observed  in  patients  with  BTHS  






























Source  or  Ref.  
  
Y5563   MATα,  his3Δ1,  leu2Δ0,  ura3Δ0,  met15Δ0,  
LYS2+,  lyp1Δ,  can1Δ::MFA1pr-­HIS3  
Tong  et  al.,  2001  
BY4741   MATα,  his3Δ1,  leu2Δ0,  ura3Δ0,  met15Δ0   Invitrogen  
BY4742   MATα,  his3Δ1,  leu2Δ0,  ura3Δ0,  lys2Δ0   Invitrogen  
crd1Δcan1Δ   MATα,  his3Δ1,  leu2Δ0,  lys2Δ0,  crd1Δ::URA3,  
can1Δ::MFA1pr-­HIS3  
This  study  
VGY1   MATα,  his3Δ1,  leu2Δ0,  lys2Δ0,  ura3Δ0,    
crd1Δ::URA3  
Gohil  et  al.,  2005  
CG922-­a   MATa,  lys2-­801,  ade2-­101,  trp1Δ1,  his3Δ200,  
leu2Δ1,  crd1Δ::URA3  
Invitrogen  
CG923-­α   MATα,  lys2-­801,  ade2-­101,  trp1Δ1,  his3Δ200,  
leu2Δ1,  crd1Δ::URA3  
Invitrogen  
pda1Δ   MATa,  his3Δ1,  leu2Δ0,  met15Δ0,  ura3Δ0,    
pda1Δ::KanMX4  
Invitrogen  
pdb1Δ   MATa,  his3Δ1,  leu2Δ0,  met15Δ0,  ura3Δ0,    
pdb1Δ::KanMX4  
Invitrogen  
lat1Δ   MATa,  his3Δ1,  leu2Δ0,  met15Δ0,  ura3Δ0,    
lat1Δ::KanMX4  
Invitrogen  





pdx1Δ   MATa,  his3Δ1,  leu2Δ0,  met15Δ0,  ura3Δ0,    
pdx1Δ::KanMX4  
Invitrogen  
acs1Δ   MATa,  his3Δ1,  leu2Δ0,  met15Δ0,  ura3Δ0,    
acs1Δ::KanMX4  
Invitrogen  
acs2Δ   MATa,  his3Δ1,  leu2Δ0,  met15Δ0,  ura3Δ0,    
acs2Δ::KanMX4  
Invitrogen  
pda1Δcrd1Δ   MATa,  his3Δ1,  leu2Δ0,  met15Δ0,  ura3Δ0,    
pda1Δ::KanMX4,  crd1Δ::KanMX4  
This  study  
pdb1Δcrd1Δ   MATa,  his3Δ1,  leu2Δ0,  met15Δ0,  ura3Δ0,    
pdb1Δ::KanMX4,  crd1Δ::KanMX4  
This  study  
lat1Δcrd1Δ   MATa,  his3Δ1,  leu2Δ0,  met15Δ0,  ura3Δ0,    
lat1Δ::KanMX4,  crd1Δ::KanMX4  
This  study  
lpd1Δcrd1Δ   MATa,  his3Δ1,  leu2Δ0,  met15Δ0,  ura3Δ0,    
lpd1Δ::KanMX4,  crd1Δ::KanMX4  
This  study  
pdx1Δcrd1Δ   MATa,  his3Δ1,  leu2Δ0,  met15Δ0,  ura3Δ0,    
pdx1Δ::KanMX4,  crd1Δ::KanMX4  
This  study  
acs1Δcrd1Δ   MATa,  his3Δ1,  leu2Δ0,  met15Δ0,  ura3Δ0,    
acs1Δ::KanMX4,  crd1Δ::KanMX4  
This  study  

















ACT1	   Forward                            ACGTTCCAGCCTTCTACGTTTCCA  
Reverse                            CGTGAGTAACACCATCACCGGAA  
	  
PDA1	   Forward                            ATTGATGGGTAGAAGAGCCGGTGT  
Reverse                            AGGCGTCCTCGTTCTTGTATTGGT  
	  
PDB1   Forward                            TCCCATCATTTGGTGTTGGTGCTG  
Reverse                            TGGAACATCGGCACCAGTAACTCT  
	  
LAT1   Forward                            AGGAACTAGTCAAGCGTGCCAGAA  
Reverse                            TCCACAGCGACCCTTTCAACAGTA  
	  
LPD1   Forward                            AGAGCCAAGACCAACCAAGACACT  
Reverse                            CATTTCACCGGCATTTGGACCGAT  
	  
PDX1   Forward                            GCAGCCAAGCCAATCTTGAACAGA  






























TABLE  2.3.    Primers  used  for  C-­terminal  tagging  of  proteins.  
5`  F2-­pda1-­HA-­tag   TCCCTGAAGATACTTGGGACTTCAAAAAGCAAGGTT
TTGCCTCTAGGGAT  CGGATCCCCGGGTTAATTAA  


































5’  Forward  HA  tag  
  
CGGATCCCCGGGTTAATTAA  













TABLE  2.4.  Synthetic   interaction  with  crd1Δ  at  30°C.  Summary  of   the   list  of  genes  
identified  as  synthetically  lethal  with  the  crd1Δ  mutant  at  30°C.  The  identified  genes  are  








Molecular  function  unknown   19  out  of  105  
genes,18.1%  
ERP2,  ERP1,  VBA4,  NBP2,  MIT1,  
RMD6,  HMF1,  CGR1,  SOH1,  
MDS3,  EMC5,  HOS4,  RAX2,  
SPH1,  NKP2,  ESC8,  APM4,  
SGO1,  TCO89  
Hydrolase  activity   15  out  of  105  
genes,14.3%  
RRT12,  DYN2,  BNA7,  PTC2,  
RSR1,  VMA16,  MYO3,  OCT1,  
DBR1,  DNM1,  ELP6,  MSG5,  
RHO2,  ARL3,  KRE6  
Transferase  activity   13  out  of  105  
genes,12.4%  
SAS4,  BUD16,  UTR2,  GUP1,  
NMA2,  KTR7,  TPK3,  RTT109,  
RCK2,  KTR5,  MET2,  MUM3  
Structural  molecule  activity   11  out  of  105  
genes,10.5%  
RPL21A,  IMG2,  STE5,  RSM24,  
RPL22B,  CHC1,  CLC1,  RPL27A,  
PIR3,  RPS12,  RTC6  
Ion  binding   10  out  of  105  
genes,  9.5%  
SHS1,  BMH2,  STE5,  GIC2,  RTF1,  
ATG27,  ISA1,  ROM2,  ISA2  
Structural  constituent  of  
ribosome  
7  out  of  105  
genes,  6.7%  
RPL21A,  IMG2,  RSM24,  RPL22B,  





7  out  of  105  
genes,  6.7%  
FCY22,  VPS73,  VMA16,  JEN1,  
COX7,  YVC1,  TOM5  
RNA  binding   7  out  of  105  
genes,  6.7%  
SRO9,  RMD9,  RTF1,  RIM4,  ELP6,  
THP1,  CBC2  
Oxidoreductase  activity   6  out  of  105  
genes,  5.7%  
SDH4,  ERG4,  SOD2,  COX7,  
GRX5  
DNA  binding   6  out  of  105  
genes,  5.7%  
RRN10,  BMH2,  ECM22,  THP1,  
TYE7,  DIG1  
Lipid  binding   6  out  of  105  
genes,  5.7%  
RVS161,  STE5,  GIC2,  ATG27,  
ROM2,  TCB1  
GTPase  activity   4  out  of  105  
genes,  3.8%  
RSR1,  DNM1,  RHO2,  ARL3  
mRNA  binding,    
peptidase  activity  
4  out  of  105  
genes,  3.8%  
SRO9,  RMD9,  RRT12,  OCT1  
ATPase  activity,  signal  
transducer  activity  
4  out  of  105  
genes,  3.8%  
VMA16,  ELP6,  RSR1,  ROM2  
Cytoskeletal  protein  binding   3  out  of  105  
genes,  2.9%  
RVS161,  BUD6,  TPM1  
Enzyme  regulator  activity   3  out  of  105  
genes,  2.9%  
GIC2,  BUD6,  IRA2  
Small  conjugating  protein  
binding  
3  out  of  105  
genes,  2.9%  
SLA1,  STP22,  VPS36  
	  	  
51	  
Kinase  activity   3  out  of  105  
genes,  2.9%  
BUD16,  TPK3,  RCK2  
Protein  binding  transcription  
factor  activity  
3  out  of  105  
genes,  2.9%  
SSN2,  RTF1,  STB1  
Nucleic  acid  binding  
transcription  factor  activity  
3  out  of  105  
genes,  2.9%  
RRN10,  ECM22,  TYE7  
Lyase  activity   3  out  of  105  
genes,  2.9%  
ARO10,  ENO1,  PSD1  
Transferase  activity,  
transferring  glycosyl  groups  
3  out  of  105  
genes,  2.9%  
UTR2,  KTR7,  KTR5  
Transcription  factor  binding   2  out  of  105  
genes,  1.9%  
STB1,  DIG1  
Phosphatase  activity   2  out  of  105  
genes,  1.9%  
PTC2,  MSG5  
Nuclease  activity,  Ligase  
activity  
2  out  of  105  
genes,  1.9%  
DBR1,  ARG1  
Enzyme  binding,  Chromatin  
binding  
2  out  of  105  
genes,  1.9%  
GIC2,  TOS4  
Hydrolase  activity,  acting  on  
glycosyl  bonds  
1  out  of  105  
genes,  1%  
KRE6  










1  out  of  105  
genes,  1%  
NMA2  





































TABLE  2.5.  Synthetic   interaction  with  crd1Δ  at  37°C.  Summary  of   the   list  of  genes  
identified  as  synthetically  lethal  with  the  crd1Δ  mutant  at  37°C.  The  identified  genes  are  









Molecular  function  unknown   24  out  of  65  
genes,  36.9%  
DEP1,  PRM9,  FIG2,  HBT1,  
RTN1,  PMP3,  RAD34,  EAF1,  
ITC1,  EMP24,  OST5,  TED1,  
MAD2,  ABM1,  BUD28,  COQ9,  
REC102,  PAU4,  AIM34,  
MDM12,  MAM3,  TMA16,  
PRM3,  NCA2  
Transferase  activity   14  out  of  65  
genes,  21.5%  
DPB3,  GRX1,  SAT4,  PAA1,  
DBF2,  MET14,  ELM1,  TGL4,  
ERG6,  GTO3,  PSK2,  PSH1,  
TUM1,  NAT5  
Kinase  activity   5  out  of  65  
genes,  7.7%  
SAT4,  DBF2,  MET14,  ELM1,  
PSK2  
Oxidoreductase  activity   4  out  of  65  
genes,  6.2%  
PDB1,  GRX1,  TSA1,  GCY1  
Hydrolase  activity   4  out  of  65  
genes,  6.2%  
GET3,  TIF2,  CPS1,  TGL4  
RNA  binding   4  out  of  65  
genes,  6.2%  
EFT2,  TIF2,  GCY1,  LEO1  
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Structural  constituent  of  
ribosome  
3  out  of  65  
genes,  4.6%  
RPL27A,  RPS24B,  RPS4A  
DNA  binding   3  out  of  65  
genes,  4.6%  
DPB3,  BDF2,  MIG2  
Lipid  binding   3  out  of  65  
genes,  4.6%  
SWH1,  TCB2,  YPR097W  
Transcription  factor  binding   3  out  of  65  
genes,  4.6%  
BDF2,  GAL80,  SIN4  
Structural  molecule  activity   3  out  of  65  
genes,  4.6%  
RPL27A,  RPS24B,  RPS4A  
Ion  binding   3  out  of  65  
genes,  4.6%  
SWH1,  LEO1,  YPR097W  
Translation  factor  activity,  
nucleic  acid  binding  
2  out  of  65  
genes,  3.1%  
EFT2,  TIF2  
Enzyme  regulator  activity   2  out  of  65  
genes,  3.1%  
GAL80,  CLN2  





2  out  of  65  
genes,  3.1%  
FLC2,  HUT1  
mRNA  binding,  peptidase  
activity  





Protein  transporter  activity,    
protein  binding  transcription  
2  out  of  65  
genes,  3.1%  
KAP114,  LEO1  
Nucleic  acid  binding  
transcription  factor  activity,    
nucleotidyl  transferase  activity  
2  out  of  65  
genes,  3.1%  
MIG2,  DPB3  




histone  binding    
2  out  of  65  
genes,  3.1%  
ERG6,  BDF2  
Helicase  activity   1  out  of  65  
genes,  1.5%  
TIF2  
Small  conjugating  protein  
binding  
1  out  of  65  
genes,  1.5%  
GGA1  
Protein  binding  transcription  
factor  activity  
1  out  of  65  
genes,  1.5%  
LEO1  
Protein  binding,  bridging   1  out  of  65  
genes,  1.5%  
INP1  












TABLE  2.6.  Genes  identified  by  SGA  as  synthetically  lethal  with  crd1Δ  at  30°C.    





SGD  Gene  description  
APM4   Mu2-­like  subunit  of  the  clathrin  associated  protein  complex  (AP-­2)  
ARG1   Arginosuccinate  synthetase  
ARL3   GTPase  of  the  Ras  superfamily  required  recruiting  Arl1p    
ARO10   Phenylpyruvate  decarboxylase  
ATG27   Type  I  membrane  protein  involved  in  autophagy    
BMH2   14-­3-­3  protein,  minor  isoform  
BNA7   Formylkynurenine  formamidase  
BUD1   Protein  kinase  that  forms  a  complex  with  Mad1p  and  Bub3p    
BUD16   Putative  pyridoxal  kinase  
BUD20   Protein  involved  in  bud-­site  selection  
BUD6   Actin-­  and  formin-­interacting  protein  
CBC2   Small  subunit  of  the  heterodimeric  cap  binding  complex    
CGR1   Protein  involved  in  nucleolar  integrity  and  processing  
CHC1   Clathrin  heavy  chain  
CLC1   Clathrin  light  chain  
COX7   Subunit  VII  of  cytochrome  c  oxidase  
DBR1   RNA  lariat  debranching  enzyme  
DIG1   Regulatory  protein  of  unknown  function  
DNM1   Dynamin-­related  GTPase  required  for  mitochondrial  fission  
DYN2   Cytoplasmic  light  chain  dynein,  microtubule  motor  protein  
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ECM22   Sterol  regulatory  element  binding  protein  
ELP6   Subunit  of  Elongator  complex  
ENO1   Enolase  I,  a  phosphopyruvate  hydratase    
ERG4   C-­24  (28)  sterol  reductase  
ERP1   Involved  in  ER  to  Golgi  transport  and  localized  to  COPII  vesicles    
ERP2   Involved  in  ER  to  Golgi  transport  and  localized  to  COPII  vesicles  
ESBP6   Protein  with  similarity  to  monocarboxylate  permeases  
ESC8   Protein  involved  in  telomeric  and  mating-­type  locus  silencing  
FCY22   Putative  purine-­cytosine  permease  
GIC2   Redundant  rho-­like  GTPase  Cdc42p  effector  
GRX5   Hydroperoxide  and  superoxide-­radical    
GUP1   Plasma  membrane  protein  involved  in  remodeling  GPI  anchors  
HMF1   Member  of  the  p14.5  protein  family  with  similarity  to  Mmf1p  
HOS4   Subunit  of  the  Set3  complex  
IMG2   Mitochondrial  ribosomal  protein  of  the  large  subunit  
IRA2   GTPase-­activating  protein  that  negatively  regulates  RAS    
ISA1   Mitochondrial  matrix  protein  involved  in  biogenesis  iron-­sulfur  
ISA2   Protein  required  for  maturation  of  mitochondrial  and  cytosolic  
JEN1   Lactate  transporter  
KRE27   Required  for  efficient  folding  of  proteins  in  the  ER  
KRE6   Protein  required  for  beta-­1,6  glucan  biosynthesis  
KTR5   Putative  mannosyltransferase  involved  in  protein  glycosylation  
KTR7   Putative  mannosyltransferase  involved  in  protein  glycosylation  
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MDS3   Putative  component  of  the  TOR  regulatory  pathway  
MET2   L-­homoserine-­O-­acetyltransferase  
MGR1   Subunit  of  the  mitochondrial  (mt)  i-­AAA  protease  supercomplex  
MIT1   Putative  protein  with  sequence  similarity  to  gluconate  transporter    
MSG5   Dual-­specificity  protein  phosphatase  
MUM3   Similarity  to  the  tafazzins  superfamily  of  acyltransferases  
MYO3   One  of  two  type  I  myosins;;  localizes  to  actin  cortical  patches  
NBP2   Protein  involved  in  the  HOG  (high  osmolarity  glycerol)  pathway  
NKP2   Non-­essential  kinetochore  protein  
NMA2   Nicotinic  acid  mononucleotide  adenylyltransferase  
OCT1   Mitochondrial  intermediate  peptidase  
PIR3   O-­glycosylated  covalently-­bound  cell  wall  protein    
PSD1   Phosphatidylserine  decarboxylase  
PTC2   Type  2C  protein  phosphatase  
RAX2   N-­glycosylated  protein  involved  in  the  maintenance  of  bud  site  
RCK2   Protein  kinase  involved  in  the  response  to  oxidative  and  osmotic    
RHO2   Non-­essential  small  GTPase  of  the  Rho/Rac  subfamily  of  Ras-­like  
RIM4   Putative  RNA-­binding  protein    
RMD6   Protein  required  for  sporulation  
RMD9   Mitochondrial  protein  required  for  respiratory  growth  
ROM2   GDP/GTP  exchange  protein  (GEP)  for  Rho1p  and  Rho2p  
RPL21A   Protein  component  of  the  large  (60S)  ribosomal  subunit  
RPL22B   Protein  component  of  the  large  (60S)  ribosomal  subunit  
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RPL27A   Protein  component  of  the  large  (60S)  ribosomal  subunit  
RPS12   Protein  component  of  the  small  (40S)  ribosomal  subunit  
RRN10   Protein  involved  in  promoting  high  level  transcription  of  rDNA  
RRT12   Probable  subtilisin-­family  protease    
RSM24   Mitochondrial  ribosomal  protein  of  the  small  subunit  
RTC6   Homolog  of  the  prokaryotic  ribosomal  protein  L36  
RTF1   Subunit  of  the  RNA  polymerase  II-­associated  Paf1  complex  
RTT109   Histone  acetyltransferase    
RVS161   Amphiphysin-­like  lipid  raft  protein  
SAS4   Subunit  of  the  SAS  complex  (Sas2p,  Sas4p,  Sas5p  
SDH4   Membrane  anchor  subunit  of  succinate  dehydrogenase    
SGO1   Component  of  the  spindle  checkpoint  
SHS1   One  of  five  related  septins  
SLA1   Cytoskeletal  protein  binding  protein    
SOD2   Mitochondrial  superoxide  dismutase  
SOH1   Subunit  of  the  RNA  polymerase  II  mediator  complex  
SPH1   Protein  involved  in  shmoo  formation  and  bipolar  bud  site  selection  
SRO9   Cytoplasmic  RNA-­binding  protein    
SSN2   Subunit  of  the  RNA  polymerase  II  mediator  complex  
SSQ1   Mitochondrial  hsp70-­type  molecular  chaperone  
STB1   Protein  with  a  role  in  regulation  of  MBF-­specific  transcription  
STE5   Pheromone-­response  scaffold  protein  
STP22   Component  of  the  ESCRT-­I  complex  
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TCB1   Lipid-­binding  protein  
TCO89   Subunit  of  TORC1  
THP1   Nuclear  pore-­associated  protein  
TOM5   Component  of  the  TOM  (translocase  of  outer  membrane)  complex  
TOS4   Forkhead  Associated  domain  
TPK3   cAMP-­dependent  protein  kinase  catalytic  subunit  
TPM1   Major  isoform  of  tropomyosin  
TYE7   Serine-­rich  protein  that  contains  a  basic-­helix-­loop-­helix  (bHLH)    
UTR2   Chitin  transglycosylase    
VBA4   Protein  of  unknown  function  suggests  a  role  in  autophagy  
VMA16   Subunit  c''  of  the  vacuolar  ATPase  
VPS36   Component  of  the  ESCRT-­II  complex  
VPS73   Mitochondrial  protein;;  mutation  affects  vacuolar  protein  sorting  















TABLE  2.7.  Genes  identified  by  SGA  as  synthetically  lethal  with  crd1Δ  at  37°C.  





SGD  gene  description  
ABM1   Protein  of  unknown  function,  required  for  microtubule  organization  
ADE6   Formylglycinamidine-­ribonucleotide  (FGAM)-­synthetase  
BDF2   Protein  involved  in  transcription  initiation  at  promoters  
BFA2   Component  of  the  GTPase-­activating  Bfa1p-­Bub2p  complex    
BUD28   ubious  open  reading  frame  
CLN2   G1  cyclin  involved  in  regulation  of  the  cell  cycle  
COQ9   Protein  required  for  ubiquinone  biosynthesis  and  respiratory  growth  
CPS1   Vacuolar  carboxypeptidase  yscS  
DBF2   Ser/Thr  kinase  involved  in  transcription  and  stress  response  
DEP1   Transcriptional  modulator  involved  in  regulation  phospholipid    
DPB3   Third-­largest  subunit  of  DNA  polymerase  II  
DSD1   D-­serine  dehydratase  (aka  D-­serine  ammonia-­lyase  
EAF1   Component  of  the  NuA4  histone  acetyltransferase  complex  
EFT2   Elongation  factor  2  (EF-­2),  also  encoded  by  EFT1  
ELM1   Serine/threonine  protein  kinase    
EMP24   Integral  membrane  component  of  ER-­derived  COPII  vesicles  
ERG6   Delta  (24)-­sterol  C-­methyltransferase  
FIG2   Involved  in  maintenance  of  cell  wall  integrity  during  mating  
FLC2   Putative  FAD  transporter;;  required  for  uptake  of  FAD  into  ER  
GAL80   Transcriptional  regulator  involved  in  the  repression  of  GAL  genes    
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GCY1   Putative  NADP  (+)  coupled  glycerol  dehydrogenase  
GET3   Involved  in  Golgi  to  ER  trafficking  and  insertion  of  proteins  into  ER    
GGA1   Golgi-­localized  protein  with  homology  to  gamma-­adaptin  
GRX1   Glutathione-­dependent  disulfide  oxidoreductase  
GTO3   Omega  class  glutathione  transferase;;  putative  cytosolic  localization  
HBT1   Substrate  of  the  Hub1p  ubiquitin-­like  protein    
HUT1   Protein  with  a  role  in  UDP-­galactose  transport  to  the  Golgi  lumen  
INP1   Peripheral  membrane  protein  of  peroxisomes    
ITC1   Component  of  the  ATP-­dependent  Isw2p-­Itc1p    
KAP114   Karyopherin,  responsible  for  nuclear  import  of  Spt15p  
LEO1   Component  of  the  Paf1  complex  
MAD2   Component  of  the  spindle-­assembly  checkpoint  complex  
MAM3   Protein  required  for  normal  mitochondrial  morphology  
MCH1   Protein  with  similarity  to  mammalian  monocarboxylate  permeases  
MDM12   Mitochondrial  outer  membrane  protein  
MET14   Adenylylsulfate  kinase  
MIG2   Protein  containing  zinc  fingers,  involved  in  repression  
NAT5   Subunit  of  the  N-­terminal  acetyltransferase  NatA    
NCA2   Protein  involved  in  regulation  of  mitochondrial  expression  of  Atp6p  
NOL4   Endoplasmic  reticulum  and  nuclear  membrane  protein  
OST5   Zeta  subunit  of  the  oligosaccharyltransferase  complex    
PAA1   Polyamine  acetyltransferase    
PAU4   Member  of  the  seripauperin  multigene  family    
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PDB1   E1  beta  subunit  of  the  pyruvate  dehydrogenase  (PDH)  complex  
PMP3   Small  plasma  membrane  protein    
PRM3   Pheromone-­regulated  protein  required  for  nuclear  envelope  fusion    
PSH1   Nuclear  protein,  putative  RNA  polymerase  II  elongation  factor  
PSK2   One  of  two  (see  also  PSK1)  PAS  domain    
RAD34   Protein  involved  in  nucleotide  excision  repair  (NER)  
REC102   Protein  involved  in  early  stages  of  meiotic  recombination  
RPS24B   Protein  component  of  the  small  (40S)  ribosomal  subunit  
RPS4A   Protein  component  of  the  small  (40S)  ribosomal  subunit  
RTN1   ER  membrane  protein  that  interacts  with  Sey1p    
SAT4   Ser/Thr  protein  kinase  involved  in  salt  tolerance  
SIN4   Subunit  of  the  RNA  polymerase  II  mediator  complex  
SWH1   Protein  similar  to  mammalian  oxysterol-­binding  protein  
TCB2   Bud-­specific  protein  with  a  potential  role  in  membrane  trafficking  
TED1   Conserved  phosphoesterase  domain-­containing  protein    
TGL4   Multifunctional  triacylglycerol  lipase  and  steryl  ester  hydrolase  
TIF2   Translation  initiation  factor  eIF4A  
TMA16   Protein  of  unknown  function  that  associates  with  ribosomes  
TSA1   Thioredoxin  peroxidase  
TUM1   Mitochondrial  protein  that  is  similar  to  mammalian  thiosulfate  
YHR010W   Protein  component  of  the  large  (60S)  ribosomal  subunit  





CHAPTER  3  THE  GLYOXYLATE  CYCLE  IS  ESSENTIAL  IN    
CARDIOLIPIN  DEFICIENT  CELLS  
INTRODUCTION    
In  the  studies  discussed  in  the  previous  chapter,  I  demonstrated  that  acetyl-­CoA  
levels   were   decreased   and   acetate   utilization   was   perturbed   in   the   crd1Δ   mutant.  
Previous  studies  reported  that  CL  mutants  exhibit  decreased  activity  of  Fe-­S  enzymes  in  
the  TCA  cycle,  and  up-­regulation  of  genes  involved  in  the  transport  of  acetyl-­CoA  and  
TCA  cycle  intermediates  into  the  mitochondria  (Patil  et  al.,  2013).  These  studies  suggest  
that  CL-­deficiency   leads  to  perturbation  of   the  TCA  cycle.  The  mechanisms  linking  CL  
deficiency   and   defects   in   the   TCA   cycle   are   not   fully   understood.   Acetyl-­CoA   is  
synthesized   and   compartmentalized   in   four   cellular   compartments,   cytosol,   nucleus,  
peroxisome,  and  mitochondria  (Krivoruchko  et  al.,  2014;;  Nielsen  et  al.,  2014,  Chen  et  al.,  
2012).  Acetyl  units  are  transported  into  the  mitochondria  as  acetylcarnitine  through  the  
carnitine  shuttle  or  converted  into  intermediates  of  the  TCA  cycle  through  the  glyoxylate  
cycle  and  transported  into  the  mitochondria  (Chen  et  al.,  2015).  Therefore,  to  maintain  
basic   cellular   functions   that   depend   on   a   functional   TCA   cycle,   I   predicted   that   CL-­
deficient  cells  require  these  pathways  to  synthesize  TCA  cycle  intermediates.  
In  Saccharomyces  cerevisiae,  precursors  for  the  carnitine  shuttle  and  glyoxylate  
cycle   are   synthesized   by   β-­oxidation   of   fatty   acids   in   the   peroxisomes.   Fatty   acids  
oxidized  to  acetyl-­CoA  inside  the  peroxisomes  are  exported  to  the  mitochondria  through  
a   carnitine-­dependent   pathway   or   utilized   by   the   glyoxylate   cycle   to   synthesize  
intermediates  of   the  TCA  cycle  (Van  der  Klei  and  Veenhuis  1997;;  Kunau  et  al.,  1995;;  
Hettema  and  Tabak  2000;;  van  Roermund  et  al.,  1995).  In  one  route,  acetyl-­CoA  enters  
the  glyoxylate  cycle,  which   is  also  described  as  a   “modified  TCA  cycle”   (Kunze  et  al.,  
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2006).  The  glyoxylate  cycle  consists  of   five  enzymes,   including  citrate  synthase   (CS),  
aconitase   (ACO),   malate   dehydrogenase   (MDH),   isocitrate   lyase   (ICL),   and   malate  
synthase  (MLS)  (Fig.  3.1).  The  first  three  enzymes  are  shared  with  the  TCA  cycle,  while  
the   last   two  enzymes  are  unique   to   the  glyoxylate  cycle.  Most  of   the  glyoxylate  cycle  
mutants,  including  icl1Δ,  msl1Δ,  cit2Δ,  aco1Δ,  and  mdh3Δ,  are  viable  and  do  not  exhibit  
growth  defects  (Lee  et  al.,  2011).  The  two-­carbon  acetyl-­CoA  is  converted  to  four-­carbon  
dicarboxylic   acids,   including   succinate   and   malate,   which   bypass   oxidative  
decarboxylation   and   are   transported   to   the   mitochondria,   where   they   are   used   to  
replenish  intermediates  of  the  TCA  cycle  (van  Roermund  et  al.,  1999).    
The  carnitine  shuttle  transfers  acetyl  units  from  the  peroxisome  (Fig.  3.2).  Acetyl-­
CoA   is   converted   to   acetylcarnitine   by   carnitine   acetyltransferase   (CAT2)   in   the  
peroxisomes.   Acetylcarnitine   is   transported   into   mitochondria   by   the   carnitine-­
acetylcarnitine  translocase  (CRC1)  and  converted  back  to  carnitine  and  acetyl-­CoA  by  
the  mitochondrial  CAT2  (Palmieri  et  al.,  1997;;  Van  Roermund  et  al.,1995).  Mitochondrial  
acetyl-­CoA   then   enters   the   TCA   cycle.   Similarly,   acetyl-­CoA   from   the   cytoplasm   is  
shuttled  into  the  mitochondria  through  the  cytoplasmic  carnitine  acetyltransferase  (YAT1  
and  YAT2),   which   is   associated  with   the  mitochondrial   outer  membrane.   The   pool   of  
acetyl-­CoA   inside   the  mitochondria   is  utilized  by   the  TCA  cycle,   the  central  metabolic  
pathway  in  the  mitochondrial  matrix.  The  TCA  cycle  is  also  required  for  biosynthesis  of  
amino  acids  and  heme.    
As  discussed  above,  TCA  cycle  deficiencies  may  be  replenished  by  the  carnitine  
shuttle  and  the  glyoxylate  cycle,  which  complement  each  other  by  replenishing  acetyl-­
CoA,  citrate,  malate,  and  succinate.  Because  crd1Δ  cells  exhibit  deficiencies  in  the  TCA  
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cycle   and   acetyl-­CoA   synthesis,   I   hypothesized   that   these   cells   require   the   carnitine  
shuttle   and/or   the   glyoxylate   cycle   for   cell   survival.   In   this   study,   I   report   that   both  
replenishing   pathways   are   required   for   optimal   growth   of   crd1Δ   cells.   Carnitine-­
acetylcarnitine   translocase   activity   is   decreased   in   the   crd1Δ   mutant,   and   carnitine  
rescues  temperature  sensitive  growth.  The  glyoxylate  cycle  is  essential  in  the  CL  mutant,  
as   double   mutants   of   crd1Δ   and   glyoxylate   cycle   mutants   were   not   viable.  
Supplementation  of  carnitine,  acetylcarnitine,  or  oleate  rescued  the  growth  defect  of  the  
crd1Δ  mutant   at   elevated   temperature.   These   results   show   for   the   first   time   that  CL-­
deficient  cells  require  the  glyoxylate  cycle  to  compensate  for  TCA  cycle  defects.  
MATERIALS  AND  METHODS  
Yeast  strains  and  growth  media  
The  yeast  S.  cerevisiae  strains  used  in  this  study  are  listed  in  Table  3.1.  Single  
deletion  mutants  were  obtained  from  the  yeast  knockout  deletion  collection  (Invitrogen).  
Double  mutants  were  obtained  by  tetrad  dissection.  Synthetic  complete  (YNBD)  medium  
contained  adenine  (20.25  mg/liter),  arginine  (20  mg/liter),  histidine  (20  mg/liter),  leucine  
(60   mg/liter),   lysine   (200   mg/liter),   methionine   (20   mg/liter),   threonine   (300   mg/liter),  
tryptophan   (20  mg/liter),   uracil   (20  mg/liter),   yeast   nitrogen   base  without   amino   acids  
(Difco),  and  glucose  (2%)  (YNBD)  or  sodium  acetate  (2%)  (YNBA)  or  oleic  acid  (0.12%)  
and   Tween   80   (0.2%)   (YNBO).   Synthetic   dropout   media   contained   all   ingredients  
mentioned  above  but   lacked  the  indicated  amino  acids.  Sporulation  medium  contained  
potassium  acetate   (1%),   glucose   (0.05%),   and   the   essential   amino   acids   required   for  
sporulation.  Complex  medium  contained  yeast  extract  (1%),  peptone  (2%),  and  glucose  
(2%)  (YPD).  Solid  medium  was  prepared  by  adding  2%  agar.  The  cells  for  carnitine,  β-­‐
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oxidation,  and  enzyme  assays  were  grown  on  minimal  glucose  medium  (YNB  with  2%  
glucose),   inoculated  at  A600  0.2  in  YNB  0.3%  glucose  medium,  and  grown  for  8  hours.  
Finally,  the  strains  were  inoculated  into  rich  oleate  medium  (YPO;;  2%  peptone,  1%  yeast  
extract,  0.12%  oleic  acid,  0.2%  Tween  80)  at  an  A600  of  0.005  and  grown  for  16  hours.  
Measurement  of  acetyl-­CoA    
Cells  were  grown  to  the  logarithmic  growth  phase  and  a  sample  (3  ml)  of  the  culture  
was  centrifuged  at  1700  g.  Pellets  were  resuspended  in  1  ml  ddH2O  and  centrifuged  for  
1  min  at  9300  g.  The  resulting  cell  pellet  was  subjected  to  cell  lysis  and  the  lysed  samples  
were  rapidly  quenched  with  130  μl  of  45:45:10  acetonitrile  /  methanol  /  H2O  +  0.1%  glacial  
acetic   acid   and   spiked   with   10   μmol   l-­1   glutaryl-­CoA   as   an   internal   standard.   The  
resuspended  extract  was  incubated  on  ice  with  intermittent  vortexing  for  15  min.  An  equal  
molar  volume  of  ammonium  hydroxide  was  added  post  incubation  to  neutralize  the  acetic  
acid,  and  each  extract  was  centrifuged  for  3  min  at  15,700  g,  transferred  to  a  new  1.5  ml  
microfuge  tube  and  centrifuged  for  5  min  at  15,700  g.  The  clarified  extract  (10  μl)  was  
injected  for  HPLC-­MS/MS  analysis  (Bennett  et  al.,  2009;;  Armando  et  al.,  2011).  (Mass  
spectrometry  was  carried  out  by  Krishna  Rao  Maddipati,  Director,  Lipidomics  Core).  
Measurement  of  respiration    
Cells  were  grown  to  the  logarithmic  phase  and  pelleted.  Protein  concentration  was  
determined  using  the  Bradford  assay.  Cells  were  then  washed  and  resuspended  in  YNBO  
to  2  mg/ml  final  protein  concentration.  Oxygen  consumption  was  measured  in  a  closed  
500  μl  chamber  equipped  with  a  micro  Clark-­type  oxygen  electrode  (Oxygraph  system,  
Hansatech)  at  30°C  and  analyzed  with  Oxygraph  software.  500  μM  KCN  was  added  to  
inhibit   cytochrome   c   oxidase.   Non-­cytochrome   c   oxidase-­based   respiration   was  
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subtracted  to  determine  oxygen  consumption  rates.  Respiration  was  defined  as  oxygen  
consumed  (nmol)/min  total  protein  (mg).  (This  experiment  was  carried  out  in  collaboration  
with  Dr.  Maik  Hüttemann,  Center  for  Molecular  Medicine  and  Genetics,  WSU).    
The  following  experiments  were  carried  out  by  Dr.  Carlo  W.  van  Roermund,  Department  
of  Genetic  Metabolic  Diseases,  Academic  Medical  Center,  Amsterdam,  The  Netherlands    
(a)  b-­oxidation  assay    
Oleate-­grown   cells   were   washed   with   water   and   resuspended   in   phosphate  
buffered  saline  (PBS)  to  an  A600  of  2.5.  Aliquots  of  20  μl  of  cell  suspension  were  used  for  
fatty  acid  b-­oxidation  measurements   in  200  μl  medium  containing  PBS  plus  10  μM  [1-­
14C]-­palmitate  or  [1-­14C]-­octanoate.  Reactions  were  allowed  to  proceed  for  6  or  12  min  at  
30°C,   followed  by   termination   of   reactions   by   adding   100  μl   of   1.3  M  perchloric   acid.  
Radiolabeled  CO2  was   trapped  overnight   in  500  μl  of  2  M  NaOH.  The   14C-­labelled  b-­
oxidation  products  were  subsequently  collected  after  extracting  the  acidified  material  with  
chloroform/methanol/heptane   as   described   (Heikoop   et   al.,   1990)   and   quantified   in   a  
liquid  scintillation  counter.  The  b-­oxidation  capacity  of  wild-­type  cells  grown  on  oleate  in  
each  experiment  was  taken  as  a  reference  (100%).    
  (b)  Carnitine  acetyltransferase  (CAT2  assay)  
Oleate-­grown   cells   (20   ml)   were   washed   twice   and   pelleted   for   carnitine  
acetyltransferase  activity.  The  cell  homogenate  was  prepared  by  disrupting  the  cell  pellet  
in  500  μl  of  0.9%  NaCl  with  200  μl  of  glass  beads  for  5  min  by  vortexing  at  4°C.  Cell  debris  
was  removed  by  centrifugation  for  1  min  at  13,000  rpm.  For  measurement  of  carnitine  
acetyltransferase,  the  assay  mixture  (final  volume  of  100  μl)  was  composed  of  40  mM  
HEPES  (2  M;;  pH  7.4),  0.1  %  triton-­x-­100,  1  mM  carnitine,  60  μM  acetyl-­CoA,  200,000  
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dpm  [1-­C14]-­acetyl-­CoA,  and  40  μl  of  homogenate.  The  reaction  mixture  was  incubated  
for  10  min  at  28°C.  The  reaction  was  stopped  with  500  μl  ice-­cold  EtOH  on  the  AG11-­8  
column.  The  column  was  washed  twice  with  500  μl  EtOH  and  we  measured  the  [1-­C14]-­
acetyl-­carnitine.	    
     (c)  Carnitine-­acetylcarnitine  translocase  (CACT  assay)    
Carnitine   acetylcarnitine   translocase   activity   was   measured   in   spheroplasts  
prepared   from  wild-­type  or  mutant  cells  grown  on  oleate.  Activity  measurements  were  
performed   in   a  medium   containing   1.2  M   sorbitol,   50  mM   KPi   pH   7.5,   1  mM   EDTA,  
200,000  d.p.m.  [1-­14C]  acetylcarnitine  (5  μM)  and  digitonized  (20  μg/ml)  spheroplasts  (100  
μg   protein).   This   digitonine   concentration   selectively   permeabilizes   the   plasma  
membrane,   as   demonstrated   by   complete   release   of   the   cytosolic   marker   enzyme  
phosphoglucose  isomerase  (PGI),  whereas  intracellular  membranes  of  mitochondria  and  
peroxisomes  remain  intact  (Verleur  et  al.,  1997).  Reactions  were  allowed  to  proceed  for  
10  min  at  28°C,  and  subsequently  stopped  by  the  addition  of  100  μl  1.3  M  perchloric  acid.  
Radiolabeled  CO2  was  trapped  overnight  in  500  μl  of  2  M  NaOH.    
(d)  Carnitine  measurement    
Oleate-­grown   cells   (20   ml)   were   washed   twice   and   disrupted   by   vigorously  
vortexing  for  30  min  at  4°C  with  ~200  μl  glass  beads  in  an  end  volume  of  400  μl.  Cell  
debris   (75  μl)  was  mixed  and  subsequently  deproteinized  with  500  μl   acetonitrile  and  
centrifuged  for  15  min  at  12,000  rpm.  The  resulting  supernatant  was  dried  under  nitrogen  
at  45°C  and  subsequently  derivatized  in  100  μl  butanol–HCl  for  15  min  at  60°C.  Samples  
were  dried  under  nitrogen  at  45°C  and  redissolved  in  140  μl  acetonitril.  Free  carnitine  was  




Perturbation  of  carnitine-­acetylcarnitine  translocase  activity  in  crd1Δ  
The  data  presented  in  the  previous  chapter  showed  that  the  loss  of  CL  leads  to  
decreased   growth   and   acetyl-­CoA   levels   on   acetate   medium.   In   S.   cerevisiae,   the  
glyoxylate  cycle  and  the  carnitine  shuttle  facilitate  growth  when  acetate  is  the  sole  carbon  
source   (Palmieri   et   al.,   1997;;   Palmieri   et   al.,   1999;;   Lee   et   al.,   2011).   Therefore,   I  
hypothesized  that  growth  defects  of  crd1Δ  on  acetate  and  at  elevated  temperature  may  
be  due  to  perturbation  of  either  or  both  of  these  pathways.  Consistent  with  my  hypothesis,  
growth   of   crd1Δ   on   acetate   medium   and   at   elevated   temperature   are   restored   by  
supplementation  of  carnitine  or  acetylcarnitine  (Fig.  3.3A  and  Fig.  3.8A).  Acetylcarnitine  
was  more  effective  than  carnitine  for  rescue  of  crd1Δ  growth  defects.  However,  acetyl-­
CoA  levels  were  not  restored  by  supplementation  of  carnitine  or  acetylcarnitine  on  acetate  
medium  (Fig.  3.3B).    
Acetyl-­CoA  that  is  produced  from  acetate  in  the  cytosol  and  fatty  acid  oxidation  in  
the  peroxisome  must  be  transported  across  the  mitochondrial  membranes  by  carnitine-­
acetylcarnitine  translocase.  Defects   in   the  carnitine  shuttle   lead  to  decreased  carnitine  
levels,   activity   of   carnitine   acetyltransferase,   and/or   activity   of   carnitine-­acetylcarnitine  
translocase  (van  der  Leij  et  al.,  2000;;  Franken  et  al.,  2008;;  van  Roermund  et  al.,  1995).  
The   observed   rescue   of   decreased   growth   on   acetate   by   carnitine   or   acetylcarnitine  
suggests  that  either  carnitine  levels,  activity  of  carnitine  acetyltransferase,  and/or  activity  
of  carnitine-­acetylcarnitine  translocase  are  decreased  in  CL-­deficient  cells.  To  address  
this  possibility,  total  free  carnitine  was  quantified  using  tandem  mass  spectrometry  and  
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found  to  be  only  marginally  reduced  (~14%)  in  crd1Δ  cells  (Fig.  3.4A).  In  addition,  activity  
of  the  carnitine  acetyltransferase  was  unaltered  in  the  crd1Δ  mutant  (Fig.  3.4B).  
Acetylcarnitine  that  is  synthesized  in  the  peroxisomes  and  cytosol  is  transported  
into   the  mitochondria  by  carnitine-­acetylcarnitine   translocase,  which   is  a  mitochondrial  
inner  membrane  protein.  Noel  and  Pande  (1986)  reported  that  CL  is  required  for  carnitine-­
acetylcarnitine   translocase   activity.   Impaired   enzyme   activity   results   in   the   inability   to  
transport  acetyl-­CoA  into  mitochondria  because  acetylcarnitine  cannot  traverse  through  
the  mitochondrial  membrane  (McGarry  and  Brown,  1997;;  Hynes  et  al.,  2011).  Therefore,  
I  addressed  the  possibility   that  decreased  growth  on  acetate   in  crd1Δ  cells  may  result  
from  decreased  carnitine-­acetylcarnitine  translocase  activity.  The  crd1Δ  mutant  exhibited  
an  ~35%  decrease  in  activity  of  carnitine-­acetylcarnitine  translocase  relative  to  wild-­type  
(Fig.   3.5).   Taken   together,   these   experiments   indicate   that   CL-­deficient   cells   have   a  
deficiency   in   transport   of   acetylcarnitine   through   the  mitochondrial   membrane   due   to  
decreased  carnitine-­acetylcarnitine  translocase  activity.  
The  glyoxylate  cycle  compensates  for  TCA  cycle  defects  in  crd1Δ  
   As  discussed  earlier,  the  glyoxylate  cycle  is  an  anaplerotic  pathway  that  provides  
TCA  cycle  metabolites  by  an  alternative  route.  If  the  TCA  cycle  is  defective  in  crd1Δ  cells,  
then  perturbation  of  the  glyoxylate  cycle  may  exacerbate  growth  defects  of  crd1Δ  cells,  
while  up-­regulation  of  the  glyoxylate  cycle  may  rescue  crd1Δ  growth  defects.  To  test  this  
prediction,  I  examined  genetic  interaction  between  crd1Δ  and  mutants  in  the  glyoxylate  
cycle.  As  predicted,  deletion  of  MLS1   in  crd1Δ   cells   leads   to   synthetic   lethality  at   the  
optimal  growth  temperature  of  30°C  (Fig.  3.6).  The  other  mutants  of  the  glyoxylate  cycle,  
including  CIT2,  SDH1,  and  SFC1,  were  synthetically  lethal  with  crd1Δ  cells  at  the  elevated  
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temperature  37°C.  (Fig.  3.7).    
Growth   of   crd1Δ   at   elevated   temperature   was   restored   by   supplementation   of  
oleate  (Fig.  3.8B).  Fatty  acids  are  converted  to  acetyl-­CoA  inside  the  peroxisome  by  β-­
oxidation.  Acetyl-­CoA  thus  generated  enters  the  glyoxylate  cycle  to  synthesize  succinate,  
malate,   and   citrate.   I   explored   the   possibility   that   supplementation   of   oleate   rescued  
growth  of  crd1Δ  cells  as  a  result  of  increased  β-­oxidation.  O2  consumption  was  measured  
in  intact  cells  grown  on  oleate.  The  rate  of  O2  uptake  in  the  crd1Δ  mutant  was  unaltered  
(Fig.  3.9A)  and  oxidation  of  oleate  was  marginally  decreased  (Fig.  3.9B).  Therefore,  the  
most  likely  mechanism  underlying  rescue  of  growth  defects  by  oleate  is  up-­regulation  of  
the  glyoxylate  cycle  to  replenish  TCA  cycle  intermediates.  These  findings  suggest  for  the  





















FIGURE   3.1.   The   glyoxylate   cycle.  Acetyl-­CoA   produced   from   β-­oxidation   of   fatty  
acids   in   the   peroxisomes   is   condensed   with   oxaloacetate   to   form   citrate,   which   is  
converted  into  isocitrate.  Isocitrate  is  converted  to  succinate  and  glyoxylate.  Glyoxylate  
is  condensed  with  another  molecule  of  acetyl-­CoA  to  form  malate,  which  is  converted  
to   oxaloacetate.   Enzymes   are   indicated   in   violet,   genes   encoding   the   respective  
















FIGURE  3.2.  The  carnitine  shuttle  (modified  from  Franken  et  al.,  2008).  Acetyl-­CoA  
produced   from   β-­oxidation   of   fatty   acids   in   the   peroxisomes   is   transported   to   the  
mitochondria   in   the   form   of   acetylcarnitine,   produced   by   the   peroxisomal   carnitine  
acetyltransferase  Cat2p.  This  enzyme  has  two  isoforms,  one  found  in  peroxisomes  and  
the   other   in  mitochondria.   Translocation   of   acetylcarnitine   across   the  mitochondrial  
membrane   is   mediated   by   the   carnitine-­acetylcarnitine   translocase,   Crc1p.   The  
mitochondrial   Cat2p   converts   acetylcarnitine   to   carnitine   and   acetyl-­CoA.   Two  
additional  carnitine  acetyltransferases  include  Yat1p,  found  on  the  outer  mitochondrial  
membrane,  and  Yat2p,  localized  in  the  cytosol.  Carnitine  is  imported  into  cells  by  the  



















FIGURE   3.3A.   Carnitine   and   acetylcarnitine   restored   the   growth   of   crd1Δ   on  
acetate.  Cells  were  pre-­cultured  in  YNBD  overnight,  serially  diluted,  plated  on  YNBA  
























FIGURE  3.3B.  Carnitine  and  acetylcarnitine  do  not  rescue  decreased  acetyl-­CoA  
levels  in  crd1Δ  on  acetate.  Wild-­type  and  crd1Δ  cells  were  grown  in  YNBA  with  or  
without  carnitine  or  acetylcarnitine  (500  mg/l)  until  cells  reach  an  A550  of  1.  Cells  were  
pelleted  and  acetyl-­CoA  was  extracted  using  glutaryl-­CoA  as  an  internal  standard.  The  
clarified  extract  (10  μl)  was  analyzed  by  HPLC-­MS/MS.  Data  shown  are  mean  ±  S.E.  



















FIGURE  3.4A.  Carnitine  levels  are  marginally  decreased  in  crd1Δ.  Wild-­type  and  
crd1Δ  cells  were  grown  in  YNBO.  Total  intracellular  carnitine  levels  were  determined  
by   tandem   mass   spectrometry   as   described   in   the   “Materials   and   Methods”.   Data  


























FIGURE  3.4B.  Carnitine  acetyltransferase  activity  is  not  decreased  in  crd1Δ.  Wild-­
type  and  crd1Δ  cells  were  grown  in  YNBO  and  carnitine  acetyltransferase  activity  was  























FIGURE  3.5.  Carnitine-­acetylcarnitine  tranlocase  activity  is  decreased  in  crd1Δ.  
Wild-­type  and  crd1Δ  cells  were  grown  in  YNBO  and  carnitine-­acetylcarnitine  tranlocase  
activity  was  measured  as  described  in  the  “Materials  and  Methods”.  Data  shown  are  
















FIGURE  3.6.  Genetic  interaction  between  crd1Δ  and  mls1Δ.  Cells  were  pre-­cultured  































FIGURE  3.7.  Genetic  interaction  between  crd1Δ  and  glyoxylate  cycle  mutants.  Cells  
were  pre-­cultured  in  YPD  overnight,  serially  diluted,  plated  on  YNBD,  and  incubated  at  
30°C  or  37°C  for  4  days.  Genetic   interaction  between  crd1Δ  and  (A)  cit2Δ,  (B)  sdh1Δ,  






























FIGURE  3.8.  Supplementation  of  carnitine,  acetylcarnitine,  or  oleate  restored  the  
growth  of  crd1Δ  at  elevated  temperature.  Cells  were  pre-­cultured  in  YNBD  overnight,  
serially  diluted,  and  plated  on  YNBD  with  or  without  carnitine  or  acetylcarnitine  (500  mg/l)  



















FIGURE  3.9A.  β-­oxidation  is  not  significantly  affected  in  crd1Δ  cells.  Wild-­type  and  
crd1Δ  cells  were  grown  in  YNBO.  (A)  O2  consumption  and  (B)  β-­oxidation  of  oleate  were  













The  studies   in   this   chapter   support   the  hypothesis   that  CL  mutants   require   the  
carnitine  shuttle  and  the  glyoxylate  cycle   for  optimal  growth.  The  crd1Δ  mutant  exhibit  
decreased  carnitine-­acetylcarnitine  translocase  activity;;  supplementation  of  carnitine  or  
acetylcarnitine   restored   growth   on   acetate   and   rescued   the   temperature   sensitive  
phenotype  of  the  mutant.  The  most  striking  finding  was  synthetic  lethality  between  crd1Δ  
and   glyoxylate   cycle   mutants.   Furthermore,   the   temperature   sensitivity   phenotype   of  
crd1Δ  cells  was  restored  by  supplementation  of  oleate.  The  most  likely  explanation  for  
this  rescue  is  that  the  glyoxylate  cycle  is  required  to  restore  TCA  cycle  metabolites  in  CL-­
deficient  cells.    
How  does  the  glyoxylate  cycle  compensate  for  TCA  cycle  defects  in  CL-­deficient  
cells?  The  glyoxylate  cycle  synthesizes  TCA  cycle  intermediates  in  the  peroxisome,  which  
are  transported  into  the  mitochondria.  In  S.cerevisiae,  the  peroxisomal  membrane  forms  
a   pore-­like   structure   that   is   permeable   to   acetylcarnitine   (van  Roermund  et   al.,   1999;;  
Kunze  and  Hartig,  2013).  Supplementation  of  carnitine   transports  acetyl-­CoA   from  the  
cytosol   to   the  peroxisome  as  acetylcarnitine,  which   is   converted   to  acetyl-­CoA   that   is  
utilized  in  the  glyoxylate  cycle.  The  glyoxylate  cycle  may  be  up-­regulated  in  crd1Δ  cells.  
Alternatively,  glyoxylate  cycle  enzyme  activities  may  be  increased  in  the  mutant.  Either  
of  these  responses  could  potentially  replenish  intermediates  of  the  TCA  cycle,  including  
succinate,  malate,  and  citrate.    
How  does  CL  deficiency   lead   to  decreased  carnitine-­acetylcarnitine   translocase  
activity?  Crc1   is   localized   in   the   inner  mitochondrial  membrane,  which  contains  CL   in  
proximity   to   the  CL-­enriched  membrane.  CL  was  shown  to  activate  Crc1   in  vitro   (Noel  
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and  Pande,  1986)  and  may  thus  be  required  for  Crc1  function  in  vivo  as  well.  The  stability  
of	  Crc1  may  also  be  decreased  in  CL-­deficient  membranes.  An  alternative  possibility  is  
that  import  of  Crc1  into  the  mitochondria  of  CL-­deficient  cells  may  be  decreased,  as  CL  
is  required  for  optimal  protein  import  (Jiang  et  al.,  2000;;  Gebert  et  al.,  2009).  
Based  on  the  data  obtained,  I  propose  the  following  model  to  elucidate  the  role  of  
CL  in  regulating  the  transport  of  acetyl-­CoA  (Fig.  3.10).  Loss  of  CL  leads  to  decreased  
carnitine-­acetylcarnitine  translocase  activity  in  the  inner  mitochondrial  membrane,  which  
disrupts   shuttling   of   acetyl-­CoA   to   the   mitochondria   from   cellular   compartments.  
Decreased  movement  of  acetylcarnitine  across   the  mitochondria   reduces   levels  of   the  
precursor   of   the   TCA   cycle   (acetyl-­CoA)   and   perturbs   synthesis   of   TCA   cycle  
intermediates.  Therefore,  CL-­deficient  cells  depend  on  the  glyoxylate  cycle  to  replenish  
intermediates  of  the  TCA  cycle.  
How  is  the  role  of  CL  in  transport  of  acetyl-­CoA  relevant  to  BTHS  and  other  cardiac  
disorders?  The  data  presented  here  suggest  for  the  first  time  that  CL  is  a  critical  regulator  
of  intracellular  transport  of  acetyl-­CoA.  Human  disorders  of  carnitine  deficiency  have  been  
described,  several  of  which  lead  to  clinical  outcomes  similar  to  those  seen  in  BTHS.  The  
deficiency   of   carnitine   palmitoyltransferase   (CPT   II)   is   associated   with   exercise  
intolerance,   carnitine-­acetylcarnitine   translocase   (CACT)   deficiency   leads   to  
cardiomyopathy   with   arrhythmia,   and   deficiency   of   the   carnitine   transporter   (OCTN2)  
results  in  cardiomyopathy  and  skeletal  myopathy  (Rinaldo  et  al.,  2002;;  Ørngreen  et  al.,  
2003;;  Longo  et  al.,  2006;;  Wanders  and  Ruiter,  2010).  In  mammals,  disruption  of  the  TCA  
cycle   perturbs   cardiac   ATP   production,   which   is   essential   for   cell   function   and   basal  
cellular  metabolism.  The  primary  source  of  energy  in  the  heart  is  ATP  that  is  produced  
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entirely  from  oxidative  phosphorylation  using  substrates  (NADH  and  FADH2)  generated  
mainly  in  the  TCA  cycle  (Kodde  et  al.,  2007;;  Stanley  et  al.,  2005).  The  results  from  my  
studies   using   yeast   as   a   model   system   suggest   that   supplementation   of   deficient  
metabolites  may  alleviate  some  of  the  clinical  presentation  observed  in  BTHS  and  other  













































FIGURE  3.10.  Model:  Glyoxylate  cycle-­dependent  transport  of  metabolites  in  CL-­
deficient  cells.  Loss  of  CL  leads  to  decreases  in  acetyl-­CoA  (Chapter  2)  and  carnitine-­
acetylcarnitine  translocase  activity,  causing  perturbation  of  acetylcarnitine  transport  into  
mitochondria.   Translocase  deficiency  may   result   in   reduced   synthesis   of   TCA  cycle  
intermediates  due  to  decreased  acetyl-­CoA.  Intermediates  of  the  TCA  cycle  supplied  
by  the  glyoxylate  cycle  replenish  these  deficiencies.    
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Source  or  Ref.	  
BY4741   MATα,  his3Δ1,  leu2Δ0,  ura3Δ0,  met15Δ0   Invitrogen  
BY4742   MATα,  his3Δ1,  leu2Δ0,  ura3Δ0,  lys2Δ0   Invitrogen  
VGY1   MATα,  his3Δ1,  leu2Δ0,  lys2Δ0,  ura3Δ0,    
crd1Δ::URA3  
Gohil  et  al.,  2005  
CG922-­a   MATa,  lys2-­801,  ade2-­101,  trp1Δ1,  his3Δ200,  
leu2Δ1,  crd1Δ::URA3  
  
CG923-­α   MATα,  lys2-­801,  ade2-­101,  trp1Δ1,  his3Δ200,  
leu2Δ1,  crd1Δ::URA3  
  
mls1Δ   MATa,  his3Δ1,  leu2Δ0,  met15Δ0,  ura3Δ0,  
mls1Δ::KanMX4  
Invitrogen  
cit2Δ   MATa,  his3Δ1,  leu2Δ0,  met15Δ0,  ura3Δ0,  
cit21Δ::KanMX4  
Invitrogen  
sdh1Δ   MATa,  his3Δ1,  leu2Δ0,  met15Δ0,  ura3Δ0,  
sdh1Δ::KanMX4  
Invitrogen  
sfc1Δ   MATa,  his3Δ1,  leu2Δ0,  met15Δ0,  ura3Δ0,  
sfc1Δ::KanMX4  
Invitrogen  
mls1Δcrd1Δ   MATa,  his3Δ1,  leu2Δ0,  met15Δ0,  ura3Δ0,  
mls1Δ::KanMX4,  crd1Δ::KanMX4  
This  study  
cit2Δcrd1Δ   MATa,  his3Δ1,  leu2Δ0,  met15Δ0,  ura3Δ0,    
cit2Δ::KanMX4,  crd1Δ::KanMX4  
This  study  
sdh1Δcrd1Δ   MATa,  his3Δ1,  leu2Δ0,  met15Δ0,  ura3Δ0,    
sdh1Δ::KanMX4,  crd1Δ::KanMX4  
This  study  










CHAPTER  4  IDENTIFICATION  OF  PHYSIOLOGICAL  MODIFIERS  THAT  
EXACERBATE  THE  LOSS  OF  TAFFAZIN  
  
INTRODUCTION  
Barth  syndrome  (BTHS),  a  rare  X-­linked  genetic  disorder,  is  caused  by  mutations  
in  the  gene  tafazzin  (TAZ).  TAZ  is  involved  in  remodeling  cardiolipin  (CL),  the  signature  
phospholipid  of  the  mitochondrial  membranes.  The  clinical  symptoms  that  characterize  
BTHS  vary  widely,  even  among  patients  with  the  identical  mutation,  and  the  mechanism  
underlying   the   pathology   of   BTHS   has   not   been   identified.   We   hypothesize   that  
physiological   modifiers   exacerbate   the   tafazzin   defect   and,   hence,   account   for   the  
diversity   in   symptoms.   Identification   of   such   physiological   modifiers   will   elucidate   the  
cellular   role  of   tafazzin  and  may  shed   light  on   the  mechanisms  underlying   the  diverse  
clinical  symptoms  in  BTHS  patients.  
Previous  studies  have  reported  that  tafazzin  is  conserved  from  yeast  to  humans  
and   suggest   the   feasibility   of   identifying   synthetic   interactions   in   yeast   that   may   be  
relevant   to  BTHS.  The  yeast  TAZ1  gene  shares  homology  with   the  human  TAZ  gene,  
G4.5.  Our   lab  constructed  a  null  mutant  of   this  gene,   taz1Δ,   by   removing  91%  of   the  
coding  sequence  (Gu  et  al.,  2004).  Phospholipid  analysis  of   the  null  mutant  showed  a  
reduced   level  of   total  CL  and  accumulation  of  MLCL   (monolysocardiolipin),   consistent  
with  defective  CL  remodeling,  as  seen  in  BTHS  cells.  The  predominant  acyl  species  found  
in   wild   type   CL  were  markedly   reduced   in   taz1Δ,   and   CL  molecules   contained  more  
saturated  fatty  acids  than  those  in  the  wild  type  (Gu  et  al.,  2004).  In  addition,  CL  in  the  
taz1Δ  mutant  contained  multiple  fatty  acyl  species,  and  these  lacked  molecular  symmetry,  
similar   to   the  finding   in  BTHS  cells  (Schlame  et  al.,  2005).  These  defects   in  yeast  are  
complemented  by  expression  of   the  human  TAZ  cDNA  (Ma  et  al.,  2004).  Our   lab  has  
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characterized   several   CL  mutants   that  may   be   used   to   assess   the   role   of   CL   in   cell  
functions.   The   current   study   utilizes   the   taz1Δ   mutant,   which   cannot   remodel   CL.  
Functional  conservation  of  CL  mutants  from  yeast  to  humans  increases  the  probability  
that   synthetic   interactions   that   occur   with   yeast   CL  mutants   will   also   be   observed   in  
mammalian  cells.  To  identify  these  physiological  factors,  we  used  the  powerful  genetic  
tool  Synthetic  Genetic  Analysis  (SGA)  to  identify  synthetic  interactions  of  tafazzin,  which  
are  likely  to  identify  genes  that  affect  its  phenotypic  expression.  
Synthetic  analysis  exploits  the  possibility   that   two  non-­lethal  mutations   in  genes  
providing  overlapping  /  essential  functions  lead  to  an  inviable  cell  when  present  together  
(Hartman  et  al.,  2001).  Synthetic  lethal  interaction  may  suggest  that  the  gene  products  
carry  out  similar  functions,  possibly  by  alternative  pathways.  In  the  yeast  S.  cerevisiae,  
synthetic  lethal  screens  traditionally  have  been  based  on  a  plasmid  dependence  assay,  
in  which  mutagenized  cells  are  screened  for  the  inability  to  lose  a  plasmid  carrying  the  
gene   of   interest.   More   recently,   SGA   methodology   (Tong   et   al.,   2004)   has   made   it  
possible  to  evaluate  double  mutants  containing  a  mutation  in  a  specific  gene  of  interest  
and  in  each  of  4,800  non-­essential  yeast  genes.  Synthetic  lethal  screens  have  elucidated  
gene  function  as  well  as  interactions  in  pathways  as  diverse  as  DNA  replication  (Grossi  
et  al.,  2004;;  Suter  et  al.,  2004),  the  MAP  kinase  cell  integrity  pathway  (Green  et  al.,  2003),  
endocytosis  (Care  et  al.,  2004),  DNA  damage  tolerance  (Hishida  et  al.,  2002),  nuclear  
migration  (Fujiwara  et  al.,  1999),  the  spindle  checkpoint  (Lee  and  Spencer,  2004),  and  
phospholipid  synthesis  (Birner  et  al.,  2003).  Previous  studies  in  our  lab  have  identified  a  
synthetic   lethal   interaction   between   the   genes   for   CL   synthase   and   mitochondrial  
phosphatidylethanolamine   (PE)   synthesis   (Gohil   et   al.,   2005).   We   expect   that   the  
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synthetic   lethality   screen   will   facilitate   the   identification   of   physiological   factors   that  
exacerbate  the  loss  of  tafazzin.    
The   SGA   screen   offers   two   important   advantages   over   classical   genetic  
approaches:  (a)  An  existing  collection  of  yeast  deletion  mutants  of  all  4,800  non-­essential  
yeast  genes  can  be  screened,  and  (b)  the  identity  of  the  mutant  is  known  immediately.  
We  implemented  the  SGA  screen  (Fig.  4.1)  to  identify  mutants  that  synthetically  interact  
with  taz1Δ  in  order  to  obtain  a  global  idea  of  pathways  that  have  overlapping  function  with  
CL  remodeling.   In   the  study  described  here,  seventy  synthetic   lethal  mutants  and  one  
hundred  and   two  synthetic   sick  mutants  were   identified  by   the  SGA  and  are  grouped  
based   on   biological   function.   Among   these,   interaction   with   genes   for   phospholipid  
deacylation,  arginine  metabolism,   iron  homeostasis,  and  vacuolar  protein  sorting  were  
validated.    
MATERIALS  AND  METHODS  
Yeast  strains  and  growth  media  
The  yeast  S.  cerevisiae  strains  used  in  this  study  are  listed  in  Table  4.1.  Single  
deletion  mutants  were  obtained  from  the  yeast  knockout  deletion  collection  (Invitrogen).  
Double  mutants  were  obtained  by  tetrad  dissection.  Synthetic  complete  (YNB)  medium  
contained  adenine  (20.25  mg/liter),  arginine  (20  mg/liter),  histidine  (20  mg/liter),  leucine  
(60   mg/liter),   lysine   (200   mg/liter),   methionine   (20   mg/liter),   threonine   (300   mg/liter),  
tryptophan   (20  mg/liter),   uracil   (20  mg/liter),   yeast   nitrogen   base  without   amino   acids  
(Difco),  and  glucose   (2%)   (YNBD)  or  sodium  acetate   (2%)   (YNBA).  Synthetic  dropout  
media  contained  all  ingredients  mentioned  above  but  lacked  specific  compounds  required  
for  selection.  Sporulation  medium  contained  potassium  acetate  (1%),  glucose  (0.05%),  
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and  the  essential  amino  acids  required  for  sporulation.  Complex  medium  contained  yeast  
extract   (1%),  peptone   (2%),  and  glucose   (2%)   (YPD).  Solid  medium  was  prepared  by  
adding  2%  agar.    
DNA  and  strain  manipulation  
To  construct  the  taz1Δcan1Δ  starting  strain,  a  1.8  kb  CAN1  deletion  cassette  was  
amplified   from   Y5563   (kindly   provided   by   Dr.   Charles   Boone)   by   sense   primer   (5’-­
TAGGGCGAACTTGAAGAATAACC-­3’)   and   antisense   primer   (5’-­
ACGAAAAATGAGTAAAAATTATCTT-­3’)   and   inserted   into   the   genome   of   BY4741  
(MATa)  with  the  disruption  confirmed  by  PCR.  The  can1Δ  mutant  was  then  crossed  to  
BY4742  (MATα)  to  obtain  a  MATα  can1Δ  strain  by  tetrad  analysis.  The  TAZ1  gene  in  the  
can1Δ   mutant   (MATα)   was   disrupted   by   a   1.8   kb  URA3   fragment   released   from   the  
PUC19  plasmid  digested  using  PvuII.  The  disruption  of  TAZ1  was  confirmed  by  PCR,  
Southern  blot,  and  phospholipid  analysis.	  
Synthetic  genetic  array  (SGA)  
The  MATα  can1Δtaz1Δ  mutant  was  crossed  to  the  array  of  deletion  mutants  in  the  
MATa  background,  in  which  the  deletions  are  linked  to  the  dominant  selectable  marker  
for  geneticin  resistance,  KanMX4.  Diploids  were  selected  and  sporulation  was  induced.  
Haploid   spore   progeny   were   transferred   to   synthetic  medium   lacking   histidine,   which  
allowed  for  selective  germination  of  MATa  cells  (by  virtue  of  the  MFA1pr-­HIS3  reporter).  
Following  two  rounds  of  selection  in  His-­  synthetic  medium,  double  mutant  MATa  progeny  
were  selected  in  Ura-­  medium  supplemented  with  geneticin.  Independent  confirmation  of  
synthetic  lethality  was  carried  out  to  rule  out  false  positives  and  false  negatives  (Tong  et  
al.,  2001).    
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Construction  of  double  mutants  by  tetrad  dissection  
The  CL  mutant  taz1Δ::URA3  MATα  was  crossed  with  mutants  of  opposite  mating  
type  obtained  from  the  yeast  deletion  collection.  The  heterozygous  diploids  were  selected  
on   dropout   medium   lacking   methionine   and   lysine,   sporulated,   and   tetrads   were  
dissected.  The  synthetic  interaction  between  CL  and  deletion  mutants  was  determined  by  
examining  the  growth  of  the  double  mutant  compared  to  isogenic  parent  strains  and  wild  
type  on  YPD.  
Colony  formation  analysis  
Cells  were  pre-­cultured  in  YPD  at  30˚C  to  the  mid-­log  phase.  The  absorbance  at  
550nm  (A550)  of  the  liquid  culture  was  determined  using  a  spectrophotometer  (Beckman).  
Cell  aliquots  were  centrifuged  and  pellets  were  re-­suspended  in  YPD  to  adjust  the  A550  
value  to  10  units  per  mL.  10  μL  of  the  above  sample  were  added  to  990  μL  of  water.  10  
μL  of  the  100X  diluted  sample  were  placed  on  a  hemocytometer  for  cell  counting  using  
light  microscopy  at  a  magnification  of  1000X.  Based  on  cell  number,  cell  aliquots  with  A550  
of  10  were  adjusted  again  and  diluted  to  2000  cells/mL,  from  which  100  μL  suspension  
that  contained  about  200  cells  were  plated  on  a  YPD  plate  and  incubated  at  30˚C  or  39˚C  
for  3  days.  The  ability  of  single  cells  to  form  colonies  was  evaluated  at  30˚C  or  39˚C.  
FM  4-­64  staining    
FM   4-­64   staining   was   performed   as   previously   described   (Conboy   and   Cyert,  
2000)  with  minor  modification.  Cell  aliquots  equivalent  to  an  A550  of  1.0  were  harvested  
by  centrifugation,  resuspended  in  100  μL  YPD,  and  incubated  at  37˚C  or  39˚C  with  0.16  
mM  FM4-­64  for  15  min.  Cells  were  pelleted  and  washed  once  with  37˚C  YPD  or  39˚C  
YPD  and  then  resuspended  in  500  μL  YPD  of  the  same  temperature  for  30  min.  The  cell  
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suspension  was  centrifuged  and  the  supernatants  were  discarded.  The  cell  pellets  were  
resuspended  in  100  μL  YPD,  from  which  3  μL  were  applied  to  the  microscope  slide  and  
observed  using  epifluorescence  microscopy  using  the  filter  for  red  fluorescence.  
RESULTS  AND  DISCUSSION  
Construction  of  the  starting  strain  for  the  synthetic  lethal  screen  
The  starting   strain  was  constructed   in   four   steps:  disruption  of  TAZ1   in  can1Δ,  
confirmation   of   disruption   by   PCR,   genetic   analysis   of   phenotypes,   and   phospholipid  
analysis.   The   CAN1   deletion   cassette   was   amplified   from   Y5563   and   inserted   into  
BY4741  (MATa),  which  was  further  crossed  with  BY4742  (MATα)  to  obtain  MATα  can1Δ  
by  tetrad  analysis  (as  explained  in  Tong  et  al.,  2001).  The  yeast  chromosomal  TAZ1  gene  
in  the  can1Δ  mutant  (BY4742  MATα)  was  disrupted  by  the  deletion  cassette  as  shown  in  
Fig.  4.2,  and  amplified  by  PCR  to  construct  the  can1Δtaz1Δ  mutant  (BY4742  MATα).  The  
disruption   of  CAN1   and  TAZ1   was   confirmed   by   PCR   and   phospholipid   analysis.   To  
confirm  mating  type,  the  starting  strain  can1Δcrd1Δ  was  crossed  to  test  strains  CG922  
(MATa)  and  CG923  (MATα)  and  replica  plated  on  minimal  medium.  The  selective  markers  
of  BY4742  MATα  can1Δtaz1Δ  mutant  were  confirmed  on  synthetic  dropout  medium.  The  
starting  strain  BY4742  MATα  can1Δtaz1Δ,   thus  constructed,  was  further  used  to  carry  
out  the  synthetic  lethal  screen.  
Genome-­wide  synthetic  lethality  screen  with  can1Δtaz1Δ    
The   query   strain,   in   which   the   taz1Δ   mutation   was   linked   to   the   dominant  
selectable  marker  URA3  and   the  reporter  construct  MFA1pr-­HIS3,  which   is  expressed  
only   in  MATa  cells  was  crossed  with   the  array  of  4,800  deletion  mutants   in   the  MATa  
background,  in  which  the  deletion  is  linked  to  the  dominant  selectable  marker  for  geneticin  
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(kanamycin)  resistance,  KanMX.  The  MATα  strain  was  lys-­  met+,  and  the  MATa  strain  was  
met-­   lys+.   Diploids   were   selected   on   plates   lacking   both   lysine   and   methionine,   and  
sporulation  was  induced.  Haploid  spore  progeny  were  transferred  to  synthetic  medium  
lacking  histidine,  which  allows  for  selective  germination  of  MATa  cells  (by  the  MFA1pr-­
HIS3   reporter).  Following   two   rounds  of   selection,   the  MATa   cells  were   transferred   to  
medium   lacking  uracil  and  containing  geneticin.  Synthetic   interaction  was   indicated  by  
decreased  growth  of  the  haploid  double  mutant  progeny.  
As  expected,  the  SGA  screen  identified  a  large  number  of  synthetic  interactions  
that   included   70   potential   synthetic   lethal   interactions   (Table   4.2   and   4.3)   and   102  
potential  sick  interactions  (Table  4.4  and  4.5),  which  were  grouped  based  on  biological  
function   (Fig.   4.3   and   4.4).   These   genes   define   many   biological   functions,   including  
hydrolase   activity,   transferase   activity,   structural   molecule   activity,   DNA   binding,  
structural  constituent  of  ribosome,  cytoskeleton  protein  binding,  oxidoreductase  activity,  
transporter  activity,  ATPase  activity,  methyltransferase  activity,  ion  binding,  lyase  activity,  
signal  transducer  activity,  phosphatase  activity,  and  others.  
Biological  processes  required  for  fitness  of  the  taz1Δ  mutant  
The   screen   identified   two   mutants,   arg3Δ   and   isa2Δ,   previously   shown   to   be  
synthetically   lethal  with   taz1Δ   (Gaspard   et   al.,   2015).  However,   two   genes   previously  
shown  to  be  synthetically  lethal  with  taz1Δ,  yme1Δ  and  tom5Δ,  were  not  identified.  This  
outcome  is  consistent  with  the  large  number  of  false  positives  and  false  negatives  that  
commonly  result   from  this  screen.  The  SGA  screen  has  large  number  of  false  positive  
and  false  negative  due  to  following  reasons:  (a)  the  selection  of  double  mutants  may  not  
be  stringent  enough,  (b)  the  genetic  background  of  the  deletion  collection  was  constructed  
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in   the   BY4741   or   BY4742   background   and   the   taz1Δ   mutant   exhibits   less   severe  
phenotype   in   this   particular   background,   and   (c)  SGA   involves   several   steps   such  as  
mating,   selection   on   drop   out  media,   and  meiotic   sporulation.   If   growth   of  mutants   is  
affected  in  these  process,  double  mutants  may  not  be  identified,  demonstrating  the  need  
for  follow-­up  studies  to  verify  findings  independently.	  Follow  up  studies  were  carried  out  
with  mutants   of   phospholipase  B  metabolism,   arginine  metabolism,  mitochondrial   iron  
metabolism,  and  vacuolar  protein  sorting.	  
a.  Phospholipase  B  and  phospholipid  metabolism.  The  screen  revealed  that  
taz1Δ   is   synthetically   sick   with   plb3Δ.   PLB3   encodes   phospholipase B 
(lysophospholipase), which hydrolyzes phosphatidylinositol and phosphatidylserine 
(Merkel et al., 1999; Merkel et al., 2005; Byrne and Wolfe, 2005). This was especially 
interesting because Taz1 is a transacylase that transfers acyl groups from phospholipids 
(independent of CoA). Synthetic lethality with phospholipases suggests that Taz1 may 
affect cellular functions as a result of affecting lysolipids other than those derived from 
CL. It remains unclear why taz1Δ  is  synthetically  sick  with  plb3Δ.  To  determine  if  other  
phospholipase  B  mutants   (plb1Δ   and  plb2Δ)   interact  with   taz1Δ,   I   constructed  double  
mutants   with   taz1Δ   and   checked   for   growth   at   elevated   temperatures   by   the   colony  
formation  assay  (Table  4.6).  I  also  tested  synthetic  interaction  with  crd1Δ  to  distinguish  
between  the  role  of  CL  depletion  vs  CL  remodeling  in  the  synthetic  interaction.  The  taz1Δ  
mutant  in  this  genetic  background  can  grow  at  temperatures  up  to  39°C,  while  the  crd1Δ  
mutant  can  grow  at  temperature  only  up  to    37°C.  As  seen  in  Table  4.6,  mutants  plb1Δ  
and   plb3Δ,   but   not   plb2Δ,   showed   genetic   interaction   with   taz1Δ.   Interestingly,   the  
phospholipase   B  mutants   did   not   genetically   interact   with   crd1Δ,   suggesting   that   the  
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function  that  was  affected  in  the  double  mutant  was  not  CL  deficiency,  but  probably  more  
related  to  CL  remodeling. 
Previous  studies  have  shown  that   the  only  phospholipase  that  deacylates  CL  is  
cardiolipin-­specific   deacylase   (CLD1),   although   the   possibility   that   enzymes   with  
phospholipase  A  or  B  activity  could  also  catalyze  deacylation  of  CL  was  not   ruled  out  
(Beranek   et   al.,   2009).   In   Penicillium   notatum,   purified   phospholipase   B   catalyzed  
deacylation   of   1,2-­diacylphospholipid   and   lysophospholipids   at   the   sn-­1   and   sn-­2  
positions  of  fatty  acids,  and  CL  acts  as  a  lipid  activator  of  catalysis  (Saito.,  2014).  Witt  et  
al.  (1984)  reported  that  phospholipase  B  exhibits  transacylase  activity  in  S.  cerevisiae.  
Based  on  these  studies,  I  hypothesize  that  tafazzin  plays  a  role  not  only  in  the  acylation  
of  MLCL  to  CL,  but  also  in  regulating  lysolipid  formation  from  other  cellular  lipids.  
b.   Arginine   metabolism.   ARG3   encodes   an   enzyme   that   catalyzes   the  
biosynthesis   of   arginine   from   ornithine,   thereby   participating   in   the   aspartate-­
argininosuccinate   shunt   (Crabeel   et   al.,   1981).   The   role   of   the   aspartate-­
argininosuccinate  shunt  is  to  break  down  ornithine  into  intermediates  of  the  TCA  cycle,  
including  fumarate  and  malate.  Recent  studies  demonstrated  that  taz1Δ  is  synthetically  
lethal  with  arg3Δ  (Beranek  et  al.,  2009).  My  observation  that  arg3Δ  is  synthetically  sick  
with   taz1Δ   confirms   the   previous   finding   and   suggests   that   the   aspartate-­
argininosuccinate  shunt  is  required  for  cells  to  survive  in  the  absence  of  tafazzin.  There  
are  at  least  two  possible  explanations  for  this  synthetic  interaction.  First,  taz1Δ  cells  may  
be  deficient  in  TCA  cycle  intermediates  fumarate  and  malate,  which  can  be  supplied  by  
the  aspartate-­argininosuccinate  shunt.  This  is  consistent  with  the  observed  decrease  in  
aconitase  and  succinate  dehydrogenase  activities  in  CL  deficient  cells,  suggesting  that  
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the  TCA  cycle  is  perturbed  (Patil  et  al.,  2013).  Second,  synthetic  lethality  may  reflect  an  
increased  need  for  glutamine.  In  yeast,  glutamate  is  converted  to  glutamine  by  glutamine  
synthetase.  Decreased  growth   of   the  crd1Δ  mutant   is   rescued  by   supplementation   of  
glutamate   (Vinay  A.   Patil,   unpublished   data).   This   deficiency  may   be   exacerbated   by  
perturbation   of   the   aspartate-­argininosuccinate   shunt,   which   converts   glutamate   to  
glutamine  and  other  intermediates  of  the  TCA  cycle.  
c.   Mitochondrial   iron   metabolism.   The   SGA   screen   identified   isa2Δ   as  
synthetically   lethal  with   taz1Δ.   ISA2   encodes   a   protein   required   for   the  maturation   of  
mitochondrial  Fe-­S  clusters.  Patil  et  al.  (2013)  showed  that  crd1Δ  cells  exhibit  defective  
Fe-­S   biogenesis,   resulting   in   perturbation   of   iron   homeostasis.   The   synthetic   lethality  
finding  suggests  that  the  taz1Δ  mutant  may  also  exhibit  Fe-­S  defects.  The  phenotypes  
observed   due   to   perturbation   of   Fe-­S   biogenesis   in   humans   include   heart   failure   and  
hypertrophic  cardiomyopathy  (Tsai  et  al.,  2010),  and  may  also  be  relevant  in  BTHS.  It  is  
unclear   how  CL   synthesis   is   linked   to  Fe-­S  biogenesis.  Decreased   import   of   proteins  
required  for  Fe-­S  biogenesis  has  been  suggested  (Patil  et  al.,  2013),  which  may  explain  
a  defect  in  both  crd1Δ  and  taz1Δ  cells.  
d.   Vacuole   protein   sorting.  APM3   encodes   the  Mu3-­like   subunit   of   the   AP-­3  
clathrin  associated  protein  complex,  which  functions  in  the  alkaline  phosphatase  pathway  
(ALP)  (Yeung  et  al.,  1999;;  Odorizzi  et  al.,  1998;;  Cowles  et  al.,  1997).  The  ALP  pathway  
bypasses  endosomal  intermediates  and  transports  alkaline  phosphatase  to  the  vacuole  
(Piper  et  al.,  1997;;  Cowles  et  al.,  1997;;  Odorizzi  et  al.,  1998).  The  screen  revealed  that  
apm3Δ  is  synthetically  sick  with  taz1Δ,  but  validation  did  not  confirm  genetic  interaction  
with  taz1Δ  or  crd1Δ.  In  fact,  follow  up  experiments  indicated  that  apm3Δ  rescued  crd1Δ  
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defects.   Previous   studies   have   shown   that   the   loss   of   CL   leads   to   vacuolar   defects,  
including  enlarged  vacuole  and  decreased  vacuole  acidification  at  elevated  temperature  
(Chen   et   al.,   2008b).   These   phenotypes   suggested   that   endocytic   trafficking  may   be  
perturbed  in  the  CL  mutant.  Interestingly,  apm3Δ  rescued  decreased  cell  growth  (Figs.  
4.5  and  4.6),  as  well  as  vacuolar  morphology  defects  of  crd1Δ  at  elevated  temperature  
(Fig.  4.7).  One  possible  explanation  for  rescue  by  apm3Δ  is  that  the  ALP  pathway  may  
be   up-­regulated   or   overactive   in   CL-­deficient   cells.   This   would   result   in   excessive  
transport  of  alkaline  phosphatase  and  the  vacuolar  t-­SNARE  Vam3p  to  the  vacuole,  which  
is  deleterious  to  cells  (Stepp  et  al.,  1997).  These  findings  suggest  that  overactive  the  ALP  
pathway  or   increased  alkaline  phosphatase   in   the   vacuole  may  be  deleterious   to  CL-­
deficient  cells.    
Conclusion  
The  SGA  screen  described  here  identified  many  genetic  interactions  with  taz1Δ,  
suggesting  that  many  cellular  pathways  are  affected  by  tafazzin.  Interesting  interactions  
were   observed   with   genes   affecting   phospholipase   B,   the   argininosuccinate   shunt,  
mitochondrial   iron   homeostasis,   and   vacuolar   protein   sorting.   The   interaction   with  
phospholipase   B   suggests   that   taffazin  may   be   involved   in   remodeling   phospholipids  
other  than  CL.  Previous  studies  reported  that  Fe-­S  biogenesis  is  perturbed  in  crd1Δ  (Patil  
et  al.,  2013).  The  genetic  interaction  studies  in  this  chapter  suggest  that  Fe-­S  biogenesis  
may  also  be  perturbed  in  taz1Δ.  The  aspartate-­argininosuccinate  shunt  functions  in  the  
synthesis   of   the   TCA   cycle   intermediates,   and   synthetic   lethality   with  mutants   in   this  
pathway  suggests  that  the  aspartate-­argininosuccinate  is  required  for  tafazzin  deficient  
	  	  
101	  
cells.   Understanding   the   role   of   tafazzin   in   Fe-­S   biogenesis   and   the   aspartate-­










































FIGURE  4.1.  Synthetic  genetic  array  (SGA)  screen  identifies  mutants  synthetically  
lethal  with  taz1Δ  (modified  from  Tong  et  al.,  2001).  A  MATα  (lys-­)  query  strain  carrying  
the  mutations  (taz1Δ::URA3  and  can1Δ::MFA1pr-­HIS3)  was  crossed  to  an  ordered  array  
of  MATa   (met-­)  viable  yeast  deletion  mutants,  each  carrying  a  gene  deletion  mutation  
linked  to  a  kanamycin-­resistance  marker  (KanMX)  to  form  diploids.  The  haploid  meiotic  
spore  progeny  are  formed  when  heterozygous  diploids  are  transferred  to  the  sporulation  
media.  Haploid   spore  progeny  were   transferred   to   synthetic  medium   lacking  histidine,  
which  allows   for  selective  germination  of  MATa  cells  which  express   the  MFA1pr-­HIS3  
reporter  specifically.  The  selected  MATa  meiotic  progeny  were  transferred  to  the  medium  
that   lacks  uracil  and  contains  kanamycin.  Uracil  auxotrophy  and  kanamycin  resistance  
















FIGURE  4.2.  Disruption  of  the  chromosomal  TAZ1  gene  by  URA3  to  obtain  BY4742  
MATα   taz1Δ::URA3   can1Δ::MFA1pr-­HIS3   (modified   from   Tong   et   al.,   2001).  
Construction   of   the   starting   strain   (taz1Δ::URA3   can1Δ::MFA1pr-­HIS3)   involved   two  
steps.  First,  the  mfa1Δ::MFA1pr-­HIS3  open  reading  frame  (ORF)  was  integrated  at  the  
CAN1   locus   such   that   its   expression   is   regulated   by   the   MFA1   promoter   (MFA1pr),  
mfa1Δ::MFA1pr-­HIS3.  Second,   the  TAZ1  gene   in   the  can1Δ::MFA1pr-­HIS3  strain  was  
disrupted  by  a  1.8   kb  URA3   fragment   generated   from  construct  DR2   to  obtain  MATα  
















FIGURE   4.3.   Functional   classification   of   genes   exhibiting   synthetic   lethal  
interaction  with  taz1Δ.  Synthetic  lethal  interactions  identified  by  SGA  were  classified  by  
biological  process  based  on  gene  ontology.  The  percentage  of  genes  representing  the  










FIGURE  4.4.  Functional  classification  of  genes  exhibiting  synthetic  sick  interaction  
with   taz1Δ.  Synthetic   sick   interactions   identified  by  SGA  were  classified  by  biological  
process   based   on   gene   ontology.   The   percentage   of   genes   representing   the   specific  


















FIGURE   4.5.   apm3Δ   suppresses   the   growth   defect   of   crd1Δ   at   elevated  
temperature.  Cells  were  pre-­cultured  in  YPD  overnight,  serially  diluted,  plated  on  YPD,  



























FIGURE   4.6.   apm3Δ   suppresses   the   growth   defect   of   crd1Δ   at   elevated  
temperature.  Cells  were  inoculated  in  YPD  at  39°C  at  an  initial  A550  of  0.05,  and  A550  was  
measured   at   the   indicated   times.   The   growth   curves   shown   in   the   figure   are  














FIGURE  4.7.  apm3Δ  rescues  the  vacuole  morphology  defect  of  crd1Δ  at  elevated  
temperature.  Cells  were  pre-­cultured   in  YPD  to  the  early   log  phase  at  30°C  and  then  
transferred  to  37°C  or  39°C  for  8  hours.  Vacuoles  were  visualized  by  staining  with  FM4-­
64  and  cells  were  observed  using  fluorescence  microscopy.  All  images  were  taken  at  the  















Source  or  Ref.  
Y5563   MATα,  his3Δ1,  leu2Δ0,  ura3Δ0,  met15Δ0,  LYS2+,  
lyp1Δ,  can1Δ::MFA1pr-­HIS3  









taz1Δcan1Δ   MATα,  his3Δ1,  leu2Δ0,  lys2Δ0,  ura3Δ0,    
taz1Δ::URA3,  can1Δ::MFA1pr-­HIS3  
This  study  
VGY1   MATα,  his3Δ1,  leu2Δ0,  lys2Δ0,  ura3Δ0,    
crd1Δ::URA3  
Gohil  et  al.,  2005  
taz1Δ   MATα,  his3Δ1,  leu2Δ0,  lys2Δ0,  ura3Δ0,    
taz1Δ::URA3  
Invitrogen  
CG922-­a   MATa,  lys2-­801,  ade2-­101,  trp1Δ1,  his3Δ200,  
leu2Δ1,  crd1Δ::URA3  
Invitrogen  
CG923-­α   MATα,  lys2-­801,  ade2-­101,  trp1Δ1,  his3Δ200,  
leu2Δ1,  crd1Δ::URA3  
Invitrogen  
plb11Δ   MATa,  his3Δ1,  leu2Δ0,  met15Δ0,  ura3Δ0,  
plb1Δ::KanMX4  
Invitrogen  





plb3Δ   MATa,  his3Δ1,  leu2Δ0,  met15Δ0,  ura3Δ0,  
plb3Δ::KanMX4  
Invitrogen  
apm3Δ   MATa,  his3Δ1,  leu2Δ0,  met15Δ0,  ura3Δ0,  
amp3Δ::KanMX4  
Invitrogen  
plb1Δcrd1Δ   MATa,  his3Δ1,  leu2Δ0,  met15Δ0,  ura3Δ0,  
plb1Δ::KanMX4,  crd1Δ::KanMX4  
This  study  
plb2Δcrd1Δ   MATa,  his3Δ1,  leu2Δ0,  met15Δ0,  ura3Δ0,  
plb2Δ::KanMX4,  crd1Δ::KanMX4  
This  study  
plb3Δcrd1Δ   MATa,  his3Δ1,  leu2Δ0,  met15Δ0,  ura3Δ0,  
plb3Δ::KanMX4,  crd1Δ::KanMX4  
This  study  
apm3Δcrd1Δ   MATa,  his3Δ1,  leu2Δ0,  met15Δ0,  ura3Δ0,  
amp3Δ::KanMX4,  crd1Δ::KanMX4  
This  study  
plb1Δtaz1Δ   MATa,  his3Δ1,  leu2Δ0,  met15Δ0,  ura3Δ0,  
plb1Δ::KanMX4,  taz1Δ::KanMX4  
This  study  
plb2Δtaz1Δ   MATa,  his3Δ1,  leu2Δ0,  met15Δ0,  ura3Δ0,  
plb2Δ::KanMX4,  taz1Δ::KanMX4  
This  study  
plb3Δtaz1Δ   MATa,  his3Δ1,  leu2Δ0,  met15Δ0,  ura3Δ0,  
plb3Δ::KanMX4,  taz1Δ::KanMX4  
This  study  








TABLE  4.2.  Synthetic  lethal  interaction  with  taz1Δ.  Summary  of  genes  identified  as  










16  out  of  70  
genes,  22.9%  
DEP1,  NPL4,  SOL2,  AHC2,  CSM1,  
FIG2,  OCA4,  IES6,  BUD13,  ICE2,  
PET130,  VPS53,  DID2,  SOV1,  
CAF120  
Hydrolase  activity   9  out  of  70  
genes,  12.9%  
NPP1,  RAD18,  TPS2,  PDR11,  SDS3,  
IMP2,  HNT3,  TAF14,  KRE6  
Transferase  activity   9  out  of  70  
genes,  12.9%  
RBK1,  BUD23,  ARE1,  SSK22,  GSC2,  
SSM4,  TRM9,  SER1,  LOA1  
Structural  molecule  
activity  
7  out  of  70  
genes,  10%  
MRPS9,  RPL21A,  RPS14A,  IMG1,  
RPS21B,  CSE2,  RPS12  
DNA  binding   7  out  of  70  
genes,  10%  
RIM1,  HCM1,  RAD18,  SPT4,  GON7,  
SSN8,  THO2  
Structural  constituent  of  
ribosome  
6  out  of  70  
genes,  8.6%  
MRPS9,  RPL21A,  RPS14A,  IMG1,  
RPS21B,  RPS12  
Enzyme  regulator  activity   6  out  of  70  
genes,  8.6%  
SLI15,  SYP1,  SED4,  SSN8,  RBK1,  
SSK22    
Transcription  factor  
activity,  protein  binding  
4  out  of  70  
genes,  5.7%  
SRB8,  SPT4,  CSE2,  TAF14  
Cytoskeletal  protein  
binding  
4  out  of  70  
genes,  5.7%  
ABP1,  YKE2,  HOF1,  PAC1  
Oxidoreductase  activity  
Isomerase  activity  
4  out  of  70  
genes,  5.7%  
TRX3,  DFG10,  CPR4,  DEG1  
Transmembrane  
transporter  activity  
3  out  of  70  
genes,  4.3%  
ERS1,  PDR11,  QDR2  
ATPase  activity   3  out  of  70  
genes,  4.3%  
RAD18,  PDR11,  TAF14  
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Methyltransferase  activity   2  out  of  70  
genes,  2.9%  
BUD23,  TRM9  
Nucleic  acid  binding  
transcription  factor  
2  out  of  70  
genes,  2.9%  
HCM1,  TAF14  
mRNA  binding   2  out  of  70  
genes,  2.9%  
RPS14A,  THO2  
Ion  binding   2  out  of  70  
genes,  2.9%  
RBK1,  ISA2  
RNA  binding   2  out  of  70  
genes,  2.9%  
RPS14A,  THO2  
Nuclease  activity   2  out  of  70  
genes,  2.9%  
NPP1,  HNT3  





2  out  of  70  
genes,  2.9%  
THR4,  TPS2  
Unfolded  protein  binding  
Signal  transducer  activity  





1  out  of  70  
genes,  1.4%  
GSC2  





1  out  of  70  
genes,  1.4%  
KRE6  
Peptidase  activity   1  out  of  70  
genes,  1.4%  
IMP2  
Other   5  out  of  70  
genes,  7.1%  






TABLE  4.3.  Genes  identified  by  SGA  as  synthetically  lethal  with  taz1Δ.    








Actin-­binding  protein  of  the  cortical  actin  cytoskeleton  
ARE1     Acyl-­CoA  sterol  acyltransferase,  isozyme  of  Are2p  
BUD13     Subunit  of  the  RES  complex  
BUD23     Protein  involved  in  bud-­site  selection  
CAF120     Part  of  the  evolutionarily  conserved  CCR4-­NOT  transcriptional  
CBS1     Mitochondrial  translational  activator  of  the  COB  mRNA  
CPR4     Peptidyl-­prolyl  cis-­trans  isomerase  (cyclophilin)  
CSE2     Subunit  of  the  RNA  polymerase  II  mediator  complex  
CSM1     Nucleolar  protein  that  forms  a  complex  with  Lrs4p    
DEG1     Non-­essential  tRNA  pseudouridine  synthase  
DEP1     Transcriptional  modulator  involved  in  phospholipid  biosynthesis  
DFG10     Protein  of  unknown  function,  involved  in  filamentous  growth  
DID2     Class  E  protein  of  the  vacuolar  protein-­sorting  (Vps)  pathway  
ERS1     Protein  with  similarity  to  human  cystinosin  
FIG2     Cell  wall  adhesin  
FYV10     Protein  of  unknown  function  
GON7     Protein  proposed  to  be  involved  in  the  modification  
GSC2     Catalytic  subunit  of  1,3-­beta-­glucan  synthase  
HCM1     Forkhead  transcription  factor  that  drives  S-­phase    
HNT3     Member  of  the  third  branch  of  the  histidine  triad  (HIT)  superfamily  
HOF1     Bud  neck-­localized  
ICE2     Integral  ER  membrane  protein  with  type-­III  transmembrane  domains  
IES6     Protein  that  associates  with  the  INO80  chromatin  remodeling  complex    
IMG1     Mitochondrial  ribosomal  protein  of  the  large  subunit  
IMP2     Transcriptional  activator  involved  in  maintenance  of  ion  homeostasis    
ISA2     Protein  required  for  maturation  of  mitochondrial  and  cytosolic  Fe/S  
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KRE6   Protein  required  for  beta-­1,6  glucan  biosynthesis  
LUG1     Putative  protein  of  unknown  function  
MRPS9     Mitochondrial  ribosomal  protein  of  the  small  subunit  
NPL4     Endoplasmic  reticulum  and  nuclear  membrane  protein  
NPP1     Nucleotide  pyrophosphatase/phosphodiesterase  family  member  
OCA4     Cytoplasmic  protein  required  for  replication  of  Brome  mosaic  virus  
PAC1     Protein  involved  in  nuclear  migration  
PDR11     ATP-­binding  cassette  (ABC)  transporter  
PDR17     Phosphatidylinositol  transfer  protein  (PITP)  
PET130     Protein  required  for  respiratory  growth  
QDR2     Multidrug  transporter  of  the  major  facilitator  superfamily  
RAD18     Protein  involved  in  postreplication  repair  
RBK1     Putative  ribokinase  
RIM1     Single-­stranded  DNA-­binding  protein    
RLF2     Largest  subunit  (p90)  of  the  Chromatin  Assembly  Complex  (CAF-­1)    
RPL21A     Protein  component  of  the  large  (60S)  ribosomal  subunit  
RPS12     Protein  component  of  the  small  (40S)  ribosomal  subunit  
RPS14A     Ribosomal  protein  59  of  the  small  subunit  
RPS21B     Protein  component  of  the  small  (40S)  ribosomal  subunit  
SAG1     Alpha-­agglutinin  of  alpha-­cells,  binds  to  Aga1p  during  agglutination  
SDS3     Component  of  the  Rpd3p/Sin3p  deacetylase  complex    
SED4     Integral  endoplasmic  reticulum  membrane  protein  
SER1     3-­phosphoserine  aminotransferase  
SLI15     Subunit  of  the  conserved  chromosomal  passenger  complex    
SOL2     Protein  with  a  possible  role  in  tRNA  export  
SOV1     Mitochondrial  protein  of  unknown  function  
SPT4     Protein  involved  in  the  regulating  Pol  I  and  Pol  II  transcription  
SRB8     Subunit  of  the  RNA  polymerase  II  mediator  complex  
SSK22     MAP  kinase  kinase  kinase  of  the  HOG1  
SSM4     Ubiquitin-­protein  ligase  involved  in  ER-­associated  protein  degradation  
SSN8     Cyclin-­like  component  of  the  RNA  polymerase  II  holoenzyme  
	  	  
115	  
SYP1     Protein  of  unknown  function    
TAF14     Subunit  of  TFIID,  TFIIF,  INO80,  SWI/SNF,  and  NuA3  complexes  
TAH1     HSP90  cofactor;;  interacts  with  Hsp82p,  Pih1p,  Rvb1  and  Rvb2  
THO2     Subunit  of  the  THO  complex  
THR4     Threonine  synthase  
TPS2     Phosphatase  subunit  of  the  trehalose-­6-­phosphate  synthase  
TRM9     tRNA  methyltransferase  
TRX3     Mitochondrial  thioredoxin  
VMA22     Peripheral  membrane  protein  that  is  required  for  vacuolar  H+-­ATPase  
VPS53     Component  of  the  GARP  (Golgi-­associated  retrograde  protein)  
VPS66     Cytoplasmic  protein  of  unknown  function    
VTH1     Putative  membrane  glycoprotein    
WHI3     RNA  binding  protein  that  sequesters  CLN3  mRNA  in  cytoplasmic  foci  


























TABLE  4.4.  Synthetic   sick   interaction  with   taz1Δ.   Summary   of   genes   identified   as  
synthetically   sick   with   the   taz1Δ   mutant.   The   identified   genes   are   grouped   based   on  







Molecular  function  unknown   18  out  of  102  
genes,  17.6%  
AIM4,  APM3,  RXT3,  MSH5,  KRE28,  
RMD6,  NIF3,  EFG1,  PEX28,  
GVP36,  VPS70,  VPS65,  PEX30,  
OPI9,  MPA43,  ZEO1,  RTT10,  NCA2  
Hydrolase  activity   18  out  of  102  
genes,  17.6%  
MMS4,  PCA1,  RRT12,  GUD1,  IRC3,  
PTP3,  RTR1,  DNF1,  RSC1,  RSR1,  
TES1,  SNO1,  ADE17,  RNH201,  
PLB3,  MET22,  ARP8,  ELP4  
Transferase  activity   18  out  of  102  
genes,  17.6%  
PMT2,  GAL1,  RKM3,  HSL7,  SHM1,  
ARE1,  ARG3,  RKM4,  GSC2,  
RPA12,  UFD4,  CST9,  VAN1,  
ADE17,  SAS2,  HRD1  
DNA  binding  
RNA  binding  
9  out  of  102  
genes,  8.8%  
RIM1,  PHO2,  CMR1,  MET32,  




9  out  of  102  
genes,  8.8%  
PCA1,  IRC3,  DNF1,  RSC1,  ARP8,  
ELP4,  SOD2,  BNA1,  CAT5  
Enzyme  regulator  activity   9  out  of  102  
genes,  8.8%  
GCS1,  BEM2,  GCN1,  BUD6,  
GAL80,  VPS75,  PCL1,  CLN2,  CLB5  
Structural  molecule  activity   8  out  of  102  
genes,  7.8%  
RPS9B,  RPS11A,  SWR1,  RPL29,  
RPL7A,  RPS27B,  RPS27A,  RPS17A  
Cytoskeletal  protein  binding  
Transcription  factor  binding  
8  out  of  102  
genes,  7.8%  
GCS1,  YKE2,  BUD6,  RBL2,  MET32,  
GAL80,  SIN4,  CTI6  
Structural  constituent  of  
ribosome  
7  out  of  102  
genes,  6.9%  
RPS9B,  RPS11A,  RPL29,  RPL7A,  
RPS27B,  RPS27A,  RPS17A  
Transmembrane  transporter          7  out  of  102  
genes,  6.9%  




Methyltransferase  activity   3  out  of  102  
genes,  2.9%  
RKM3,  HSL7,  RKM4  
Nucleic  acid  binding  
transcription    factor  
3  out  of  102  
genes,  2.9%  
PHO2,  MET32,  HAP5  
Transferase  activity,    
transferring  glycosyl  
3  out  of  102  
genes,  2.9%  
PMT2,  GSC2,  VAN1  
Phosphatase  activity   3  out  of  102  
genes,  2.9%  
PTP3,  RTR1,  MET22  
Transcription  factor  activity,    
protein  binding  
2  out  of  102  
genes,  2%  
MET32,  SRB2  
Nuclease  activity   2  out  of  102  
genes,  2%  
MMS4,  RNH201  
Kinase  activity   2  out  of  102  
genes,  2%  
GAL1,  ADO1  
Histone  binding   2  out  of  102  
genes,  2%  
VPS75,  CTI6  
Ligase  activity   2  out  of  102  
genes,  2%  
ADE5,7,  ADE12  
Chromatin  binding   2  out  of  102  
genes,  2%  
LIF1,  CST9  
Signal  transducer  activity  
GTPase  activity  
2  out  of  102  
genes,  2%  
RSR1,  SLG1  
Unfolded  protein  binding   2  out  of  102  
genes,  2%  
VMA22,  SSQ1  
Peptidase  activity   1  out  of  102  
genes,  1%  
RRT12  
Protein  binding,  bridging   1  out  of  102  
genes,  1%  
PEX14  







1  out  of  102  
genes,  1%  
RPA12  
Ion  binding   1  out  of  102  
genes,  1%  
PCA1  










































TABLE  4.5.  Genes  identified  by  SGA  as  synthetically  sick  with  taz1Δ.  









ADE5,7     Bifunctional  enzyme  of  the  'de  novo'  purine  nucleotide  biosynthetic  
ADO1     Adenosine  kinase,  required  for  the  utilization  of  S-­adenosylmethionine    
AIM4     Protein  proposed  to  be  associated  with  the  nuclear  pore  complex  
APM3     Mu3-­like  subunit  of  the  clathrin  associated  protein  complex  (AP-­3)  
ARE1     Acyl-­CoA  sterol  acyltransferase,  isozyme  of  Are2p  
ARG3     Ornithine  carbamoyltransferase    
ARP8     Nuclear  actin-­related  protein  involved  in  chromatin  remodeling  
BEM2     Rho  GTPase  activating  protein  (RhoGAP)  
BNA1     hydroxyanthranilic  acid  dioxygenase  
BUD6     Actin-­  and  formin-­interacting  protein  
CAT5     Protein  required  for  ubiquinone  (Coenzyme  Q)  biosynthesis  
CLB5     B-­type  cyclin  involved  in  DNA  replication  during  S  phase  
CLN2     G1  cyclin  involved  in  regulation  of  the  cell  cycle  
CST9     SUMO  E3  ligase  
CTI6     Protein  that  relieves  transcriptional  repression    
CUE4     Protein  of  unknown  function;;  has  a  CUE  domain  that  binds  ubiquitin  
DFG10   Protein  of  unknown  function,  involved  in  filamentous  growth  
DNF1     Aminophospholipid  translocase  (flippase)    
EFG1     Essential  protein  required  for  maturation  of  18S  rRNA  
ELP4     Subunit  of  Elongator  complex  
FMP37     Putative  protein  of  unknown  function  
GAL1     Galactokinase  
GAL3     Transcriptional  regulator  involved  in  activation  of  the  GAL  genes  
GAL80     Transcriptional  regulator  involved  in  the  repression  of  GAL  genes    
GAP1     General  amino  acid  permease  
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GCN1     Positive  regulator  of  the  Gcn2p  kinase  activity  
GCS1     ADP-­ribosylation  factor  GTPase  activating  protein  (ARF  GAP)  
GSC2     Catalytic  subunit  of  1,3-­beta-­glucan  synthase  
GUD1     Guanine  deaminase  
GUP2     Probable  membrane  protein    
GVP36     BAR  domain-­containing  protein  that  localizes  to  Golgi  vesicles  
HAP5     Subunit  of  the  heme-­activated    
HRD1     Ubiquitin-­protein  ligase  required  for  endoplasmic  reticulum  
HSL7     Protein  arginine  N-­methyltransferase    
HUT1     Protein  with  a  role  in  UDP-­galactose  transport  to  the  Golgi  lumen  
IRC3     Putative  protein  of  unknown  function  
JLP2     Protein  of  unknown  function  
KRE28     Protein  of  unknown  function  that  localizes  to  the  nuclear  
LIF1     Component  of  the  DNA  ligase  IV  complex    
LRC3     Putative  protein  of  unknown  function  
MAM33     Acidic  protein  of  the  mitochondrial  matrix  
MCH5     Plasma  membrane  riboflavin  transporter  
MDE1     5'-­methylthioribulose-­1-­phosphate  dehydratase  
MET22     Bisphosphate-­3'-­nucleotidase  
MET32     Zinc-­finger  DNA-­binding  protein  
MMS4     Subunit  of  the  structure-­specific  Mms4p-­Mus81p  endonuclease    
MNR2     Putative  magnesium  transporter  
MPA43     Putative  protein  of  unknown  function  
MSH5     Protein  of  the  MutS  family  
NCA2     Protein  involved  in  regulation  of  mitochondrial  ATP  synthase  
OCA2     Putative  protein  with  similarity  to  predicted  tyrosine  phosphatases  
OPI9     Dubious  open  reading  frame  unlikely  to  encode  a  protein  
OSW3     Putative  protein  of  unknown  function  
PCA1     Cadmium  transporting  P-­type  ATPase  
PCL1     Pho85  cyclin  of  the  Pcl1,2-­like  subfamily  
PEX14     Peroxisomal  membrane  peroxin    
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PEX28   Peroxisomal  integral  membrane  peroxin  
PEX30     Peroxisomal  integral  membrane  protein  
PHO2     Homeobox  transcription  factor  
PLB3     Phospholipase  B  (lysophospholipase)    
PMT2     Protein  O-­mannosyltransferase  
PTP3     Phosphotyrosine-­specific  protein  phosphatase    
RBL2     Protein  involved  in  microtubule  morphogenesis  
RIM1     Single-­stranded  DNA-­binding  protein    
RKM3     Ribosomal  lysine  methyltransferase    
RKM4     Ribosomal  lysine  methyltransferase    
RLF2     Largest  subunit  (p90)  of  the  Chromatin  Assembly  Complex  (CAF-­1)  
RMD6     Protein  required  for  sporulation  
RNH201     Ribonuclease  H2  catalytic  subunit  
RPA12       RNA  polymerase  I  subunit  A12.2  
RPL29     Protein  component  of  the  large  (60S)  ribosomal  subunit  
RPL7A     Protein  component  of  the  large  (60S)  ribosomal  subunit  
RPS11A     Protein  component  of  the  small  (40S)  ribosomal  subunit  
RPS17A     Ribosomal  protein  51  (rp51)  of  the  small  (40s)  subunit  
RPS27A     Protein  component  of  the  small  (40S)  ribosomal  subunit  
RPS27B     Protein  component  of  the  small  (40S)  ribosomal  subunit  
RPS9B     Protein  component  of  the  small  (40S)  ribosomal  subunit  
RSC1     Component  of  the  RSC  chromatin  remodeling  complex  
RSR1     GTP-­binding  protein  of  the  ras  superfamily    
RTR1     Protein  with  a  role  in  transcription  
RTT10     Cytoplasmic  protein  with  a  role  in  regulation  of  Ty1  transposition  
RXT3     Subunit  of  the  RPD3L  complex  
SAS2     Histone  acetyltransferase  (HAT)  catalytic  subunit  of  the  SAS  complex  
SEC66     Non-­essential  subunit  of  Sec63  complex    
SHM1     Mitochondrial  serine  hydroxymethyltransferase  
SIN4     Subunit  of  the  RNA  polymerase  II  mediator  complex  
SLG1     Sensor-­transducer  of  the  stress-­activated  PKC1-­MPK1  
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SNO1     Protein  of  unconfirmed  function  
SOD2     Mitochondrial  superoxide  dismutase  
SRB2     Subunit  of  the  RNA  polymerase  II  mediator  complex  
SSQ1     Mitochondrial  hsp70-­type  molecular  chaperone  
SWR1     Swi2/Snf2-­related  ATPase    
TAT2     High  affinity  tryptophan  and  tyrosine  permease  
TDH2     Glyceraldehyde-­3-­phosphate  dehydrogenase  
TES1     Peroxisomal  acyl-­CoA  thioesterase    
TLG2     Syntaxin-­like  t-­SNARE  that  forms  a  complex  with  Tlg1p  and  Vti1p    
UFD4     Ubiquitin-­protein  ligase  (E3)  that  interacts  with  Rpt4p  and  Rpt6p  
VAN1     Component  of  the  mannan  polymerase  I  
VMA22     Peripheral  membrane  protein  that  is  required  for  vacuolar  H+-­ATPase    
VPS28     Component  of  the  ESCRT-­I  complex    
VPS65     Dubious  open  reading  frame  
VPS70     Protein  of  unknown  function  involved  in  vacuolar  protein  sorting  
VPS75     NAP  family  histone  chaperone;;  binds  to  histones  and  Rtt109p  
WHI3     RNA  binding  protein  that  sequesters  CLN3  mRNA  in  cytoplasmic  foci  
YKE2     Subunit  of  the  heterohexameric  Gim/prefoldin  protein  complex    




















TABLE  4.6.  Genetic  interaction  of  CL  mutants  with  phospholipase  B  mutants.  The  
phospholipase  B  mutants  were  crossed  with  the  CL  mutants  to  obtain  double  mutants.  
Genetic  interaction  was  determined  based  on  the  viability  of  the  double  mutants.    
Key:  (-­):  no  growth;;  (+/-­):  poor  growth;;  (+):  good  growth.  
  
Phospholipase  B  mutants   Growth  of  double  mutants  
   taz1∆   crd1∆  
   30°C   39°C   30°C   37°C  
plb1∆   +   +/-­   +   +  
plb2∆   +   +   +   +  
plb3∆   +   +/-­   +   +  

















CHAPTER  5  FUTURE  DIRECTIONS  
The  studies  described   in   this   thesis   identified   the   fascinating  new   role  of  CL   in  
acetyl-­CoA   metabolism,   which   interconnects   metabolic   pathways   crucial   for   energy  
metabolism.   The   powerful   SGA   tool   was   used   to   identify   cellular   and   biochemical  
processes  in  which  CL  may  play  a  role.  The  data  presented  in  Chapters  2  and  3  indicate  
that  the  loss  of  CL  leads  to  perturbation  of  synthesis  and  transport  of  acetyl-­CoA,  which  
very  likely  results  in  perturbation  of  the  TCA  cycle  and  metabolic  deficiencies  observed  in  
the  CL  mutant.  However,  the  mechanism  underlying  defective  acetyl-­CoA  homeostasis  
and   TCA   cycle   defects   in   CL-­deficient   cells   is   not   understood.   Chapter   4   identifies  
potential  physiological  modifiers  that  exacerbate  the  loss  of  tafazzin.  Characterization  of  
these  may  contribute  to  our  understanding  of  the  basis  for  the  variation  in  symptoms  in  
BTHS.  In  this  chapter,  I  suggest  exciting  future  studies  that  would  push  our  knowledge  of  
the  role  of  CL  in  cellular  functions  to  interesting  new  directions  by  addressing  the  following  
questions.    
1.   What  is  the  role  of  CL  in  acetate  utilization?  
The  studies  presented   in  Chapter  2  show  that   the   loss  of  CL   leads  to  defective  
acetate  utilization,  which  results  in  perturbation  of  the  PDH-­bypass  pathway.  This  is  the  
first  report  to  show  that  a  phospholipid  might  be  required  for  synthesis  of  acetyl-­CoA.  As  
an  indication  of  defective  acetate  utilization,  the  growth  and  acetyl-­CoA  levels  of  crd1Δ  
were  decreased  when  acetate  was  provided  as  the  sole  carbon  source  (Fig.  2.4  &  2.5).  
However,   it   is   unclear   how  CL   in   the  mitochondrial  membrane   is   involved   in   acetate  
utilization,  which  is  largely  carried  out  in  the  mitochondrial  outer  membrane  and  cytosol.  
Future  experiments  to  elucidate  the  mechanism  underlying  the  role  of  CL  in  conversion  
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of  acetate  to  acetyl-­CoA  should  determine  if  gene  expression,  enzyme  activity,  import  into  
the   mitochondria,   and/or   stability   of   acetyl-­CoA   synthetase   (ACS1   and   ACS2)   are  
decreased  in  crd1Δ.  This  study  may  uncover  a  novel  mechanism  whereby  synthesis  of  
acetyl-­CoA   in   different   organelles   is   controlled   by   CL,   which   is   predominantly   in   the  
mitochondria.  
2.   Is  CL  required  for  acetyl-­CoA  synthesis  in  mammals?  
In  chapter  2,  I  showed  that  acetyl-­CoA  levels  are  decreased  in  CL-­deficient  cells  
due  to  perturbation  of  the  PDH-­bypass.  This  identifies  a  novel  role  of  CL  in  acetyl-­CoA  
synthesis   in   yeast   cells.   I   suggest   future  experiments   to   determine  acetyl-­CoA   levels,  
acetate  utilization,  and  activity  of  acetyl-­CoA  synthetase  and  PDH  in  mammalian  cells.  If  
experiments  reveal  that  CL  is  required  for  acetyl-­CoA  synthesis  in  mammals  as  in  yeast,  
this  may  suggest   that   the  synthesis  of  acetyl-­CoA   is  a  physiological  modifier   that  may  
contribute   to   the  disparities   in   the  clinical  phenotypes  observed   in  BTHS  patients  and  
other  cardiac  disorders.  These  experiments  may  shed  light  on  treatments  for  BTHS  that  
are  targeted  to  these  deficiencies.      
3.   Why  is  carnitine  acetylcarnitine  translocase  activity  decreased  in  crd1Δ?  
The   experiment   illustrated   in   Fig.   3.5   indicates   that   activity   of   carnitine-­
acetylcarnitine  translocase  is  decreased  in  crd1Δ,  although  carnitine  levels  and  carnitine  
acetylcarnitine   transferase   activity   are   not   altered.   What   is   the   cause   of   decreased  
translocase  activity  in  crd1Δ?  At  least  three  possibilities  could  explain  this  decrease.  First,  
the   mRNA   levels   of   CRC1   may   be   decreased   in   crd1Δ.   Second,   based   on   studies  
showing  that  CL  is  required  for  optimal  mitochondrial  protein  import  (Jiang  et  al.,  2000;;  
Gebert  et  al.,  2009;;  Kutik  et  al.,  2008),  import  of  mitochondrial  Crc1  may  be  decreased  
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due  to  CL  deficiency.  Third,  the  stability  of  Crc1  may  depend  on  interaction  with  CL.  Based  
on  these  experiments,  it  will  be  interesting  to  determine  if  mammalian  cells  exhibit  similar  
carnitine-­acetylcarnitine   translocase   defects,   and   if   supplementation   of   acetylcarnitine  
rescues  some  phenotypes  observed  in  BTHS.  
4.  How  does  the  glyoxylate  cycle  rescue  crd1Δ  mutant  defects?  
The  data  presented  in  Chapter  3  show  that  the  glyoxylate  cycle  is  essential  in  CL-­
deficient  cells.  My  studies  revealed  that  crd1Δ  is  synthetically  lethal  with  mutants  in  the  
glyoxylate  cycle,  suggesting  that  intermediates  of  the  glyoxylate  cycle  may  compensate  
for  crd1Δ  deficiencies.  However,  the  mechanism  by  which  the  glyoxylate  cycle  rescues  
crd1Δ  mutant  defects  is  not  known.  At  least  two  possibilities  could  explain  rescue  by  the  
glyoxylate  cycle.  First,  the  mRNA  levels  of  glyoxylate  cycle  genes  may  be  up-­regulated  
in   crd1Δ.   Second,   the   activity   of   citrate   synthase   (CS),   aconitase   (ACO),   malate  
dehydrogenase   (MDH),   isocitrate   lyase   (ICL),   and   malate   synthase,   enzymes   that  
synthesize  TCA  cycle   intermediates  through  the  glyoxylate  cycle,  may  be   increased  in  
crd1Δ.  This  may  result  in  increased  synthesis  of  succinate,  malate,  and  citrate,  which  are  
expected  to  replenish  deficiencies  resulting  from  perturbed  acetyl-­CoA  synthesis.    
5.  What  is  the  role  of  CL  in  the  cell  integrity  pathway?    
  
In   order   to   identify   physiological   modifiers   that   exacerbate   the   loss   of   CL,   I  
performed  a  genome  wide  SGA  screen  with  crd1Δ  and  taz1Δ,  as  described  in  Chapters  
2   and   4.   Among   the   genetic   interactions   uncovered   in   these   screens,   I   would   draw  
attention  of  future  students  to  the  cell  integrity  pathway.  Previous  studies  have  reported  
that  the  PKC-­Slt2  pathway  is  defective  in  pgs1Δ  cells,  which  exhibit  decreased  viability  at  
high   temperatures   and   a   defective   cell   integrity   pathway   due   to   decreased   Slt2p  
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phosphorylation   (Zhong   et   al.,2007).   The   mechanism   underlying   decreased   Slt2p  
phosphorylation  in  the  CL  mutant  is  unknown.  
SDP1   encodes   stress-­inducible   dual-­specificity   MAP   kinase   phosphatase   that  
dephosphorylates  Slt2p   (Hahn   et   al.,   2002;;  Byrne   et   al.,   2005;;  Collister   et   al.,   2002).  
During   heat   shock,   Sdp1p   is   localized   to   mitochondria   and   cytosolic   puncta,   and   is  
sequestered  from  Slt2p.  When  cells  undergo  heat  stress  adaptation,  Sdp1p  is  released  
from   cytoplasmic   and  mitochondrial   puncta   and   is   thus   accessible   to   carry   out   Slt2p  
dephosphorylation  and  inactivation  (Kuravi  et  al.,  2011).  Defective  Slt2p  phosphorylation  
in  the  pgs1Δ  mutant  could  result  from  release  of  Sdp1p  from  sequestration,  resulting  in  
increased  Sdp1p  phosphatase  levels  in  the  cytosol  and  dephosphorylation  of  Slt2p  before  
it  moves  into  the  nucleus.  At  least  two  possibilities  could  explain  this  decrease.  First,  CL  
mutants  may  exhibit  increased  activity  of  Sdp1p.  Second,  upstream  effectors  of  the  PKC-­
Slt2   pathway   may   not   be   activated   in   CL-­deficient   cells.   Future   experiments   should  
address  these  possibilities.  
In  conclusion,  one  of  the  enigmas  of  BTHS  (and  other  monogenic  disorders)  is  that  
the  disorder  is  characterized  by  a  wide  disparity  of  symptoms  ranging  from  asymptomatic  
to  newborn  death,  even  in  the  presence  of  identical  tafazzin  mutations.  This  indicates  that  
physiological  modifiers  affect  the  clinical  outcome.  The  underlying  pathology  of  BTHS  and  
the  physiological  modifiers  that  affect  the  clinical  outcome  of  this  disorder  remain  to  be  
identified.  The  studies  described  in  Chapters  2  and  3  show,  for  the  first  time,  that  CL  is  
required  for  optimal  acetyl-­CoA  metabolism,  which  is  essential  for  basal  functioning  of  the  
TCA   cycle.   I   invite  my   colleagues   in   the  Greenberg   lab   to   discover   the  mechanisms  
whereby  CL  participates  in  acetyl-­CoA  metabolism.  I  anticipate  that  the  results  will  lead  
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to  breakthroughs  that  will  pave  the  way  for  a  better  understanding  of  cellular  pathways  
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The   phospholipid   cardiolipin   (CL)   is   crucial   for   many   cellular   functions   and  
signaling  pathways,  both  inside  and  outside  of  mitochondria.  My  thesis  focuses  on  the  
role   of   CL   in   energy  metabolism.   Many   reactions   of   electron   transport   and   oxidative  
phosphorylation,   the   transport   of   metabolites   needed   for   these   processes,   and   the  
stabilization   of   electron   transport   chain   supercomplexes,   require   CL.   Recent   studies  
indicate  that  CL  is  required  for  the  synthesis  of   iron-­sulfur  (Fe-­S)  co-­factors,  which  are  
essential   for   numerous   metabolic   pathways.   Activation   of   carnitine-­acetylcarnitine  
translocase,  which   transports  acetyl-­CoA   into   the  mitochondria,   is  CL  dependent.  The  
presence  of  substantial  amounts  of  CL  in  the  peroxisomal  membrane  suggests  that  CL  
may   be   important   for   peroxisomal   functions.   Understanding   the   role   of   CL   in   energy  
metabolism   may   identify   physiological   modifiers   that   exacerbate   the   loss   of   CL   and  
underlie  the  variation  in  symptoms  observed  in  Barth  syndrome,  a  genetic  disorder  of  CL  
metabolism.  
In  order  to  identify  biochemical  pathways  exacerbated  by  the  loss  of  CL,  I  carried  
out  a  Synthetic  Genetic  Array  (SGA)  screen  of  the  yeast  CL  mutant  crd1Δ.  The  results  
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indicated   that   crd1Δ   is   synthetically   lethal   with   mutants   in   pyruvate   dehydrogenase  
(PDH),  which  catalyzes  the  conversion  of  pyruvate  to  acetyl-­CoA.  Previous  studies  have  
shown   that   synthesis   of   acetyl-­CoA   depends   primarily   on   pyruvate   conversion   in   the  
mitochondria  and  the  cytosol.  The  crd1Δ  mutant  exhibited  decreased  acetyl-­CoA  levels  
and  decreased  growth  on  acetate  as  a  sole  carbon  source.  Gene  expression  and  protein  
levels   of   PDH   were   increased,   but   PDH   specific   activity   remained   unaltered.   These  
findings   suggest   that   defective   ability   to   convert   acetate   to   acetyl-­CoA   and   possibly  
decreased  enzymatic  activity  of  PDH  may  account  for  perturbed  acetyl-­CoA  synthesis  in  
CL-­deficient  cells.    
Consistent  with  a  requirement  for  CL  in  acetyl-­CoA  synthesis,  perturbation  of  CL  
synthesis   leads   to   decreased   activity   of   carnitine-­acetylcarnitine   translocase,   a  
transporter  found  in  the  mitochondrial  membrane  specific  for  import  of  acetylcarnitine  into  
the  mitochondria.  Growth  of  crd1Δ  at  elevated   temperature  and  on  acetate  medium   is  
restored   by   supplementation   of   carnitine,   acetylcarnitine,   or   oleate.   Interestingly,  
synthetic   lethality   was   observed   between   crd1Δ   and  mutants   in   the   glyoxylate   cycle,  
suggesting  that  this  cycle  is  essential  to  replenish  TCA  cycle  intermediates  in  CL-­deficient  
cells.  The  studies  described  in  this  thesis  are  the  first  to  demonstrate  that  CL  is  required  
for  synthesis  and  transport  of  acetyl-­CoA.  
To  obtain  an  understanding  of  tafazzin  function,  an  SGA  screen  was  carried  out  to  
identify   mutants   that   synthetically   interact   with   taz1Δ.   Interesting   interactions   were  
observed  with  phospholipase  B,  ornithine  carbamoyltransferase,  and  genes  required  for  
mitochondrial  iron  homeostasis  and  vacuolar  protein  sorting.  These  findings  suggest  that  
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